Original Article
Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes
N Engl J Med 2005; 353:2643-2653December 22, 2005
- Abstract
Background
Intensive diabetes therapy aimed at achieving near normoglycemia reduces the risk of microvascular and neurologic complications of type 1 diabetes. We studied whether the use of intensive therapy as compared with conventional therapy during the Diabetes Control and Complications Trial (DCCT) affected the long-term incidence of cardiovascular disease.
Methods
The DCCT randomly assigned 1441 patients with type 1 diabetes to intensive or conventional therapy, treating them for a mean of 6.5 years between 1983 and 1993. Ninety-three percent were subsequently followed until February 1, 2005, during the observational Epidemiology of Diabetes Interventions and Complications study. Cardiovascular disease (defined as nonfatal myocardial infarction, stroke, death from cardiovascular disease, confirmed angina, or the need for coronary-artery revascularization) was assessed with standardized measures and classified by an independent committee.
Results
During the mean 17 years of follow-up, 46 cardiovascular disease events occurred in 31 patients who had received intensive treatment in the DCCT, as compared with 98 events in 52 patients who had received conventional treatment. Intensive treatment reduced the risk of any cardiovascular disease event by 42 percent (95 percent confidence interval, 9 to 63 percent; P=0.02) and the risk of nonfatal myocardial infarction, stroke, or death from cardiovascular disease by 57 percent (95 percent confidence interval, 12 to 79 percent; P=0.02). The decrease in glycosylated hemoglobin values during the DCCT was significantly associated with most of the positive effects of intensive treatment on the risk of cardiovascular disease. Microalbuminuria and albuminuria were associated with a significant increase in the risk of cardiovascular disease, but differences between treatment groups remained significant (P≤0.05) after adjusting for these factors.
Conclusions
Intensive diabetes therapy has long-term beneficial effects on the risk of cardiovascular disease in patients with type 1 diabetes.
Media in This Article
Figure 1
Cumulative Incidence of the First of Any of the Predefined Cardiovascular Disease Outcomes (Panel A) and of the First Occurrence of Nonfatal Myocardial Infarction, Stroke, or Death from Cardiovascular Disease (Panel B).Table 1
Clinical Characteristics of the DCCT/EDIC Cohort.Article Activity
- Article
Type 1 diabetes mellitus is associated with long-term complications that affect the eyes, kidneys, and peripheral and autonomic nervous systems.1 Although the pathophysiological basis of these complications remains uncertain, hyperglycemia appears to play a central role. Epidemiologic studies have demonstrated a strong association between the level of glycemia and the occurrence of these diabetic complications.2 The Diabetes Control and Complications Trial (DCCT) and the Epidemiology of Diabetes Interventions and Complications (EDIC) study, DCCT's long-term follow-up study, have demonstrated a consistent salutary effect of intensive therapy, aimed at achieving glucose control as close to the nondiabetic range as safely possible, on the development and progression of retinopathy, nephropathy, and neuropathy.3,4 The DCCT/EDIC study has established a causal role of hyperglycemia in the development and progression of the microvascular complications of type 1 diabetes.
Although cardiovascular disease is not specific to diabetes, it is more prevalent among patients with type 1 or type 2 diabetes than among those without diabetes.5,6 Type 1 diabetes is associated with at least a 10-fold increase in cardiovascular disease as compared with an age-matched nondiabetic population.6,7 An association between hyperglycemia and cardiovascular disease has been suggested by some,8 but not all,9 studies of patients with type 1 diabetes. However, controlled clinical trials of patients with type 1 or type 2 diabetes have not demonstrated a reduction in the occurrence of cardiovascular disease with long-term intensive diabetes therapy. During the DCCT, fewer cardiovascular events occurred in the intensive-treatment group than in the conventional-treatment group, but the small number of events in the relatively young cohort precluded a determination of whether the use of intensive diabetes therapy affected the risk of cardiovascular disease.10 Using long-term follow-up data on the DCCT/EDIC cohort, we evaluated whether intensive therapy reduces the risk of cardiovascular events among patients with type 1 diabetes.
Methods
Detailed descriptions of the methods of the DCCT and EDIC follow-up study have been published previously.3,4,11,12 The DCCT, a randomized, controlled clinical trial conducted between 1983 and 1993, was designed to compare the effects of an intensive diabetes treatment regimen with those of conventional therapy.
Study Population
Of the 1441 patients with type 1 diabetes who were 13 to 40 years old at the time of randomization, 1422 completed the DCCT; the mean follow-up was 6.5 years. At baseline, eligibility criteria excluded patients with a history of cardiovascular disease or with hypertension (defined by a blood pressure of 140/90 mm Hg or more) or hypercholesterolemia (defined by a serum cholesterol level obtained after an overnight fast that was at least 3 SD above age- and sex-specific means).11 Of the surviving cohort, 1394 — representing 97 percent of the original cohort — agreed to join the long-term EDIC follow-up study in 1994. The current report includes follow-up data obtained through February 1, 2005, at which point 93 percent of the original cohort (96 percent of 1397 surviving participants) remained in the study. The DCCT/EDIC study was approved by the institutional review boards of all participating centers, and all participants provided written informed consent.
Study Procedures
During the DCCT, participants were examined annually. Glycosylated hemoglobin values were measured quarterly,13 and fasting lipid levels, serum creatinine values, and other risk factors for cardiovascular disease were measured annually in a central laboratory.11 Microalbuminuria and albuminuria were defined by urinary albumin excretion of at least 40 mg in a 24-hour period and of at least 300 mg in a 24-hour period, respectively.11 Renal disease was defined by the development of a serum creatinine level of at least 2 mg per deciliter (177 μmol per liter) or the need for dialysis or kidney transplantation. Electrocardiograms were obtained and examined annually by readers who were unaware of patients' treatment assignments. During the EDIC follow-up study, the methods used in the DCCT were continued, but glycosylated hemoglobin was measured annually and fasting lipid levels and renal function were measured in alternate years.12
Treatment
Intensive therapy consisted of three or more daily injections of insulin or treatment with an external insulin pump, with dose adjustments based on at least four self-monitored glucose measurements per day. Daily glucose goals were 70 to 120 mg per deciliter (3.9 to 6.7 mmol per liter) before meals and peak levels of less than 180 mg per deciliter (10.0 mmol per liter) after meals. The goal for glycosylated hemoglobin was less than 6.05 percent — 2 SD above the mean value for persons without diabetes. Conventional therapy had no glucose goals beyond those needed to prevent symptoms of hyperglycemia and hypoglycemia and consisted of one or two daily injections of insulin. The absolute difference between groups in the mean glycosylated hemoglobin value at the end of the mean 6.5 years of the DCCT was approximately 2 percentage points (7.4 percent in the intensive-treatment group vs. 9.1 percent in the conventional-treatment group, P<0.01). At the end of the DCCT, the conventional-treatment group was offered intensive treatment and all participants returned to their own health care providers for diabetes care. Subsequently, differences in treatment dissipated, with only a trivial, nonsignificant difference between groups in the fraction of patients using three or more daily injections of insulin or an insulin pump (Table 1Table 1
Clinical Characteristics of the DCCT/EDIC Cohort.). Differences in the mean (±SD) glycosylated hemoglobin value also narrowed in the intensive-treatment and conventional-treatment groups over the entire 11 years of the EDIC follow-up study (8.0±1.2 percent and 8.2±1.2 percent, respectively; P=0.03).Outcomes
The primary outcome was the time to the first of any of the following cardiovascular events: nonfatal myocardial infarction or stroke; death judged to be due to cardiovascular disease; subclinical myocardial infarction; angina, confirmed by ischemic changes on exercise tolerance testing or by clinically significant obstruction on coronary angiography; or the need for revascularization with angioplasty or coronary-artery bypass.14 Subclinical (“silent”) myocardial infarctions were identified on the annual electrocardiograms.15
Medical records describing cardiovascular events, including electrocardiographic findings and cardiac enzyme levels, were submitted for adjudication to a committee whose three members were unaware of patients' treatment assignments. Only cardiovascular events that were considered definite were counted.16
Statistical Analysis
The DCCT/EDIC Study Research Group specified in 1996 that no analyses comparing the cardiovascular events between groups would be performed until 50 patients in the original conventional-treatment group had had a cardiovascular event, providing the study with a statistical power of 85 percent to detect a 50 percent reduction in the risk of cardiovascular events between groups. No interim analyses were performed until that milestone was reached at the beginning of 2005. This article is based on all events that had occurred as of February 1, 2005. Analyses were conducted according to the intention-to-treat principle on the basis of the original DCCT treatment assignment. Results that were nominally significant (two-sided P<0.05) are cited.
Clinical characteristics were compared with the use of the Wilcoxon rank-sum test for quantitative variables and the chi-square test for categorical variables.17 The cumulative incidence of a cardiovascular event (the first of any) within groups was estimated according to the Kaplan–Meier method, the difference between groups was evaluated by means of the log-rank test, and the hazard ratio comparing intensive with conventional treatment and 95 percent confidence intervals were estimated by means of a Cox proportional-hazards model. The corresponding risk reduction was calculated as 100×(1−the hazard ratio). Event rates, including multiple events in the same patient, are presented as the number per 100 patient-years, and the difference was evaluated, with allowance for repeated events and overdispersion.18 Proportional-hazards models were used to assess the effects of time-dependent covariates (mean glycosylated hemoglobin value updated to the time of the cardiovascular event during the DCCT or, if no event occurred during the DCCT, to the end of the DCCT; or the development of renal disease, microalbuminuria, or albuminuria) and the effect of the treatment group, after adjustment for such covariates.19 The effect of the glycosylated hemoglobin value during the EDIC trial was not assessed in these analyses.
The DCCT and EDIC studies were designed entirely by the DCCT/EDIC Study Research Group, which collected the data. The writing committee prepared the article and vouches for its completeness and accuracy.
Results
The major characteristics relevant to cardiovascular disease are described at baseline, at the end of the DCCT, and at year 11 of the EDIC study (Table 1). At baseline, no patients in the DCCT had hypertension or hypercholesterolemia, on the basis of the standards at the time, and only 5 percent had microalbuminuria (urinary albumin excretion of at least 40 mg per 24 hours). There were no significant differences between the intensive-treatment and conventional-treatment groups in any risk factors for cardiovascular disease at baseline, except for a minimally higher systolic blood pressure in the conventional-treatment group. At the end of the DCCT, the two groups had diverged with regard to the prevalence of several established and putative risk factors for cardiovascular disease. Microalbuminuria and albuminuria were more prevalent (13 percent vs. 7 percent, P<0.01, and 3 percent vs. 1 percent, P<0.05, respectively) in the conventional-treatment group than in the intensive-treatment group, and the glycosylated hemoglobin value was higher (9.1±1.5 percent vs. 7.4±1.1 percent, P<0.01) in the conventional-treatment group. By year 11 of the EDIC study, the prevalences of microalbuminuria and albuminuria remained greater in the former conventional-treatment group and the prevalence of a serum creatinine value of at least 2 mg per deciliter was also significantly greater in this group (2 percent vs. 0 percent, P<0.05). There were only trivial or nonsignificant differences between the groups in the prevalence of other conventional risk factors for cardiovascular disease at the end of the DCCT and at year 11 of the EDIC study; the absolute difference in the glycosylated hemoglobin value between groups was only 0.1 percent at year 11 of the EDIC study (P=0.38) (Table 1).
A total of 144 cardiovascular events occurred in 83 patients during the mean 17 years of follow-up, 46 among 31 patients originally assigned to intensive treatment and 98 among 52 patients originally assigned to conventional treatment (Table 2Table 2
Cardiovascular Events in Each Original Treatment Group of the DCCT.). The respective event rates were 0.38 and 0.80 per 100 patient-years (P=0.007). Although the rates of individual clinical events that made up the main outcome were not significantly different between groups, they were consistently lower, usually by at least 50 percent, in the intensive-treatment group than in the conventional-treatment group.A life-table analysis of the cumulative incidence of a first cardiovascular event showed that intensive treatment was associated with a 42 percent reduction in risk, as compared with conventional treatment (95 percent confidence interval, 9 to 63 percent; P=0.02) (Figure 1AFigure 1
Cumulative Incidence of the First of Any of the Predefined Cardiovascular Disease Outcomes (Panel A) and of the First Occurrence of Nonfatal Myocardial Infarction, Stroke, or Death from Cardiovascular Disease (Panel B).). The risk of the first occurrence of nonfatal myocardial infarction, stroke, or death from cardiovascular disease was reduced 57 percent with intensive treatment, as compared with conventional treatment (95 percent confidence interval, 12 to 79 percent; P=0.02) (Figure 1B).Proportional-hazards models, adjusted for selected baseline factors, were used to assess the association of time-dependent covariates with the risk of cardiovascular disease in the combined cohort and the effect of the DCCT treatment group before and after adjustment for each factor (Table 3Table 3
Proportional-Hazards Models of the Effect of Time-Dependent Covariates on the Risk of Cardiovascular Disease and of the Effect of the Treatment Group after Adjustment for the Time-Dependent Covariate.). The hazard ratio for intensive as compared with conventional treatment, adjusted only for baseline factors, was 0.53 (P=0.005). A history of renal disease did not have a significant effect on the risk of cardiovascular disease or on the treatment-group effect, perhaps because of the small number of such patients (35). A history of microalbuminuria or of albuminuria was significantly associated with an increase in the risk of cardiovascular disease by a factor of more than 2.5 and explained part of the treatment-group effect, as reflected by the increase in the hazard ratio and P value. The difference in cardiovascular disease outcomes between groups remained significant after adjustment for these factors.An updated glycosylated hemoglobin value during the DCCT (mean glycosylated hemoglobin value updated to the time of the cardiovascular event during the DCCT or, if no event occurred during the DCCT, to the end of the DCCT) that was 10 percent lower in one patient than in another (e.g., 7.2 percent vs. 8.0 percent) was associated with a hazard ratio of 0.80, representing a 20 percent reduction in the risk of a cardiovascular event (95 percent confidence interval, 9 to 30 percent; P<0.001). The use of the updated log mean glycosylated hemoglobin value during the DCCT explained a large part of the treatment-group effect on the risk of cardiovascular disease, the treatment-group hazard ratio being closer to 1 and no longer significant (P=0.61) after adjustment. There were no significant differences between groups in the use of medications known to affect the risk of cardiovascular disease, except for the use of beta-blockers, which was more common in the conventional-treatment group than in the intensive-treatment group (7 percent vs. 3 percent, P<0.05) at year 11 of the EDIC study (Table 1).
We determined which baseline characteristics of the entire cohort in the DCCT were associated with the occurrence of the cardiovascular disease outcome independent of treatment assignment (Table 4Table 4
Clinical Characteristics of EDIC Participants at Baseline in the DCCT According to the Presence or Absence of Cardiovascular Disease over the Course of the DCCT/EDIC Study.). At baseline, older age (31 vs. 27 years), a longer duration of diabetes (7 vs. 6 years), the presence of retinopathy, current smoking, a higher body-mass index (24.0 vs. 23.3), higher total and low-density lipoprotein cholesterol levels (194 vs. 175 mg per deciliter [5.0 vs. 4.5 mmol per liter] and 127 vs. 109 mg per deciliter [3.3 vs. 2.8 mmol per liter], respectively), higher glycosylated hemoglobin levels (9.5 percent vs. 9.0 percent), and a higher albumin excretion rate (19.3 vs. 15.7 mg per 24 hours), and assignment to conventional treatment were all associated with the development of cardiovascular disease.Discussion
Controlled clinical trials involving patients with type 1 diabetes and those with type 2 diabetes have conclusively demonstrated that intensive diabetes therapy aimed at lowering glycemic levels reduces the risk of diabetic retinopathy, nephropathy, and neuropathy.3,20 In addition, the DCCT/EDIC study demonstrated that a period of approximately 6.5 years of intensive diabetes therapy had a long-term, sustained effect on the subsequent risk of microvascular complications.4 The pathophysiological mechanisms responsible for the improvement in outcomes and for the prolonged effects of early intervention remain unclear; we have referred to the latter phenomenon as “metabolic memory.” It is in this context that we evaluated the effect of intensive diabetes therapy on the long-term risk of cardiovascular disease.
The primary outcome was defined as a cardiovascular event that included clinical findings or the need for revascularization. As compared with conventional therapy, intensive diabetes therapy reduced the risk of a cardiovascular event by 42 percent and reduced the risk of severe clinical events, including nonfatal myocardial infarction, stroke, or death from cardiovascular disease, by 57 percent. The risk of each of the individual cardiovascular events was reduced to a similar degree. These findings extend our previous observations that intensive as compared with conventional therapy reduces the progression of atherosclerosis, measured by carotid intima–media thickness, and the prevalence of coronary-artery calcification.21,22
There are several potential explanations for the effectiveness of a period of intensive diabetes management on the long-term risk of cardiovascular disease outcomes. First, the same glycemic mechanisms that reduce the incidence of microvascular disease may also apply to the development of atherosclerosis and resulting cardiovascular disease. Patients who had a cardiovascular event were more likely to have had retinopathy and had higher albumin excretion rates at baseline. Epidemiologic evidence has shown that any elevation in glycemia, even within the subdiabetic range, increases the risk of cardiovascular disease.23 Thus, a reduction in the glycosylated hemoglobin value might be expected to have beneficial effects on cardiovascular disease. The long-term effect of hyperglycemia on the risk of microvascular complications may be mediated by the generation of advanced glycation end products, which have been implicated in cardiovascular disease.24-26
Alternatively, the beneficial effect of intensive therapy on the risk of cardiovascular disease may be a result of the reduction in the incidence of microvascular disease. Both renal disease and autonomic neuropathy have been proposed as risk factors for cardiovascular disease.27-29 To the extent that intensive therapy reduces these risk factors,3,30 cardiovascular disease may also be reduced.
Microalbuminuria and albuminuria were each strongly associated with an increased risk of cardiovascular disease, and each explained some, but not all, of the DCCT treatment-group effect. The treatment-group effect remained significant after adjustment for these factors, suggesting that other effects of intensive therapy are at work. Adjusting for the updated mean glycosylated hemoglobin value during the DCCT explained the majority of the effect of intensive as compared with conventional therapy on the risk of cardiovascular disease. The results demonstrate that differences in glycosylated hemoglobin values during the DCCT accounted for much of the cardiovascular benefit accompanying intensive therapy, mediated in part by the reduction in the incidence of microalbuminuria or albuminuria.
We believe that the DCCT/EDIC study is unique in its long-term objective documentation of glycemic control, established and putative risk factors for cardiovascular disease, and the status of microvascular and cardiovascular complications. The virtually complete follow-up for more than two decades of the DCCT/EDIC cohort, whose members at baseline had no or minimal microvascular disease, no hypertension or hypercholesterolemia (by the standards at the time), and no clinical evidence of cardiovascular disease at baseline, facilitated the study of incident cardiovascular disease. However, several caveats apply to our data. First, the total number of events remains relatively low, precluding definitive assessment of treatment effects on the risks of the different types of cardiovascular events. Second, some of the cardiovascular events, such as the need for revascularization, are dependent on clinicians' judgment and are subject to application bias. Third, the fraction of silent myocardial infarctions was relatively high as compared with that in other studies.9 Finally, the interventions were unmasked during the DCCT and EDIC study, thus possibly introducing bias in the ascertainment of cardiovascular events or in the application of therapies that may have affected the risk of cardiovascular disease.
Although we cannot entirely discount these sources of potential bias, the uniform collection of historic data, the clinical severity of the cardiovascular outcomes, the masked adjudication of events, and the treatment of the DCCT/EDIC participants predominantly by non-DCCT clinicians for most of their follow-up substantially diminish the risk of bias. Although the relatively large fraction of silent myocardial infarctions is noteworthy, other studies have demonstrated that their outcome may be as severe as that of symptomatic infarctions.31 In addition, the difference between the treatment groups in the frequency of silent infarctions, detected on electrocardiograms obtained annually by graders who were unaware of patients' study assignments, paralleled the other outcomes. The only difference in medications between groups that may have confounded the outcome was the more common use of beta-blockers in the conventional-treatment group. This would have decreased the relative benefits of intensive therapy on the risk of cardiovascular disease.
The salutary effect of a mean of 6.5 years of intensive therapy on the risk of cardiovascular events is evidence that intensive diabetes management reduces the incidence of cardiovascular disease. This benefit reinforces the original DCCT message that intensive therapy should be implemented as early as possible in people with type 1 diabetes. The relative reduction in the risk of nonfatal myocardial infarctions, stroke, and death from cardiovascular disease, of 57 percent — the most clinically compelling outcome — exceeds the reductions in risk achieved with other proven interventions, such as medications that lower cholesterol and blood pressure. The large reduction in the risk of cardiovascular events will further improve the projected long-term health and economic benefits of intensive therapy for diabetes.32
Supported by contracts with the Division of Diabetes, Endocrinology and Metabolic Disease of the National Institute of Diabetes and Digestive and Kidney Diseases and by the General Clinical Research Center Program, National Center for Research Resources. No other potential conflict of interest relevant to this article was reported.
Source Information
The Writing Committee — David M. Nathan, M.D. (chair), Patricia A. Cleary, M.S., Jye-Yu C. Backlund, M.S., Saul M. Genuth, M.D., John M. Lachin, D.Sc., Trevor J. Orchard, M.D., Philip Raskin, M.D., and Bernard Zinman, M.D. — vouches for the accuracy and integrity of the data.
Address reprint requests to the DCCT/EDIC Research Group at Box NDIC/DCCT, Bethesda, MD 20892, or at dnathan@partners.org.
Persons and institutions participating in the DCCT/EDIC Study Research Group are listed in the Appendix.
Appendix
The following persons and institutions participated in the DCCT/EDIC Study Research Group: Study Chairs — S. Genuth, D.M. Nathan; Albert Einstein College of Medicine — S. Engel, J.B. Friday, H. Martinez (past), H. Shamoon, H. Engel; Case Western Reserve University — W. Dahms, L. Mayer, S. Pendegras, H. Zegarra, D. Miller, L. Singerman, S. Smith-Brewer, S. Genuth (past); Cornell University Medical Center — D. Brillion, M. Lackaye, M. Heinemann, V. Reppuci, T. Lee; Henry Ford Health System — F. Whitehouse, D. Kruger, A. Galpern, J.D. Carey; International Diabetes Center — R. Bergenstal, M. Johnson, D. Kendall, M. Spencer, D. Noller, K. Morgan, D. Etzwiler (deceased); Joslin Diabetes Center — A. Jacobson, E. Golden, G. Sharuk, Paul Arrigg, R. Baeser, O. Ganda, J. Rosenzweig, H. Wolpert, P. Economides, O. Handy, L. Rand (past); Massachusetts General Hospital — D.M. Nathan, M. Larkin, S. Fritz (past), J. Godine, C. McKitrick, P. Lou; Mayo Foundation — F.J. Service, G. Ziegler, J. Pach, J. Lindsey; Medical University of South Carolina — J. Colwell, D. Wood, R. Mayfield, K. Hermayer, M. Szpiech, T. Lyons, J. Parker, A. Farr, S. Elsing, T. Thompson, J. Selby, M. Bracey; Northwestern University — M. Molitch, B. Schaefer, L. Jampol, D. Weinberg, A. Lyon, Z. Strugula, J. Shankle, P. Astlesford; University of California, San Diego — O. Kolterman, G. Lorenzi, M. Goldbaum; University of Iowa — W. Sivitz, M. Bayless, R. Zeither (past), T. Weingeist, E. Stone, H. Culver Boidt, K. Gehres, S. Russell; University of Maryland School of Medicine — M. Hebdon, D. Counts, S. Johnsonbaugh, A. Kowarski (past), D. Ostrowski (past), T. Donner, S. Steidl, B. Jones; University of Michigan — W. Herman, D. Greene (past), C. Martin, M.J. Stevens, A.K. Vine, S. Elner; University of Minnesota — J. Bantle, B. Rogness, T. Olsen, E. Steuer; University of Missouri — D. Hainsworth, D. Goldstein (past), S. Hitt, J. Giangiacomo; University of New Mexico — D. Schade, M. Burge, J. Canady, M. Schluter, A. Das, D. Hornbeck (past); University of Pennsylvania — S. Schwartz, P.A. Bourne, B.J. Maschak-Carey (past), L. Baker (deceased), S. Braunstein, A. Brucker; University of Pittsburgh — T. Orchard, N. Silvers, T. Songer, B. Doft, S. Olson, R.L. Bergren, L. Lobes, M. Fineman, A. Drash (past); University of South Florida — J. Malone, E.A. Tanaka, J. Vaccaro-Kish (past), C. Berger, R. Gstalder, P.R. Pavan, A. Morrison; University of Tennessee — S. Dagogo-Jack, C. Wigley, S. Schussler (past), A. Kitabchi, H. Lambeth (past), M.B. Murphy, S. Moser, D. Meyer, A. Iannacone, M. Bryer-Ash (past), E. Chaum; University of Texas Southwestern University Medical Center — P. Raskin, S. Strowig, A. Edwards, J. Alappatt (past), C. Wilson (past), S. Park (past), Y. He; University of Toronto — B. Zinman, A. Barnie, S. MacLean, R. Devenyi, M. Mandelcorn, M. Brent; University of Washington — J. Palmer, S. Catton, J. Kinyoun, L. Van Ottingham (past), J. Ginsberg (past); University of Western Ontario — J. Dupre, J. Harth, C. Canny (past), D. Nicolle; Vanderbilt University — M. May, J. Lipps, R. Lorenz (past), L. Survant, S. Feman (past), K. Tawansy, A. Agarwal, T. Adkins; Washington University, St. Louis — N. White, L. Levandoski, J. Santiago (deceased), I. Boniuk, G. Grand, M. Thomas, D. Burgess, D. Joseph, K. Blinder, G. Shah; Yale University School of Medicine — W. Tamborlane, P. Gatcomb, K. Stoessel, K. Taylor; Clinical Coordinating Center (Case Western Reserve University) — B. Dahms, R. Trail, J. Quin; Data-Coordinating Center (George Washington University, Biostatistics Center) — J. Lachin, P. Cleary, D. Kenny (past), J. Backlund, W. Sun, B. Rutledge, B. Waberski, K. Klump, K. Chan, L. Diminick, B. Petty (past), A. Determan (past), M. Hawkins; National Institute of Diabetes and Digestive and Kidney Disease Program Office — C. Cowie, J. Fradkin, C. Siebert (past), R. Eastman (past); Central Fundus Photograph Reading Center (University of Wisconsin) — M. Davis, R. Danis, L. Hubbard, P. Geithman, L. Kastorff, M. Neider, D. Badal, B. Esser, K. Miner, H. Wabers, K. Glander, J. Joyce, N. Robinson, C. Hurtenbach, C. Hannon; Central Biochemistry Laboratory (University of Minnesota) — M. Steffes, J. Bucksa, B. Chavers; Central Carotid Ultrasound Unit (New England Medical Center) — D. O'Leary, L. Funk, J. Polak; Central Electrocardiographic Reading Unit (University of Minnesota) — R. Crow, C. O'Donnell (past), B. Gloeb, S. Thomas; Computed Tomography Reading Center (Harbor UCLA Research and Education Institute) — R. Detrano, N. Wong, M. Fox, L. Kim, R. Oudiz; External Advisory Committee — G. Weir (chair), C. Clark, R. D'Agostino, M. Espeland, B. Klein, T. Manolio, L. Rand, D. Singer, M. Stern; Molecular Risk Factors Program Project (Medical University of South Carolina) — M. Lopes-Virella, W.T. Garvey, T.J. Lyons, A. Jenkins, R. Klein, G. Virella, A.A. Jaffa, D. Zheng, D. Lackland, D. McGee, R.K. Mayfield, M. Brabham; Genetic Studies Group (Hospital for Sick Children) — A. Boright, A. Paterson, S. Scherer, B. Zinman; Lipoprotein Distribution/Obesity Group (University of Washington) — J. Brunzell, J. Hokanson, S. Marcovina, J. Purnell, S. Sibley, S. Deeb, K. Edwards; Editor, EDIC Publications — D.M. Nathan.
- References
References
1
Nathan DM . Long-term complications of diabetes mellitus. N Engl J Med 1993;328:1676-1685
Full Text | Web of Science | Medline2
Klein R ,Klein BE ,Moss SE ,Davis MD ,DeMets DL . Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA 1988;260:2864-2871
CrossRef | Web of Science | Medline3
Diabetes Control and Complications Trial Research Group
Full Text | Web of Science | Medline4
Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group
Full Text | Web of Science | Medline5
Krolewski AS ,Kosinski EJ ,Warram JH , et al. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol 1987;59:750-755
CrossRef | Web of Science | Medline6
Laing SP ,Swerdlow AJ ,Slater SD , et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia 2003;46:760-765
CrossRef | Web of Science | Medline7
Dorman JS ,LaPorte RE ,Kuller LH , et al. The Pittsburgh insulin-dependent diabetes mellitus (IDDM) morbidity and mortality study: mortality results. Diabetes 1984;33:271-276
CrossRef | Web of Science | Medline8
Lehto S ,Ronnemaa T ,Pyorala K ,Laakso M . Poor glycemic control predicts coronary heart disease events in patients with type 1 diabetes without nephropathy. Arterioscler Thromb Vasc Biol 1999;19:1014-1019
CrossRef | Web of Science | Medline9
Orchard TJ ,Olson JC ,Erbey JR , et al. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 2003;26:1374-1379
CrossRef | Web of Science | Medline10
Diabetes Control and Complications Trial Research Group
CrossRef | Web of Science | Medline11
Diabetes Control and Complications Trial Research Group
CrossRef | Web of Science | Medline12
Epidemiology of Diabetes Interventions and Complications (EDIC): design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 1999;22:99-111
CrossRef | Web of Science | Medline13
Feasibility of centralized measurements of glycated hemoglobin in the Diabetes Control and Complications Trial (DCCT): a multicenter study. Clin Chem 1987;33:2267-2271
Web of Science | Medline14
Epidemiology of Diabetes Interventions and Complications Research Group. Protocol, 1996. (Accessed November 23, 2005, at http://www.bsc.gwu.edu/bsc/studies/edic.html.)
15
Grimm RH Jr ,Tillinghast S ,Daniels K , et al. Unrecognized myocardial infarction: experience in the Multiple Risk Factor Intervention Trial (MRFIT). Circulation 1987;75:II-6-II-8
Web of Science16
Backlund JY ,Determan A ,Cleary P . Validation of deaths and reported cardiovascular cerebrovascular events. Control Clin Trials 2003;23:2S-2S17
Snedecor GW, Cochran WG. Statistical methods. 7th ed. Ames: Iowa State University Press, 1980.
18
Lachin JM. Biostatistical methods: the assessment of relative risks. New York: John Wiley, 2000.
19
Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. 2nd ed. New York: John Wiley, 2002.
20
UK Prospective Diabetes Study (UKPDS) Group
CrossRef | Web of Science | Medline21
Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group
Full Text | Web of Science | Medline22
Cleary P ,Orchard T ,Zinman B , et al. Coronary calcification in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort. Diabetes 2003;52:Suppl 2:A152-A152 abstract.
Web of Science23
Khaw KT ,Wareham N ,Bingham S ,Luben R ,Welch A ,Day N . Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European Prospective Investigation into Cancer in Norfolk. Ann Intern Med 2004;141:413-420
Web of Science | Medline24
Vlassara H ,Palace MR . Diabetes and advanced glycation endproducts. J Intern Med 2002;251:87-101
CrossRef | Web of Science | Medline25
Monnier VM ,Bautista O ,Kenny D , et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. Diabetes 1999;48:870-880
CrossRef | Web of Science | Medline26
Basta G ,Schmidt AM ,De Caterina R . Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004;63:582-592
CrossRef | Web of Science | Medline27
Laing SP ,Swerdlow AJ ,Slater SD , et al. The British Diabetic Association Cohort Study, II: cause-specific mortality in patients with insulin-treated diabetes mellitus. Diabet Med 1999;16:466-471
CrossRef | Web of Science | Medline28
Tuomilehto J ,Borch-Johnsen K ,Molarius A , et al. Incidence of cardiovascular disease in Type 1 (insulin-dependent) diabetic subjects with and without diabetic nephropathy in Finland. Diabetologia 1998;41:784-790
CrossRef | Web of Science | Medline29
Didangelos TP ,Arsos GA ,Karamitsos DT ,Athyros VG ,Karatzas ND . Left ventricular systolic and diastolic function in normotensive type 1 diabetic patients with and without autonomic neuropathy: a radionuclide ventriculography study. Diabetes Care 2003;26:1955-1960
CrossRef | Web of Science | Medline30
Diabetes Control and Complications Trial Research Group
CrossRef | Web of Science | Medline31
Kannel WB ,Abbott RB . Incidence and prognosis of unrecognized myocardial infarction: an update on the Framingham Study. N Engl J Med 1984;311:1144-1147
Full Text | Web of Science | Medline32
Diabetes Control and Complications Trial Research Group
CrossRef | Web of Science
- Citing Articles (749)
Citing Articles
1
Jeffrey I. Mechanick, Albert E. Marchetti, Caroline Apovian, Alexander Koglin Benchimol, Peter H. Bisschop, Alexis Bolio-Galvis, Refaat A. Hegazi, David Jenkins, Enrique Mendoza, Miguel Leon Sanz, Wayne Huey-Herng Sheu, Patrizio Tatti, Man-Wo Tsang, Osama Hamdy. (2012) Diabetes-Specific Nutrition Algorithm: A Transcultural Program to Optimize Diabetes and Prediabetes Care. Current Diabetes Reports
CrossRef2
Concetta Suraci, Franca Mulas, Maria Chiara Rossi, Sandro Gentile, Carlo Bruno Giorda. (2012) Management of newly diagnosed patients with type 2 diabetes: what are the attitudes of physicians? A SUBITO!AMD survey on the early diabetes treatment in Italy. Acta Diabetologica
CrossRef3
Solène Le Douairon Lahaye, Arlette Gratas-Delamarche, Ludivine Malardé, Sami Zguira, Sophie Vincent, Sophie Lemoine Morel, François Carré, Françoise Rannou Bekono. (2012) Combined insulin treatment and intense exercise training improved basal cardiac function and Ca 2+ -cycling proteins expression in type 1 diabetic rats. Applied Physiology, Nutrition, and Metabolism 37:1, 53-62
CrossRef4
Jennifer L. Sherr, Stuart A. Weinzimer. (2012) Diabetes Types 1 and 2 in the Pediatric Population. Pediatric Annals 41:2, 63-63
CrossRef5
Hiroyuki Sasamura, Hiroshi Itoh. (2012) ‘Memory’ and ‘legacy’ in hypertension and lifestyle-related diseases. Hypertension Research
CrossRef6
(2012) Panretinal Photocoagulation for Diabetic Retinopathy. New England Journal of Medicine 366:3, 277-279
Full Text7
Miranda W. Langendam, Yoeri M Luijf, Lotty Hooft, J Hans DeVries, Aart H Mudde, Rob JPM Scholten, Miranda W. Langendam. 2012. Continuous glucose monitoring systems for type 1 diabetes mellitus. .
CrossRef8
Christine Hamann, Stephan Kirschner, Klaus-Peter Günther, Lorenz C. Hofbauer. (2012) Bone, sweet bone—osteoporotic fractures in diabetes mellitus. Nature Reviews Endocrinology
CrossRef9
Brittany Law, Vennece Fowlkes, Jack G. Goldsmith, Wayne Carver, Edie C. Goldsmith. (2012) Diabetes-Induced Alterations in the Extracellular Matrix and Their Impact on Myocardial Function. Microscopy and Microanalysis1-13
CrossRef10
Gail D. Baura. 2012. Artificial Pancreas. , 423-452.
CrossRef11
Clement Lo, Sophia Zoungas. (2012) Reducing renal failure: how low do glucose levels need to go?. Diabetes Management 2:1, 25-32
CrossRef12
William T. Cefalu. (2012) Evolving Treatment Strategies for the Management of Type 2 Diabetes. The American Journal of the Medical Sciences 343:1, 21-26
CrossRef13
Toyoaki Murohara. (2012) Dipeptidyl Peptidase-4 Inhibitor. Journal of the American College of Cardiology 59:3, 277-279
CrossRef14
Eva Horová, Jiří Mazoch, Jiřina HiIgertová, Jan Kvasnička, Jan Škrha, Jan Šoupal, Martin Prázný. (2012) Acute Hyperglycemia Does Not Impair Microvascular Reactivity and Endothelial Function during Hyperinsulinemic Isoglycemic and Hyperglycemic Clamp in Type 1 Diabetic Patients. Experimental Diabetes Research 2012, 1-8
CrossRef15
Nikhil Tandon, Mohammed K. Ali, K.M. Venkat Narayan. (2012) Pharmacologic Prevention of Microvascular and Macrovascular Complications in Diabetes Mellitus. American Journal Cardiovascular Drugs1
CrossRef16
Ofelia Llamazares Iglesias, Julia Sastre Marcos, Virginia Peña Cortés, Alessandra Luque Pazos, Bárbara Cánovas Gaillemin, Almudena Vicente Delgado, Amparo Marco Martínez, José López López. (2012) Control metabólico y de factores de riesgo cardiovascular en una cohorte de pacientes con diabetes mellitus. Resultados a los 4 años. Endocrinología y Nutrición
CrossRef17
Kevin Kaiserman, Henry Rodriguez, Amanda Stephenson, Linda Wolka, Jessie L. Fahrbach. (2012) Continuous Subcutaneous Insulin Infusion of Insulin Lispro in Children and Adolescents with Type 1 Diabetes. Endocrine Practice 1:-1, 1-24
CrossRef18
John Armato, Ralph A. DeFronzo, Muhammad Abdul-Ghani, Ron Ruby. (2012) Successful Treatment of Prediabetes in Clinical Practice: Targeting Insulin Resistance and Beta Cell Dysfunction. Endocrine Practice 1:-1, 1-21
CrossRef19
Marina Scavini, Emanuele Bosi, Antonio Ceriello, Francesco Giorgino, Massimo Porta, Antonio Tiengo, Giacomo Vespasiani, Davide Bottalico, Raffaele Marino, Christopher Parkin, Erminio Bonizzoni, Domenico Cucinotta. (2011) Prospective, randomized trial on intensive SMBG management added value in non-insulin-treated T2DM patients (PRISMA): a study to determine the effect of a structured SMBG intervention. Acta Diabetologica
CrossRef20
The DCCT/EDIC Research Group. (2011) Intensive Diabetes Therapy and Glomerular Filtration Rate in Type 1 Diabetes. New England Journal of Medicine 365:25, 2366-2376
Full Text21
2011. Complications Associated with Diabetes. , 201-249.
CrossRef22
Louisa Villeneuve, Rama Natarajan. 2011. Role of Epigenetics in the Complications Associated with Diabetes and Related Metabolic Disorders. , 41-60.
CrossRef23
Aria Setoodeh, Fereydoun Mostafavi, Tina Hedayat. (2011) Glycemic Control in Iranian Children with Type 1 Diabetes Mellitus: Effect of Gender. The Indian Journal of Pediatrics
CrossRef24
Heidi Buysse, Georges De Moor, Pascal Coorevits, Georges Van Maele, Jean Kaufman, Johannes Ruige. (2011) Main characteristics of type 1 and type 2 diabetic patients interested in the use of a telemonitoring platform. Journal of Nursing and Healthcare of Chronic Illness 3:4, 456-468
CrossRef25
Natasha A. Deters, Rebecca A. Stokes, Jenny E. Gunton. (2011) Islet Transplantation: Factors in Short-Term Islet Survival. Archivum Immunologiae et Therapiae Experimentalis 59:6, 421-429
CrossRef26
Trond Jenssen, Anders Hartmann. (2011) Prevention and management of transplant-associated diabetes. Expert Opinion on Pharmacotherapy 12:17, 2641-2655
CrossRef27
Nobuhiko Togashi, Takuto Maeda, Hideaki Yoshida, Masayuki Koyama, Marenao Tanaka, Masato Furuhashi, Kazuaki Shimamoto, Tetsuji Miura. (2011) Angiotensin II receptor activation in youth triggers persistent insulin resistance and hypertension—a legacy effect?. Hypertension Research
CrossRef28
Simon G. Anderson, Ram P. Narayanan, Jehad Amlesh, Mohammad Z. Qureshi, Adrian Hugh Heald. (2011) Type 1 diabetes in Cheshire: Cardiometabolic risk factor trends (2004–2009). Primary Care Diabetes
CrossRef29
O. Kordonouri. (2011) Diabetesprävention bei Kindern. Der Diabetologe
CrossRef30
K. L. Rensing, A. Q. Reuwer, B. J. Arsenault, J. H. von der Thüsen, J. B. L. Hoekstra, J. J. P. Kastelein, Th. B. Twickler. (2011) Reducing cardiovascular disease risk in patients with type 2 diabetes and concomitant macrovascular disease: can insulin be too much of a good thing?. Diabetes, Obesity and Metabolism 13:12, 1073-1087
CrossRef31
Assam El-Osta. (2011) Glycemic memory. Current Opinion in Lipidology1
CrossRef32
Richard R. Rubin, Mark Peyrot. (2011) Health-Related Quality of Life and Treatment Satisfaction in the Sensor-Augmented Pump Therapy for A1C Reduction 3 (STAR 3) Trial. Diabetes Technology & Therapeutics111201125050002
CrossRef33
A. Grimaldi. (2011) L’éducation thérapeutique du patient diabétique, ou apprendre à gérer l’incertitude. Médecine des Maladies Métaboliques 5:6, 638-642
CrossRef34
Ravichandran Ramasamy, Shi Fang Yan, Ann Marie Schmidt. (2011) Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Annals of the New York Academy of Sciences 1243:1, 88-102
CrossRef35
Laurence S Lim, Tien Y Wong. (2011) Lipids and diabetic retinopathy. Expert Opinion on Biological Therapy1-13
CrossRef36
Shiela M. Strauss, Janet Tuthill, Geetika Singh, David Rindskopf, Jack A. Maggiore, Robert Schoor, Anya Brodsky, Adi Einhorn, Amanda Hochstein, Stefanie Russell, Mary Rosedale. (2011) A Novel Intra-Oral Diabetes Screening Approach in Periodontal Patients: Results of a Pilot Study. Journal of Periodontology1-10
CrossRef37
Robert J. Ligthelm. (2011) Insulin analogues: how observational studies provide key insights into management of patients with type 2 diabetes mellitus. Current Medical Research and Opinion1-13
CrossRef38
Morris Mosseri, Deepak L Bhatt, Itamar Raz. (2011) Ask the Experts: Cardiovascular complications in diabetic patients. Diabetes Management 1:6, 565-570
CrossRef39
Philip E. Cryer. (2011) Death during Intensive Glycemic Therapy of Diabetes: Mechanisms and Implications. The American Journal of Medicine 124:11, 993-996
CrossRef40
Brian K Irons. (2011) Diagnosis of diabetes mellitus as a cardiovascular risk equivalent or risk factor and implications in drug therapy management. Diabetes Management 1:6, 615-626
CrossRef41
Aline Pertile Remor, Filipe José de Matos, Karina Ghisoni, Thiago Lenoir da Silva, Greici Eidt, Marília Búrigo, Andreza Fabro de Bem, Paulo César Lock Silveira, Andrés de León, Maria Cecilia Sanchez, Alexandre Hohl, Viviane Glaser, Carlos-Alberto Gonçalves, André Quincozes-Santos, Rafael Borba Rosa, Alexandra Latini. (2011) Differential effects of insulin on peripheral diabetes-related changes in mitochondrial bioenergetics: Involvement of advanced glycosylated end products. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1812:11, 1460-1471
CrossRef42
Louis Monnier, Claude Colette, David Owens. (2011) The glycemic triumvirate and diabetic complications: Is the whole greater than the sum of its component parts?. Diabetes Research and Clinical Practice
CrossRef43
Antonio Pérez, Josep Franch, Aleix Cases, José Ramón González Juanatey, Pedro Conthe, Eva Gimeno, Arantxa Matali. (2011) Relación del grado de control glucémico con las características de la diabetes y el tratamiento de la hiperglucemia en la diabetes tipo 2. Estudio DIABES. Medicina Clínica
CrossRef44
Julio Wainstein, Leonid Katz, Samuel S. Engel, Lei Xu, Gregory T. Golm, Shehla Hussain, Edward A. O'Neill, Keith D. Kaufman, Barry J. Goldstein. (2011) Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycemic control compared with pioglitazone monotherapy in patients with type 2 diabetes. Diabetes, Obesity and Metabolismno-no
CrossRef45
Karin E. Bornfeldt, Ira Tabas. (2011) Insulin Resistance, Hyperglycemia, and Atherosclerosis. Cell Metabolism 14:5, 575-585
CrossRef46
Emaad M. Abdel-Rahman, Lawand Saadulla, W. Brian Reeves, Alaa S. Awad. (2011) Therapeutic Modalities in Diabetic Nephropathy: Standard and Emerging Approaches. Journal of General Internal Medicine
CrossRef47
A. Caduff, H. U. Lutz, L. Heinemann, G. Benedetto, M. S. Talary, S. Theander. (2011) Dynamics of blood electrolytes in repeated hyper- and/or hypoglycaemic events in patients with type 1 diabetes. Diabetologia 54:10, 2678-2689
CrossRef48
Yoshifumi Saisho, Kumiko Tanaka, Takayuki Abe, Akira Shimada, Toshihide Kawai, Hiroshi Itoh. (2011) Glycated albumin to glycated hemoglobin ratio reflects postprandial glucose excursion and relates to beta cell function in both type 1 and type 2 diabetes. Diabetology International 2:3, 146-153
CrossRef49
Tadasu Kasahara, Toshika Otani, Hiroshi Maruyama, Yasuko Uchigata, Yasuhiko Iwamoto. (2011) A 60-year old patient with mild complications who developed type 1 diabetes with coma at 1 year and 7 months. Diabetology International 2:3, 154-158
CrossRef50
S. L. Ellis, E. G. Moser, J. K. Snell-Bergeon, A. S. Rodionova, R. M. Hazenfield, S. K. Garg. (2011) Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial. Diabetic Medicine 28:10, 1176-1181
CrossRef51
Richard J. MacIsaac, George Jerums. (2011) Intensive Glucose Control and Cardiovascular Outcomes in Type 2 Diabetes. Heart, Lung and Circulation 20:10, 647-654
CrossRef52
A. M. James Shapiro. (2011) State of the Art of Clinical Islet Transplantation and Novel Protocols of Immunosuppression. Current Diabetes Reports 11:5, 345-354
CrossRef53
, S. Gudbjörnsdottir, B. Eliasson, K. Eeg-Olofsson, B. Zethelius, J. Cederholm. (2011) Additive effects of glycaemia and dyslipidaemia on risk of cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register. Diabetologia 54:10, 2544-2551
CrossRef54
T. J. Orchard. (2011) EnRAGEd about death in type 1 diabetes. Diabetologia 54:10, 2480-2482
CrossRef55
M. Y. Tan, J. M. Magarey, S. S. Chee, L. F. Lee, M. H. Tan. (2011) A brief structured education programme enhances self-care practices and improves glycaemic control in Malaysians with poorly controlled diabetes. Health Education Research 26:5, 896-907
CrossRef56
David Kerr, Helen Partridge. (2011) Deus ex machina: The use of technology in type 1 diabetes. Primary Care Diabetes 5:3, 159-165
CrossRef57
A. Chaudhuri, P. Dandona. (2011) Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes. Diabetes, Obesity and Metabolism 13:10, 869-879
CrossRef58
J. I. Vidal Pardo, T. R. Pérez Castro, X. L. López Álvarez, F. J. García Soidán, M. I. Santiago Pérez, J. Muñiz. (2011) Quality of care of patients with type-2 diabetes in Galicia (NW Spain) [OBTEDIGA project]. International Journal of Clinical Practice 65:10, 1067-1075
CrossRef59
Kwame S. Amankwah. (2011) Is Hemoglobin A1c an Adequate Marker for Disease Severity and Outcome in Limb Threatening Ischemia?. Journal of Surgical Research
CrossRef60
Asako Nishimura, Taro Hayakawa, Yu Yamamoto, Mami Hamori, Keiko Tabata, Keiko Seto, Nobuhito Shibata. (2011) Controlled release of insulin from self-assembling nanofiber hydrogel, PuraMatrix™: Application for the subcutaneous injection in rats. European Journal of Pharmaceutical Sciences
CrossRef61
S. S. Moisa, A. D. Nozdrachev. (2011) Disturbances of carbohydrate metabolism and factors stimulating its development in ontogenesis. Advances in Gerontology 1:4, 310-316
CrossRef62
Olga Ellina, Antonios Chatzigeorgiou, Sophia Kouyanou, Maria Lymberi, Christina Mylona-Karagianni, Emmanouil Tsouvalas, Elli F. Kamper. (2011) Extracellular matrix-associated (GAGs, CTGF), angiogenic (VEGF) and inflammatory factors (MCP-1, CD40, IFN-γ) in type 1 diabetes mellitus nephropathy. Clinical Chemistry and Laboratory Medicine---
CrossRef63
M. H. Kollef, Y. Golan, S. T. Micek, A. F. Shorr, M. I. Restrepo. (2011) Appraising Contemporary Strategies to Combat Multidrug Resistant Gram-Negative Bacterial Infections-Proceedings and Data From the Gram-Negative Resistance Summit. Clinical Infectious Diseases 53:suppl 2, S33-S55
CrossRef64
Siri Carlsen, Per Hyltoft Petersen, Svein Skeie, Øyvind Skadberg, Sverre Sandberg. (2011) Within-subject biological variation of glucose and HbA 1c in healthy persons and in type 1 diabetes patients. Clinical Chemistry and Laboratory Medicine 49:9, 1501-1507
CrossRef65
D. Simmons, H. Wenzel. (2011) Diabetes inpatients: a case of lose, lose, lose. Is it time to use a ‘diabetes-attributable hospitalization cost’ to assess the impact of diabetes?. Diabetic Medicine 28:9, 1123-1130
CrossRef66
Nathan R. Hill, Nick S. Oliver, Pratik Choudhary, Jonathan C. Levy, Peter Hindmarsh, David R. Matthews. (2011) Normal Reference Range for Mean Tissue Glucose and Glycemic Variability Derived from Continuous Glucose Monitoring for Subjects Without Diabetes in Different Ethnic Groups. Diabetes Technology & Therapeutics 13:9, 921-928
CrossRef67
Ming-ming CAO, Nan-wei TONG. (2011) Stratifying and tailoring HbA1c control targets for adults with Type 2 diabetes: Interpretation of the consensus proposed by the Chinese Society of Endocrinology. Journal of Diabetes 3:3, 201-207
CrossRef68
Sho-ichi Yamagishi, Takanori Matsui. (2011) Nitric oxide, a janus-faced therapeutic target for diabetic microangiopathy—Friend or foe?. Pharmacological Research 64:3, 187-194
CrossRef69
Zachary Bloomgarden, Yehuda Handelsman, Daniel Einhorn. (2011) Diabetes cardiovascular treatment = Sugar + BP + lipids. Journal of Diabetesno-no
CrossRef70
K. Yamada, A. Hirakata, V. Tchipashvili, A. Shimizu, H. Iwaki, A. Griesemer, P. Vallabhajosyula, S. Moran, D. H. Sachs. (2011) Composite Islet-kidneys From Single Baboon Donors Cure Diabetes Across Fully Allogenic Barriers. American Journal of Transplantationno-no
CrossRef71
Jaime S Rosa, Stacy R Oliver, Rebecca L Flores, Jerry Ngo, Ginger L Milne, Frank P Zaldivar, Pietro R Galassetti. (2011) Altered inflammatory, oxidative, and metabolic responses to exercise in pediatric obesity and type 1 diabetes. Pediatric Diabetes 12:5, 464-472
CrossRef72
Ralph A. DeFronzo, Muhammad Abdul-Ghani. (2011) Assessment and Treatment of Cardiovascular Risk in Prediabetes: Impaired Glucose Tolerance and Impaired Fasting Glucose. The American Journal of Cardiology 108:3, 3B-24B
CrossRef73
Peter M. Nilsson. (2011) Target blood pressure in diabetes patients with hypertension —What is the accumulated evidence in 2011?. Journal of Zhejiang University SCIENCE B 12:8, 611-623
CrossRef74
S.-W. Oh, H. J. Lee, H. J. Chin, J.-I. Hwang. (2011) Adherence to clinical practice guidelines and outcomes in diabetic patients. International Journal for Quality in Health Care 23:4, 413-419
CrossRef75
Patrick A. Rowe, Kylie Kavanagh, Li Zhang, H. James Harwood, Janice D. Wagner. (2011) Short-term hyperglycemia increases arterial superoxide production and iron dysregulation in atherosclerotic monkeys. Metabolism 60:8, 1070-1080
CrossRef76
Dimitrios T. Karamitsos. (2011) Antiatheromatic effects of insulin. Diabetes Research and Clinical Practice 93, S105-S108
CrossRef77
Chi Yuen Chan, Ruijie Li, Joseph Yat Sun Chan, Qing Zhang, Chin Pang Chan, Ming Dong, Bryan P. Yan, Yat-Yin Lam, Cheuk-Man Yu. (2011) The Value of Admission HbA1c Level in Diabetic Patients With Acute Coronary Syndrome. Clinical Cardiology 34:8, 507-512
CrossRef78
Jorge Plutzky. (2011) Macrovascular Effects and Safety Issues of Therapies for Type 2 Diabetes. The American Journal of Cardiology 108:3, 25B-32B
CrossRef79
Sharon B. Dybicz, Stephen Thompson, Sandra Molotsky, Bruce Stuart. (2011) Prevalence of Diabetes and the Burden of Comorbid Conditions Among Elderly Nursing Home Residents. The American Journal of Geriatric Pharmacotherapy 9:4, 212-223
CrossRef80
Rachel A. Jones, Natalie Sinn, Karen J. Campbell, Kylie Hesketh, Elizabeth Denney-Wilson, Philip J. Morgan, David R. Lubans, Anthea Magarey. (2011) The importance of long-term follow-up in child and adolescent obesity prevention interventions. International Journal of Pediatric Obesity 6:3-4, 178-181
CrossRef81
Massimo Volpe, Francesco Cosentino, Giuliano Tocci, Francesca Palano, Francesco Paneni. (2011) Antihypertensive Therapy in Diabetes: The Legacy Effect and RAAS Blockade. Current Hypertension Reports 13:4, 318-324
CrossRef82
Sherita Hill Golden. (2011) Emerging Therapeutic Approaches for the Management of Diabetes Mellitus and Macrovascular Complications. The American Journal of Cardiology 108:3, 59B-67B
CrossRef83
Marcus Lind, Ioannis Bounias, Marita Olsson, Soffia Gudbjörnsdottir, Ann-Marie Svensson, Annika Rosengren. (2011) Glycaemic control and incidence of heart failure in 20 985 patients with type 1 diabetes: an observational study. The Lancet 378:9786, 140-146
CrossRef84
Sagit Zolotov, Dafna Ben Yosef, Naphtali D Rishe, Yelena Yesha, Eddy Karnieli. (2011) Metabolic profiling in personalized medicine: bridging the gap between knowledge and clinical practice in Type 2 diabetes. Personalized Medicine 8:4, 445-456
CrossRef85
Cosimo Giannini, A. Mohn, F. Chiarelli, C. J. H. Kelnar. (2011) Macrovascular angiopathy in children and adolescents with type 1 diabetes. Diabetes/Metabolism Research and Reviews 27:5, 436-460
CrossRef86
George Dailey. (2011) Rapid-acting insulin glulisine: an update on clinical experience. Expert Review of Endocrinology & Metabolism 6:4, 527-542
CrossRef87
Susan L. Johnson, Laura N. McEwen, Christopher A. Newton, Catherine L. Martin, Philip Raskin, Jeffrey B. Halter, William H. Herman. (2011) The impact of continuous subcutaneous insulin infusion and multiple daily injections of insulin on glucose variability in older adults with type 2 diabetes. Journal of Diabetes and its Complications 25:4, 211-215
CrossRef88
Drazenka Pongrac Barlovic, Aino Soro
Paavonen, Karin A. M. Jandeleit
CrossRef89
Lionel H Opie. (2011) Glycaemia and heart failure in diabetes types 1 and 2. The Lancet 378:9786, 103-104
CrossRef90
Louisa M Villeneuve, Marpadga A Reddy, Rama Natarajan. (2011) Epigenetics: deciphering its role in diabetes and its chronic complications. Clinical and Experimental Pharmacology and Physiology 38:7, 451-459
CrossRef91
Po-Hsun Huang, Jia-Shiong Chen, Hsiao-Ya Tsai, Yung-Hsiang Chen, Feng-Yen Lin, Hsin-Bang Leu, Tao-Cheng Wu, Shing-Jong Lin, Jaw-Wen Chen. (2011) Globular adiponectin improves high glucose-suppressed endothelial progenitor cell function through endothelial nitric oxide synthase dependent mechanisms. Journal of Molecular and Cellular Cardiology 51:1, 109-119
CrossRef92
Garth J.S. Cooper. (2011) Therapeutic Potential of Copper Chelation with Triethylenetetramine in Managing Diabetes Mellitus and Alzheimerʼs Disease. Drugs 71:10, 1281-1320
CrossRef93
Sanjay Gandhi, Ido Weinberg, Ronan Margey, Michael R. Jaff. (2011) Comprehensive Medical Management of Peripheral Arterial Disease. Progress in Cardiovascular Diseases 54:1, 2-13
CrossRef94
Stavroula Kousteni. (2011) FoxO1, the transcriptional chief of staff of energy metabolism. Bone
CrossRef95
Tomohiro Nishizawa, Karin E. Bornfeldt. (2011) Diabetic vascular disease and the potential role of macrophage glucose metabolism. Annals of Medicine1-9
CrossRef96
Bianca Hemmingsen, Søren S Lund, Christian Gluud, Allan Vaag, Thomas Almdal, Christina Hemmingsen, Jørn Wetterslev, Bianca Hemmingsen. 2011. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. .
CrossRef97
Jardena J. Puder, Christian Schindler, Lukas Zahner, Susi Kriemler. (2011) Adiposity, fitness and metabolic risk in children: A cross-sectional and longitudinal study. International Journal of Pediatric Obesity 6:2-2, e297-e306
CrossRef98
Angela Yee-Moon WANG. (2011) Cardiovascular risk in diabetic end-stage renal disease patients. Journal of Diabetes 3:2, 119-131
CrossRef99
, L. G. Mellbin, K. Malmberg, A. Norhammar, H. Wedel, L. Rydén. (2011) Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin–Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study. Diabetologia 54:6, 1308-1317
CrossRef100
Richard E Gilbert, Qingling Huang, Kerri Thai, Suzanne L Advani, Kodie Lee, Darren A Yuen, Kim A Connelly, Andrew Advani. (2011) Histone deacetylase inhibition attenuates diabetes-associated kidney growth: potential role for epigenetic modification of the epidermal growth factor receptor. Kidney International 79:12, 1312-1321
CrossRef101
Frank Waldron-Lynch, Kevan C. Herold. (2011) Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes. Nature Reviews Drug Discovery 10:6, 439-452
CrossRef102
Nicole S Glaser, David H Geller, Andrea Haqq, Stephen Gitelman, Mary Malloy, . (2011) Detecting and treating hyperlipidemia in children with type 1 diabetes mellitus: are standard guidelines applicable to this special population?*. Pediatric Diabetes 12:4pt2, 442-459
CrossRef103
Stuart Little, James Shaw, Philip Home. (2011) Hypoglycemia Rates with Basal Insulin Analogs. Diabetes Technology & Therapeutics 13:S1, S-53-S-64
CrossRef104
AO Oduwole, RI Uko, T Tade, OK Doherty, R Nwodo, EO Imafidon. (2011) The effect of home visits on the quality of life of children and adolescents with type 1 diabetes mellitus. Pediatric Diabetes 12:4pt1, 335-340
CrossRef105
A. Pfützner, E. Paz-Pacheco, E. Allen, R. Frederich, R. Chen, . (2011) Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity and Metabolism 13:6, 567-576
CrossRef106
Kristen J. Nadeau, Jane E. B. Reusch. (2011) Cardiovascular Function/Dysfunction in Adolescents with Type 1 Diabetes. Current Diabetes Reports 11:3, 185-192
CrossRef107
Antonella Brunello, Rachna Kapoor, Martine Extermann. (2011) Hyperglycemia During Chemotherapy for Hematologic and Solid Tumors Is Correlated With Increased Toxicity. American Journal of Clinical Oncology 34:3, 292-296
CrossRef108
Geremia B. Bolli, Anna Marinelli Andreoli, Paola Lucidi. (2011) Optimizing the Replacement of Basal Insulin in Type 1 Diabetes Mellitus: No Longer an Elusive Goal in the Post-NPH Era. Diabetes Technology & Therapeutics 13:S1, S-43-S-52
CrossRef109
George Dailey. (2011) Overall Mortality in Diabetes Mellitus: Where Do We Stand Today?. Diabetes Technology & Therapeutics 13:S1, S-65-S-74
CrossRef110
Roberto Testa, Fabiola Olivieri, Antonio Ceriello, Lucia Sala. (2011) Biologia dell’invecchiamento. La Rivista Italiana della Medicina di Laboratorio - Italian Journal of Laboratory Medicine 7:2, 65-72
CrossRef111
Satish K. Garg, Emily G. Moser. (2011) How Basal Insulin Analogs Have Changed Diabetes Care. Diabetes Technology & Therapeutics 13:S1, S-1-S-4
CrossRef112
Ibiayi Dagogo-Jack, Samuel Dagogo-Jack. (2011) Dissociation Between Cardiovascular Risk Markers and Clinical Outcomes in African Americans: Need for Greater Mechanistic Insight. Current Cardiovascular Risk Reports 5:3, 200-206
CrossRef113
M. A. Reddy, R. Natarajan. (2011) Epigenetic mechanisms in diabetic vascular complications. Cardiovascular Research 90:3, 421-429
CrossRef114
Baris Afsar, Rengin Elsurer. (2011) The primary arteriovenous fistula failure—a comparison between diabetic and non-diabetic patients: glycemic control matters. International Urology and Nephrology
CrossRef115
Kim Henriksen, Inger Byrjalsen, Per Qvist, Henning Beck-Nielsen, Gitte Hansen, Bente J. Riis, Hans Perrild, Ole Lander Svendsen, Jeppe Gram, Morten A. Karsdal, Claus Christiansen, . (2011) Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy. Diabetes/Metabolism Research and Reviews 27:4, 392-401
CrossRef116
K. A. Han, Y. Patel, A. A. Lteif, R. Chisholm, Kieren J. Mather. (2011) Contributions of dysglycaemia, obesity, and insulin resistance to impaired endothelium-dependent vasodilation in humans. Diabetes/Metabolism Research and Reviews 27:4, 354-361
CrossRef117
Jodie Katon, Michelle A. Williams, Gayle Reiber, Edith Miller. (2011) Antepartum A1C, maternal diabetes outcomes, and selected offspring outcomes: an epidemiological review. Paediatric and Perinatal Epidemiology 25:3, 265-276
CrossRef118
D. Albrecht, J. Puder, U. Keller, H. Zulewski. (2011) Potential of education-based insulin therapy for achievement of good metabolic control: a real-life experience. Diabetic Medicine 28:5, 539-542
CrossRef119
Katrien Benhalima, Eberhard Standl, Chantal Mathieu. (2011) The importance of glycemic control: how low should we go with HbA1c? Start early, go safe, go low. Journal of Diabetes and its Complications 25:3, 202-207
CrossRef120
Aaron M. Secrest, Tina Costacou, Bruce Gutelius, Rachel G. Miller, Thomas J. Songer, Trevor J. Orchard. (2011) Associations Between Socioeconomic Status and Major Complications in Type 1 Diabetes: The Pittsburgh Epidemiology of Diabetes Complication (EDC) Study. Annals of Epidemiology 21:5, 374-381
CrossRef121
Edwin B. Fisher, Marian L. Fitzgibbon, Russell E. Glasgow, Debra Haire-Joshu, Laura L. Hayman, Robert M. Kaplan, Marilyn S. Nanney, Judith K. Ockene. (2011) Behavior Matters. American Journal of Preventive Medicine 40:5, e15-e30
CrossRef122
Andrew Advani, Qingling Huang, Kerri Thai, Suzanne L. Advani, Kathryn E. White, Darren J. Kelly, Darren A. Yuen, Kim A. Connelly, Philip A. Marsden, Richard E. Gilbert. (2011) Long-Term Administration of the Histone Deacetylase Inhibitor Vorinostat Attenuates Renal Injury in Experimental Diabetes through an Endothelial Nitric Oxide Synthase-Dependent Mechanism. The American Journal of Pathology 178:5, 2205-2214
CrossRef123
Pieter Gillard, Chantal Mathieu. (2011) Immune and cell therapy in type 1 diabetes: too little too late?. Expert Opinion on Biological Therapy 11:5, 609-621
CrossRef124
Brian M. Cummins, Jongdoo Lim, Eric E. Simanek, Michael V. Pishko, Gerard L. Coté. (2011) Encapsulation of a Concanavalin A/dendrimer glucose sensing assay within microporated poly (ethylene glycol) microspheres. Biomedical Optics Express 2:5, 1243
CrossRef125
Adie Viljoen, Alan J. Sinclair. (2011) Diabetes and Insulin Resistance in Older People. Medical Clinics of North America 95:3, 615-629
CrossRef126
Amparo B. Gonzalez, Daniela Salas, Guillermo E. Umpierrez. (2011) Special considerations on the management of Latino patients with type 2 diabetes mellitus. Current Medical Research and Opinion 27:5, 969-979
CrossRef127
Hunter Wessells, David F. Penson, Patricia Cleary, Brandy N. Rutledge, John M. Lachin, Kevin T. McVary, David S. Schade, Aruna V. Sarma. (2011) Effect of Intensive Glycemic Therapy on Erectile Function in Men With Type 1 Diabetes. The Journal of Urology 185:5, 1828-1834
CrossRef128
Edelmiro Menéndez Torre, Francisco Javier Lafita Tejedor, Sara Artola Menéndez, Jesús Millán Núñez-Cortés, Ángeles Alonso García, Manuel Puig Domingo, José Ramón García Solans, Fernando Álvarez Guisasola, Javier García Alegría, Javier Mediavilla Bravo, Carlos Miranda Fernández-Santos, Ramón Romero González. (2011) Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2. Atención Primaria 43:4, 202.e1-202.e9
CrossRef129
Sei J. Lee, W. John Boscardin, Irena Stijacic Cenzer, Elbert S. Huang, Kathy Rice-Trumble, Catherine Eng. (2011) The Risks and Benefits of Implementing Glycemic Control Guidelines in Frail Older Adults with Diabetes Mellitus. Journal of the American Geriatrics Society 59:4, 666-672
CrossRef130
A. R. Miller, T. D. Nebesio, L. A. DiMeglio. (2011) Insulin dose changes in children attending a residential diabetes camp. Diabetic Medicine 28:4, 480-486
CrossRef131
Tomohisa Tada, Takeshi Kimura, Takeshi Morimoto, Koh Ono, Yutaka Furukawa, Yoshihisa Nakagawa, Hitoshi Nakashima, Akira Ito, Nobuo Siode, Masanobu Namura, Naoto Inoue, Hideo Nishikawa, Koichi Nakao, Kazuaki Mitsudo. (2011) Comparison of Three-Year Clinical Outcomes After Sirolimus-Eluting Stent Implantation Among Insulin-Treated Diabetic, Non–Insulin-Treated Diabetic, and Non-Diabetic Patients from j-Cypher Registry. The American Journal of Cardiology 107:8, 1155-1162
CrossRef132
David Simmons, Patrick English, Peter Robins, Andrew Craig, Rachael Addicott. (2011) Should diabetes be commissioned through multidisciplinary networks, rather than Practice Based Commissioning?. Primary Care Diabetes 5:1, 39-44
CrossRef133
Matthew C Riddle. (2011) Glycemic control and cardiovascular mortality. Current Opinion in Endocrinology, Diabetes and Obesity 18:2, 104-109
CrossRef134
Mariela Glandt, Zachary T. Bloomgarden. (2011) Hypertension in Diabetes: Treatment Considerations. The Journal of Clinical Hypertension 13:4, 314-318
CrossRef135
Richard B. Aguilar. (2011) Evaluating Treatment Algorithms for the Management of Patients With Type 2 Diabetes Mellitus: A Perspective on the Definition of Treatment Success. Clinical Therapeutics 33:4, 408-424
CrossRef136
Ronald J. Pettis, Barry Ginsberg, Laurence Hirsch, Diane Sutter, Steven Keith, Elaine McVey, Noel G. Harvey, Marcus Hompesch, Leszek Nosek, Christoph Kapitza, Lutz Heinemann. (2011) Intradermal Microneedle Delivery of Insulin Lispro Achieves Faster Insulin Absorption and Insulin Action than Subcutaneous Injection. Diabetes Technology & Therapeutics 13:4, 435-442
CrossRef137
S. D. Aspriello, A. Zizzi, G. Tirabassi, E. Buldreghini, T. Biscotti, E. Faloia, D. Stramazzotti, M. Boscaro, M. Piemontese. (2011) Diabetes mellitus-associated periodontitis: differences between type 1 and type 2 diabetes mellitus. Journal of Periodontal Research 46:2, 164-169
CrossRef138
Shanmugam Kondeti Ramudu, K. Mallikarjuna, Sathyavelu Reddy Kesireddy. (2011) Efficacy of ethanolic extract of ginger on kidney lipid metabolic profiles in diabetic rats. International Journal of Diabetes in Developing Countries 31:2, 97-103
CrossRef139
Elizabeth A. Pyatak. (2011) The Role of Occupational Therapy in Diabetes Self-Management Interventions. OTJR: Occupation, Participation, Health 31:2, 89-96
CrossRef140
A. Patel, E. Maissi, H.-C. Chang, I. Rodrigues, M. Smith, S. Thomas, T. Chalder, U. Schmidt, J. Treasure, K. Ismail. (2011) Motivational enhancement therapy with and without cognitive behaviour therapy for Type 1 diabetes: economic evaluation from a randomized controlled trial. Diabetic Medicine 28:4, 470-479
CrossRef141
Alexandria M. Dailey, Lisa R. Tannock. (2011) Extreme Insulin Resistance: Indications and Approaches to the Use of U-500 Insulin in Type 2 Diabetes Mellitus. Current Diabetes Reports 11:2, 77-82
CrossRef142
Sho-ichi Yamagishi. (2011) Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Experimental Gerontology 46:4, 217-224
CrossRef143
Rami Almokayyad, Robert Cuddihy. 2011. What is the Role of Self-Monitoring in Diabetes? Is there a Role for Postprandial Glucose Monitoring? How does Continuous Glucose Monitoring Integrate into Clinical Practice?. , 41-55.
CrossRef144
Deepika S. Reddy, Vivian Fonseca. 2011. Screening Patients with Prediabetes and Diabetes for Cardiovascular Disease. , 34-40.
CrossRef145
DeFronzo, Ralph A., Tripathy, Devjit, Schwenke, Dawn C., Banerji, MaryAnn, Bray, George A., Buchanan, Thomas A., Clement, Stephen C., Henry, Robert R., Hodis, Howard N., Kitabchi, Abbas E., Mack, Wendy J., Mudaliar, Sunder, Ratner, Robert E., Williams, Ken, Stentz, Frankie B., Musi, Nicolas, Reaven, Peter D., . (2011) Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance. New England Journal of Medicine 364:12, 1104-1115
Full Text146
Faer S Morrison, Karen A Johnstone, Lorna W Harries. (2011) Physiological effects of Type 2 diabetes on mRNA processing and gene expression. Expert Review of Endocrinology & Metabolism 6:2, 255-267
CrossRef147
Sofiya Milman, Jill P. Crandall. (2011) Mechanisms of Vascular Complications in Prediabetes. Medical Clinics of North America 95:2, 309-325
CrossRef148
E. Menéndez Torre, J. Lafita Tejedor, S. Artola Menéndez, J. Millán Núñez-Cortés, Á. Alonso García, M. Puig Domingo, J.R. García Solans, F. Álvarez Guisasola, J. García Alegría, J. Mediavilla Bravo, C. Miranda Fernández-Santos, R. Romero González. (2011) Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2. Revista Clínica Española 211:3, 147-155
CrossRef149
Rosalinda Madonna, Raffaele De Caterina. (2011) Cellular and molecular mechanisms of vascular injury in diabetes — Part I: Pathways of vascular disease in diabetes. Vascular Pharmacology 54:3-6, 68-74
CrossRef150
Philip E Otterbeck, Mary Ann Banerji. (2011) The efficacy and safety of vildagliptin in the GALIANT trial: chronic kidney disease and other applications. Expert Review of Endocrinology & Metabolism 6:2, 143-151
CrossRef151
Sho-ichi Yamagishi, Sayaka Maeda, Takanori Matsui, Seiji Ueda, Kei Fukami, Seiya Okuda. (2011) Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes. Biochimica et Biophysica Acta (BBA) - General Subjects
CrossRef152
C. Lamanna, M. Monami, N. Marchionni, E. Mannucci. (2011) Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes, Obesity and Metabolism 13:3, 221-228
CrossRef153
Harold E. Lebovitz. (2011) Type 2 diabetes mellitus—current therapies and the emergence of surgical options. Nature Reviews Endocrinology 7:7, 408-419
CrossRef154
Andrea E. Scaramuzza, Dario Iafusco, Ivana Rabbone, Riccardo Bonfanti, Fortunato Lombardo, Riccardo Schiaffini, Pietro Buono, Sonia Toni, Valentino Cherubini, Gian Vincenzo Zuccotti, for the Diabetes Study Gr. (2011) Use of Integrated Real-Time Continuous Glucose Monitoring/Insulin Pump System in Children and Adolescents with Type 1 Diabetes: A 3-Year Follow-Up Study. Diabetes Technology & Therapeutics 13:2, 99-103
CrossRef155
Taro Hayakawa, Michiyo Ishii, Megumi Watanabe, Hiroya Iwase, Asako Nishimura, Takako Monden, Kenji Kamiuchi, Motohide Isono, Nobuhito Shibata. (2011) Replacement of neutral protamine Hagedorn insulin with the long-acting insulin analogue, detemir, improves glycemic control without weight gain in basal-bolus insulin therapy in Japanese patients with type 1 diabetes. Journal of Diabetes Investigation 2:1, 71-77
CrossRef156
Thomas G. Brott, Jonathan L. Halperin, Suhny Abbara, J. Michael Bacharach, John D. Barr, Ruth L. Bush, Christopher U. Cates, Mark A. Creager, Susan B. Fowler, Gary Friday, Vicki S. Hertzberg, E. Bruce McIff, Wesley S. Moore, Peter D. Panagos, Thomas S. Riles, Robert H. Rosenwasser, Allen J. Taylor. (2011) 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease. Journal of the American College of Cardiology 57:8, e16-e94
CrossRef157
K. H. Yoon, G. R. Shockey, R. Teng, G. T. Golm, P. R. Thakkar, A. G. Meehan, D. E. Williams-Herman, K. D. Kaufman, J. M. Amatruda, H. Steinberg. (2011) Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes. International Journal of Clinical Practice 65:2, 154-164
CrossRef158
M. Kacerovsky, A. Brehm, M. Chmelik, A. I. Schmid, J. Szendroedi, G. Kacerovsky-Bielesz, P. Nowotny, A. Lettner, M. Wolzt, J. G. Jones, M. Roden. (2011) Impaired insulin stimulation of muscular ATP production in patients with type 1 diabetes. Journal of Internal Medicine 269:2, 189-199
CrossRef159
B. Charbonnel, B. Cariou. (2011) Pharmacological management of type 2 diabetes: the potential of incretin-based therapies. Diabetes, Obesity and Metabolism 13:2, 99-117
CrossRef160
Eiichi Araki, Hideo Fukushima, Hideki Kishikawa. (2011) HbA1c: The lower the better?. Journal of Diabetes Investigation 2:1, 45-47
CrossRef161
, P. Zimmer. (2011) Bedeutung von körperlicher Aktivität beim Typ-1-Diabetes. Der Diabetologe 7:1, 27-30
CrossRef162
Thomas G. Brott, Jonathan L. Halperin, Suhny Abbara, J. Michael Bacharach, John D. Barr, Ruth L. Bush, Christopher U. Cates, Mark A. Creager, Susan B. Fowler, Gary Friday, Vicki S. Hertzberg, E. Bruce McIff, Wesley S. Moore, Peter D. Panagos, Thomas S. Riles, Robert H. Rosenwasser, Allen J. Taylor. (2011) 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive Summary. Journal of the American College of Cardiology 57:8, 1002-1044
CrossRef163
Toshiko Takao, Takehiko Ide, Hiroyuki Yanagisawa, Masatoshi Kikuchi, Shoji Kawazu, Yutaka Matsuyama. (2011) The effects of fasting plasma glucose variability and time-dependent glycemic control on the long-term risk of retinopathy in type 2 diabetic patients. Diabetes Research and Clinical Practice 91:2, e40-e42
CrossRef164
Mark Stolar. (2011) Addressing Cardiovascular Risk in Patients With Type 2 Diabetes: Focus on Primary Care. The American Journal of the Medical Sciences 341:2, 132-140
CrossRef165
Jessica Beckwith, John A. Nyman, Brian Flanagan, Rudolf Schrover, Henk-Jan Schuurman. (2011) A health economic analysis of clinical islet transplantation. Clinical Transplantationno-no
CrossRef166
Ahamed Seyd P.T., Paul K. Joseph, Jeevamma Jacob. (2011) Automated Diagnosis of Diabetes Using Heart Rate Variability Signals. Journal of Medical Systems
CrossRef167
Hirohito Sone. (2011) Prevention and management of atherosclerotic complications of diabetes. Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics 48:3, 253-256
CrossRef168
Matthias Oelze, Maike Knorr, Swenja Schuhmacher, Tjebo Heeren, Christian Otto, Eberhard Schulz, Kurt Reifenberg, Philip Wenzel, Thomas Münzel, Andreas Daiber. (2011) Vascular Dysfunction in Streptozotocin-Induced Experimental Diabetes Strictly Depends on Insulin Deficiency. Journal of Vascular Research 48:4, 275-284
CrossRef169
Rama S Dwivedi, James G Herman, Timothy A McCaffrey, Dominic S C Raj. (2011) Beyond genetics: epigenetic code in chronic kidney disease. Kidney International 79:1, 23-32
CrossRef170
Ebenezer A. Nyenwe, Terri W. Jerkins, Guillermo E. Umpierrez, Abbas E. Kitabchi. (2011) Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. Metabolism 60:1, 1-23
CrossRef171
Thomas G. Brott, Jonathan L. Halperin, Suhny Abbara, J. Michael Bacharach, John D. Barr, Ruth L. Bush, Christopher U. Cates, Mark A. Creager, Susan B. Fowler, Gary Friday, Vicki S. Hertzberg, E. Bruce McIff, Wesley S. Moore, Peter D. Panagos, Thomas S. Riles, Robert H. Rosenwasser, Allen J. Taylor, Alice K. Jacobs, Sidney C. Smith, Jeffery L. Anderson, Cynthia D. Adams, Nancy Albert, Christopher E. Buller, Mark A. Creager, Steven M. Ettinger, Robert A. Guyton, Jonathan L. Halperin, Judith S. Hochman, Sharon Ann Hunt, Harlan M. Krumholz, Frederick G. Kushner, Bruce W. Lytle, Rick A. Nishimura, E. Magnus Ohman, Richard L. Page, Barbara Riegel, William G. Stevenson, Lynn G. Tarkington, Clyde W. Yancy. (2011) 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive summary. Catheterization and Cardiovascular Interventionsn/a-n/a
CrossRef172
Jin Sook Kwon, Yong Sook Kim, Ae Shin Cho, Jeong Sook Kim, Seo Yeon Jeong, Moon Hwa Hong, Myung Ho Jeong, Youngkeun Ahn. (2011) Origin of Restenosis after Drug-Eluting Stent Implantation in Hyperglycemia is Inflammatory Cells and Thrombus. Journal of Atherosclerosis and Thrombosis 18:7, 604-615
CrossRef173
Wendy A Davis. (2011) Predicting severe hypoglycemia in the community: a review of recent evidence. Diabetes Management 1:1, 109-128
CrossRef174
Matthias Huber, Peter Heiduschka, Focke Ziemssen, Juliane Bolbrinker, Reinhold Kreutz. (2011) Microangiopathy and visual deficits characterize the retinopathy of a spontaneously hypertensive rat model with type 2 diabetes and metabolic syndrome. Hypertension Research 34:1, 103-112
CrossRef175
Chia-Hung Lin, Chung-Huei Huang, Jir-Shiong Tsai, Sheng-Hwu Hsieh, Jui-Hung Sun, Bie-Yui Huang, Miau-Ju Huang, Yu-Yao Huang. (2011) Effects of a novel short-term continuous subcutaneous insulin infusion program evaluated by continuous glucose monitoring on young adult type 1 diabetic patients in Taiwan. Endocrine Journal 58:10, 835-840
CrossRef176
Mark Angelo, Charles Ruchalski, Barbara J. Sproge. (2011) An Approach to Diabetes Mellitus in Hospice and Palliative Medicine. Journal of Palliative Medicine 14:1, 83-87
CrossRef177
Edelmiro Menéndez Torre, Francisco Javier Lafita Tejedor, Sara Artola Menéndez, Jesús Millán Núñez-Cortés, Ángeles Alonso García, Manuel Puig Domingo, José Ramón García Solans, Fernando Álvarez Guisasola, Javier García Alegría, Javier Mediavilla Bravo, Carlos Miranda Fernández-Santos, Ramón Romero González. (2011) Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2. Clínica e Investigación en Arteriosclerosis 23:1, 40-48
CrossRef178
Fatemeh Moheimani, Joanne T. M. Tan, Bronwyn E. Brown, Alison K. Heather, David M. van Reyk, Michael J. Davies. (2011) Effect of Exposure of Human Monocyte-Derived Macrophages to High, versus Normal, Glucose on Subsequent Lipid Accumulation from Glycated and Acetylated Low-Density Lipoproteins. Experimental Diabetes Research 2011, 1-10
CrossRef179
A. Sambanis. 2011. Artificial Organs | Pancreas. , 699-711.
CrossRef180
Edelmiro Menéndez Torre, Francisco Javier Lafita Tejedor, Sara Artola Menéndez, Jesús Millán Núñez-Cortés, Ángeles Alonso García, Manuel Puig Domingo, José Ramón García Solans, Fernando Álvarez Guisasola, Javier García Alegría, Javier Mediavilla Bravo, Carlos Miranda Fernández-Santos, Ramón Romero González. (2011) Recommendations for the pharmacological treatment of hyperglycemia in type 2 diabetes. Endocrinología y Nutrición (English Edition) 58:3, 112-120
CrossRef181
Ulrich M. Vischer. (2011) Glycemic Targets for Elderly Diabetic Patients Need Reappraisal. Journal of the American Medical Directors Association 12:1, 9-11
CrossRef182
Abdelmoneim Awad, Hala Dalle, Hannes Enlund. (2011) Diabetic Patients’ Knowledge of Therapeutic Goals in Kuwait. Medical Principles and Practice 20:2, 118-123
CrossRef183
Lisa M Younk, Maia Mikeladze, Donna Tate, Stephen N Davis. (2011) Exercise-related hypoglycemia in diabetes mellitus. Expert Review of Endocrinology & Metabolism 6:1, 93-108
CrossRef184
Robert Ratner, Jenny Han, Dawn Nicewarner, Irina Yushmanova, Byron J Hoogwerf, Larry Shen. (2011) Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovascular Diabetology 10:1, 22
CrossRef185
Hyun Jeong Jeon, Tae Keun Oh. (2011) Comparison of Vildagliptin-Metformin and Glimepiride-Metformin Treatments in Type 2 Diabetic Patients. Diabetes & Metabolism Journal 35:5, 529
CrossRef186
Kiranmai Durvasula, Peter M. Thulé, Athanassios Sambanis. (2011) Combinatorial insulin secretion dynamics of recombinant hepatic and enteroendocrine cells. Biotechnology and Bioengineeringn/a-n/a
CrossRef187
Hiroaki Muramoto, Kin-ya Kitada, Hisao Mutoh, Masayoshi Takeuchi. (2011) Serum levels of advanced glycation end-products in hemodialysis patients. Nihon Toseki Igakkai Zasshi 44:10, 1015-1021
CrossRef188
P. Georgiou, C. Toumazou. (2011) Semiconductors for early detection and therapy. Electronics Letters 47:26, S4
CrossRef189
In-Kyung Jeong, Da Hee Oh, Seung-Joon Park, Ja-Heon Kang, Sunshin Kim, Myung-Shik Lee, Myung-Jun Kim, Yoo-Chul Hwang, Kyu Jeong Ahn, Ho-Yeon Chung, Min-Kyung Chae, Hyung-Joon Yoo. (2011) Inhibition of NF-κB prevents high glucose-induced proliferation and plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Experimental and Molecular Medicine 43:12, 684
CrossRef190
Juliet A. Emamaullee, Michael McCall, A.M. James Shapiro. 2011. Clinical Islet Transplantation. , 795-816.
CrossRef191
Andrew Siebel, Ana Fernandez, Assam El-Osta. 2010. Glycemic Memory and Epigenetic Changes. , 215-227.
CrossRef192
Om P. Ganda. (2010) The Role of Bile Acid Sequestrants in the Management of Type 2 Diabetes Mellitus. Metabolic Syndrome and Related Disorders 8:S1, S-15-S-21
CrossRef193
Larry A. Distiller, Barry I. Joffe, Vanessa Brown, Greg B. Distiller. (2010) The Effect of Features of the Metabolic Syndrome on Atherosclerotic Risk in Relatively Long-Surviving Patients with Type 1 Diabetes. Metabolic Syndrome and Related Disorders 8:6, 539-543
CrossRef194
D. M. Maahs, L. G. Ogden, D. Dabelea, J. K. Snell-Bergeon, S. R. Daniels, R. F. Hamman, M. Rewers. (2010) Association of glycaemia with lipids in adults with type 1 diabetes: modification by dyslipidaemia medication. Diabetologia 53:12, 2518-2525
CrossRef195
Howard Zisser, Robin Wagner, Stefan Pleus, Cornelia Haug, Nina Jendrike, Chris Parkin, Matthias Schweitzer, Guido Freckmann. (2010) Clinical Performance of Three Bolus Calculators in Subjects with Type 1 Diabetes Mellitus: A Head-to-Head-to-Head Comparison. Diabetes Technology & Therapeutics 12:12, 955-961
CrossRef196
R. Valdes-Gonzalez, A. L. Rodriguez-Ventura, D. J. G. White, E. Bracho-Blanchet, A. Castillo, B. Ramírez-González, M. G. López-Santos, B. H. León-Mancilla, L. M. Dorantes. (2010) Long-term follow-up of patients with type 1 diabetes transplanted with neonatal pig islets. Clinical & Experimental Immunology 162:3, 537-542
CrossRef197
Marion J. Franz, Margaret A. Powers, Carolyn Leontos, Lea Ann Holzmeister, Karmeen Kulkarni, Arlene Monk, Naomi Wedel, Erica Gradwell. (2010) The Evidence for Medical Nutrition Therapy for Type 1 and Type 2 Diabetes in Adults. Journal of the American Dietetic Association 110:12, 1852-1889
CrossRef198
Taina K. Mattila, Anthonius de Boer. (2010) Influence of Intensive versus Conventional Glucose Control on Microvascular and Macrovascular Complications in Type 1 and 2 Diabetes Mellitus. Drugs 70:17, 2229-2245
CrossRef199
Jiung-Pang Huang, Shiang-Suo Huang, Jen-Ying Deng, Chih-Chun Chang, Yuan-Ji Day, Li-Man Hung. (2010) Insulin and resveratrol act synergistically, preventing cardiac dysfunction in diabetes, but the advantage of resveratrol in diabetics with acute heart attack is antagonized by insulin. Free Radical Biology and Medicine 49:11, 1710-1721
CrossRef200
A. Petrelli, A. Maestroni, G. P. Fadini, D. Belloni, M. Venturini, M. Albiero, S. Kleffel, B. G. Mfarrej, A. Del Maschio, P. Maffi, A. Avogaro, E. Ferrero, G. Zerbini, A. Secchi, P. Fiorina. (2010) Improved Function of Circulating Angiogenic Cells Is Evident in Type 1 Diabetic Islet-Transplanted Patients. American Journal of Transplantation 10:12, 2690-2700
CrossRef201
Luciano Pirola, Aneta Balcerczyk, Jun Okabe, Assam El-Osta. (2010) Epigenetic phenomena linked to diabetic complications. Nature Reviews Endocrinology 6:12, 665-675
CrossRef202
J. K. Snell-Bergeon, R. Roman, D. Rodbard, S. Garg, D. M. Maahs, I. E. Schauer, B. C. Bergman, G. L. Kinney, M. Rewers. (2010) Glycaemic variability is associated with coronary artery calcium in men with Type 1 diabetes: the Coronary Artery Calcification in Type 1 Diabetes study. Diabetic Medicine 27:12, 1436-1442
CrossRef203
(2010) Retinopathy Progression in Type 2 Diabetes. New England Journal of Medicine 363:22, 2171-2174
Full Text204
(2010) Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. New England Journal of Medicine 363:21, 2070-2071
Full Text205
Paul J. Beisswenger. (2010) Glycation and biomarkers of vascular complications of diabetes. Amino Acids
CrossRef206
R. Kahn. (2010) Guidelines: we’ll always need them, we sometimes dislike them, and we have to make them better. Diabetologia 53:11, 2280-2284
CrossRef207
S Cleland. (2010) Insulin resistance in type 1 diabetes: a recipe for double diabetes?. Practical Diabetes International 27:9, 388-390
CrossRef208
Patrick Murray, Gary W. Chune, Vasudevan A. Raghavan. (2010) Legacy Effects from DCCT and UKPDS: What They Mean and Implications for Future Diabetes Trials. Current Atherosclerosis Reports 12:6, 432-439
CrossRef209
T. J. Orchard, A. M. Secrest, R. G. Miller, T. Costacou. (2010) In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 53:11, 2312-2319
CrossRef210
M.-C. Brindisi, B. Bouillet, B. Vergès, S. Halimi. (2010) Cardiovascular complications in type 1 diabetes mellitus. Diabetes & Metabolism 36:5, 341-344
CrossRef211
T. Fujikawa, J.-C. Chuang, I. Sakata, G. Ramadori, R. Coppari. (2010) Leptin therapy improves insulin-deficient type 1 diabetes by CNS-dependent mechanisms in mice. Proceedings of the National Academy of Sciences 107:40, 17391-17396
CrossRef212
Gianluca Perseghin, Guido Lattuada, Francesco De Cobelli, Antonio Esposito, Tamara Canu, Francesca Ragogna, Paola Maffi, Paola Scifo, Antonio Secchi, Alessandro Del Maschio. (2010) Left ventricular function and energy homeostasis in patients with type 1 diabetes with and without microvascular complications. International Journal of Cardiology
CrossRef213
George Bakris, Joseph Vassalotti, Eberhard Ritz, Christoph Wanner, George Stergiou, Mark Molitch, Richard Nesto, George A Kaysen, James R Sowers. (2010) National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. Kidney International 78:8, 726-736
CrossRef214
Raffaele Teperino, Kristina Schoonjans, Johan Auwerx. (2010) Histone Methyl Transferases and Demethylases; Can They Link Metabolism and Transcription?. Cell Metabolism 12:4, 321-327
CrossRef215
Michinari Nakamura, Takeshi Yamashita, Junji Yajima, Yuji Oikawa, Koichi Sagara, Akira Koike, Hajime Kirigaya, Kazuyuki Nagashima, Hitoshi Sawada, Tadanori Aizawa. (2010) Brachial-ankle pulse wave velocity as a risk stratification index for the short-term prognosis of type 2 diabetic patients with coronary artery disease. Hypertension Research 33:10, 1018-1024
CrossRef216
Christian Weber. (2010) Challenges in funding diabetes care: a health economic perspective. Expert Review of Pharmacoeconomics & Outcomes Research 10:5, 517-524
CrossRef217
T. Anderbro, S. Amsberg, U. Adamson, J. Bolinder, P.-E. Lins, R. Wredling, E. Moberg, J. Lisspers, U.-B. Johansson. (2010) Fear of hypoglycaemia in adults with Type 1 diabetes. Diabetic Medicine 27:10, 1151-1158
CrossRef218
Hyun-Sun Lee, Yoon-Chang Koo, Hyung Joo Suh, Kyung-Yong Kim, Kwang-Won Lee. (2010) Preventive effects of chebulic acid isolated from Terminalia chebula on advanced glycation endproduct-induced endothelial cell dysfunction. Journal of Ethnopharmacology 131:3, 567-574
CrossRef219
J. S. Yudkin, B. Richter, E. A. M. Gale. (2010) Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Diabetologia 53:10, 2079-2085
CrossRef220
Roberto Testa, Anna Rita Bonfigli, Maurizio Marra, Ivano Testa. (2010) In the Light of the Metabolic Memory Theory, Should Not All Aged People with Dysglycemia Be Treated?. Rejuvenation Research 13:5, 599-605
CrossRef221
Linda A. DiMeglio, Aneesh Tosh, Chandan Saha, Myka Estes, Julie Mund, Laura E. Mead, Izlin Lien, David A. Ingram, Laura S. Haneline. (2010) Endothelial Abnormalities in Adolescents with Type 1 Diabetes: A Biomarker for Vascular Sequelae?. The Journal of Pediatrics 157:4, 540-546
CrossRef222
David M. Maahs, Nancy A. West, Jean M. Lawrence, Elizabeth J. Mayer-Davis. (2010) Epidemiology of Type 1 Diabetes. Endocrinology & Metabolism Clinics of North America 39:3, 481-497
CrossRef223
Dídac Mauricio, Ferran Rius. (2010) Controversias actuales en los objetivos de control glucémico. ¿Qué reflexiones exigen los resultados de los últimos estudios para abordar la diabetes mellitus tipo 2?. Medicina Clínica 135, 2-5
CrossRef224
Jesse Foote, Jennifer Giuseffi, Medha N. Munshi. (2010) Diabetes in the Elderly. Current Cardiovascular Risk Reports 4:5, 347-353
CrossRef225
KENJI SHIMA, MACHIKO KOMATSU, KAZUHIKO KAWAHARA, JUN MINAGUCHI, SHU KAWASHIMA. (2010) Stringent glycaemic control prolongs survival in diabetic patients with end-stage renal disease on haemodialysis. Nephrology 15:6, 632-638
CrossRef226
Antonios Chatzigeorgiou, Vaggelis Harokopos, Christina Mylona-Karagianni, Emmanouil Tsouvalas, Vassilis Aidinis, Elli Kamper. (2010) The pattern of inflammatory/anti-inflammatory cytokines and chemokines in type 1 diabetic patients over time. Annals of Medicine 42:6, 426-438
CrossRef227
Sanjeev N. Mehta, Joseph I. Wolfsdorf. (2010) Contemporary Management of Patients with Type 1 Diabetes. Endocrinology & Metabolism Clinics of North America 39:3, 573-593
CrossRef228
Amulya T. Siram, Robert Yanagisawa, Maria Skamagas. (2010) Weight Management in Type 2 Diabetes Mellitus. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 77:5, 533-548
CrossRef229
L. Yvonne Melendez-Ramirez, Robert J. Richards, William T. Cefalu. (2010) Complications of Type 1 Diabetes. Endocrinology & Metabolism Clinics of North America 39:3, 625-640
CrossRef230
P.P. Casado, J. Szymaniec, P. Conthe. (2010) ¿Qué ha cambiado en la estrategia terapéutica de la diabetes mellitus tipo 2?. Revista Clínica Española 210, 18-25
CrossRef231
Arjang Djamali, Carolynn E Pietrangeli, Robert D Gordon, Christophe Legendre. (2010) Potential of emerging immunosuppressive strategies to improve the posttransplant cardiovascular risk profile. Kidney International 78, S15-S21
CrossRef232
Hussein H. Karnib, Fuad N. Ziyadeh. (2010) The cardiorenal syndrome in diabetes mellitus. Diabetes Research and Clinical Practice 89:3, 201-208
CrossRef233
Philip E. Cryer. (2010) Hypoglycemia in Type 1 Diabetes Mellitus. Endocrinology & Metabolism Clinics of North America 39:3, 641-654
CrossRef234
A. Sainio, T. Jokela, M. I. Tammi, H. Jarvelainen. (2010) Hyperglycemic conditions modulate connective tissue reorganization by human vascular smooth muscle cells through stimulation of hyaluronan synthesis. Glycobiology 20:9, 1117-1126
CrossRef235
José Miguel González Clemente, Gemma Llauradó Cabot. (2010) Parámetros de control glucémico: nuevas perspectivas en la evaluación del diabético. Medicina Clínica 135, 15-19
CrossRef236
Fernando Álvarez Guisasola. (2010) Actualización sobre la última familia de fármacos orales comercializados para el tratamiento de la diabetes tipo 2: los inhibidores de la DPP-4. Aportaciones respecto a las otras familias de antidiabéticos orales. Atención Primaria 42, 33-40
CrossRef237
R. Boizel, G. Bruttmann, P. Y. Benhamou, S. Halimi, F. Stanke-Labesque. (2010) Regulation of oxidative stress and inflammation by glycaemic control: evidence for reversible activation of the 5-lipoxygenase pathway in type 1, but not in type 2 diabetes. Diabetologia 53:9, 2068-2070
CrossRef238
Stuart J Brink. (2010) Pediatric and adolescent multidisciplinary diabetes team care. Pediatric Diabetes 11:5, 289-291
CrossRef239
D. Hill, M. Fisher. (2010) The effect of intensive glycaemic control on cardiovascular outcomes. Diabetes, Obesity and Metabolism 12:8, 641-647
CrossRef240
C. Nordin. (2010) The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence. Diabetologia 53:8, 1552-1561
CrossRef241
L. M. Delahanty. (2010) An expanded role for dietitians in maximising retention in nutrition and lifestyle intervention trials: implications for clinical practice. Journal of Human Nutrition and Dietetics 23:4, 336-343
CrossRef242
R. S. Mughal, J. L. Scragg, P. Lister, P. Warburton, K. Riches, D. J. O’Regan, S. G. Ball, N. A. Turner, K. E. Porter. (2010) Cellular mechanisms by which proinsulin C-peptide prevents insulin-induced neointima formation in human saphenous vein. Diabetologia 53:8, 1761-1771
CrossRef243
E. S. Kilpatrick, A. S. Rigby, S. L. Atkin. (2010) For debate.Glucose variability and diabetes complication risk: we need to know the answer. Diabetic Medicine 27:8, 868-871
CrossRef244
A. Ceriello, M. A. Ihnat. (2010) ‘Glycaemic variability’: a new therapeutic challenge in diabetes and the critical care setting. Diabetic Medicine 27:8, 862-867
CrossRef245
B. A. LEMKES, J. HERMANIDES, J. H. DEVRIES, F. HOLLEMAN, J. C. M. MEIJERS, J. B. L. HOEKSTRA. (2010) Hyperglycemia: a prothrombotic factor?. Journal of Thrombosis and Haemostasis 8:8, 1663-1669
CrossRef246
Ronald Klein. (2010) Intensive treatment of hyperglycaemia: ACCORD. The Lancet 376:9739, 391-392
CrossRef247
, Rodica Pop-Busui, William H. Herman, Eva L. Feldman, Phillip A. Low, Catherine L. Martin, Patricia A. Cleary, Barbara H. Waberski, John M. Lachin, James W. Albers. (2010) DCCT and EDIC Studies in Type 1 Diabetes: Lessons for Diabetic Neuropathy Regarding Metabolic Memory and Natural History. Current Diabetes Reports 10:4, 276-282
CrossRef248
S. Gupta, T. Chattopadhyay, M. Pal Singh, A. Surolia. (2010) Supramolecular insulin assembly II for a sustained treatment of type 1 diabetes mellitus. Proceedings of the National Academy of Sciences 107:30, 13246-13251
CrossRef249
2010. Macrovascular Disease in Diabetes. , 152-160.
CrossRef250
Bergenstal, Richard M., Tamborlane, William V., Ahmann, Andrew, Buse, John B., Dailey, George, Davis, Stephen N., Joyce, Carol, Peoples, Tim, Perkins, Bruce A., Welsh, John B., Willi, Steven M., Wood, Michael A., . (2010) Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. New England Journal of Medicine 363:4, 311-320
Full Text251
Riccardo Candido, Mark E. Cooper, Karin A. M. Jandeleit-Dahm. 2010. The Pathogenesis of Macrovascular Complications Including Atherosclerosis in Diabetes. , 635-656.
CrossRef252
Peter M. Nilsson, Adie Viljoen, Anthony S. Wierzbicki. 2010. Cardiovascular Risk Factors. , 657-683.
CrossRef253
Joseph A. Aloi, Anthony L. McCall. 2010. How to use Type 2 Diabetes Treatments in Clinical Practice: Combination Therapies. , 494-513.
CrossRef254
Christine Chan, Marian Rewers. 2010. Diabetes in Childhood. , 857-874.
CrossRef255
Colum F. Amory, Jesse Weinberger. 2010. Cerebrovascular Disease. , 698-709.
CrossRef256
Wing-Yee So, Juliana C. N. Chan. 2010. The Role of the Multidisciplinary Team. , 969-983.
CrossRef257
Philip E. Cryer. 2010. Hypoglycemia in Diabetes. , 528-545.
CrossRef258
Andrew J. Farmer. 2010. Monitoring Diabetes. , 399-409.
CrossRef259
Aparna Brown, L. Raymond Reynolds, Dennis Bruemmer. (2010) Intensive glycemic control and cardiovascular disease: an update. Nature Reviews Cardiology 7:7, 369-375
CrossRef260
Andre Pascal Kengne, Fiona Turnbull, Stephen MacMahon. (2010) The Framingham Study, Diabetes Mellitus and Cardiovascular Disease: Turning Back the Clock. Progress in Cardiovascular Diseases 53:1, 45-51
CrossRef261
J. Reckless, A. Robinson. (2010) Benefits and risks around glycaemic control in diabetes: where are we now?. International Journal of Clinical Practice 64:8, 1001-1003
CrossRef262
Pan Chang Yu, Zsolt Bosnyak, Antonio Ceriello. (2010) The importance of glycated haemoglobin (HbA1c) and postprandial glucose (PPG) control on cardiovascular outcomes in patients with type 2 diabetes. Diabetes Research and Clinical Practice 89:1, 1-9
CrossRef263
G. Schernthaner, A. H. Barnett, D. J. Betteridge, R. Carmena, A. Ceriello, B. Charbonnel, M. Hanefeld, R. Lehmann, M. T. Malecki, R. Nesto, V. Pirags, A. Scheen, J. Seufert, A. Sjohölm, A. Tsatsoulis, R. DeFronzo. (2010) Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia 53:7, 1258-1269
CrossRef264
Gunn B.B. Kristensen, Sverre Sandberg. (2010) Self-monitoring of blood glucose with a focus on analytical quality: an overview. Clinical Chemistry and Laboratory Medicine 48:7, 963-972
CrossRef265
Carolyn K. Shue, Laura L. S. O'Hara, David Marini, Jim McKenzie, Melanie Schreiner. (2010) Diabetes and Low-Health Literacy: A Preliminary Outcome Report of a Mediated Intervention to Enhance Patient-Physician Communication. Communication Education 59:3, 360-373
CrossRef266
Hidenori Koyama, Yoshiki Nishizawa. (2010) AGEs/RAGE in CKD: irreversible metabolic memory road toward CVD?. European Journal of Clinical Investigation 40:7, 623-635
CrossRef267
J.G. Garweg, A. Wenzel. (2010) Diabetische Makulopathie und Retinopathie. Der Ophthalmologe 107:7, 628-635
CrossRef268
E. Lukich, Z. Matas, M. Boaz, M. Shargorodsky. (2010) Increasing derangement of glucose homeostasis is associated with increased arterial stiffness in patients with diabetes, impaired fasting glucose and normal controls. Diabetes/Metabolism Research and Reviews 26:5, 365-370
CrossRef269
Lisbeth Minet, Sine Møller, Werner Vach, Lis Wagner, Jan Erik Henriksen. (2010) Mediating the effect of self-care management intervention in type 2 diabetes: A meta-analysis of 47 randomised controlled trials. Patient Education and Counseling 80:1, 29-41
CrossRef270
J. A. Dave, M. E. Engel, R. Freercks, J. Peter, W. May, M. Badri, L. Van Niekerk, N. S. Levitt. (2010) Abnormal glucose metabolism in non-diabetic patients presenting with an acute stroke: prospective study and systematic review. QJM 103:7, 495-503
CrossRef271
Jakob Grauslund, Trine M.M. Jørgensen, Mads Nybo, Anders Green, Lars M. Rasmussen, Anne Katrin Sjølie. (2010) Risk factors for mortality and ischemic heart disease in patients with long-term type 1 diabetes. Journal of Diabetes and its Complications 24:4, 223-228
CrossRef272
Eiichi Araki, Takeshi Nishikawa. (2010) Oxidative stress: A cause and therapeutic target of diabetic complications. Journal of Diabetes Investigation 1:3, 90-96
CrossRef273
Henry Anhalt, Nancy J.V. Bohannon. (2010) Insulin Patch Pumps: Their Development and Future in Closed-Loop Systems. Diabetes Technology & Therapeutics 12:S1, S-51-S-58
CrossRef274
Donald K. Zettervall, Laura Shane-McWhorter, Curtis Triplitt. (2010) Diabetes in the Elderly: Exercising Your Clinical Skills. The Consultant Pharmacist 25:0, 1-37
CrossRef275
Stephen Tonna, Assam El-Osta, Mark E. Cooper, Chris Tikellis. (2010) Metabolic memory and diabetic nephropathy: potential role for epigenetic mechanisms. Nature Reviews Nephrology 6:6, 332-341
CrossRef276
Janice C. Zgibor, Kristine Ruppert, Trevor J. Orchard, Sabita S. Soedamah-Muthu, John Fuller, Nish Chaturvedi, Mark S. Roberts. (2010) Development of a coronary heart disease risk prediction model for type 1 diabetes: The Pittsburgh CHD in Type 1 Diabetes Risk Model. Diabetes Research and Clinical Practice 88:3, 314-321
CrossRef277
Kylie Kavanagh, Kathleen K. Brown, Mandy L. Berquist, Li Zhang, Janice D. Wagner. (2010) Fluid compartmental shifts with efficacious pioglitazone therapy in overweight monkeys: implications for peroxisome proliferator-activated receptor–γ agonist use in prediabetes. Metabolism 59:6, 914-920
CrossRef278
HELEN L PILMORE. (2010) Review: Metformin: Potential benefits and use in chronic kidney disease. Nephrology 15:4, 412-418
CrossRef279
Massimo Volpe, Claudio Borghi, Paolo Cavallo Perin, Massimo Chiariello, Enzo Manzato, Roberto Miccoli, Maria Grazia Modena, Gabriele Riccardi, Giorgio Sesti, Antonio Tiengo, Bruno Trimarco, Diego Vanuzzo, Paolo Verdecchia, Augusto Zaninelli, Stefano Del Prato. (2010) Cardiovascular Prevention in Subjects with Impaired Fasting Glucose or Impaired Glucose Tolerance. High Blood Pressure & Cardiovascular Prevention 17:2, 73-102
CrossRef280
Munehiro Kitada, Zhaoyun Zhang, Akira Mima, George L King. (2010) Molecular mechanisms of diabetic vascular complications. Journal of Diabetes Investigation 1:3, 77-89
CrossRef281
M. L. Marcovecchio, P. H. Tossavainen, D. B. Dunger. (2010) Prevention and treatment of microvascular disease in childhood type 1 diabetes. British Medical Bulletin 94:1, 145-164
CrossRef282
Anne Pavy-Le Traon, Sébastien Fontaine, Gérard Tap, Brigitte Guidolin, Jean-Michel Senard, Hélène Hanaire. (2010) Cardiovascular autonomic neuropathy and other complications in type 1 diabetes. Clinical Autonomic Research 20:3, 153-160
CrossRef283
M. Lind, A. Odén, M. Fahlén, B. Eliasson. (2010) The shape of the metabolic memory of HbA1c: re-analysing the DCCT with respect to time-dependent effects. Diabetologia 53:6, 1093-1098
CrossRef284
Satish K. Garg. (2010) Impact of Insulin Delivery Devices in Diabetes Care. Diabetes Technology & Therapeutics 12:S1, S-1-S-3
CrossRef285
David Kerr, Tolu Olateju. (2010) Pascal's Wager: Combining Continuous Glucose Monitoring and Continuous Subcutaneous Insulin Infusion. Diabetes Technology & Therapeutics 12:S1, S-43-S-50
CrossRef286
Mariska van Vliet, Josine C. Van der Heyden, Michaela Diamant, Inès A. Von Rosenstiel, Roger K. Schindhelm, Henk J. Aanstoot, Henk J. Veeze. (2010) Overweight Is Highly Prevalent In Children with Type 1 Diabetes And Associates with Cardiometabolic Risk. The Journal of Pediatrics 156:6, 923-929
CrossRef287
Chun-Yu Zhang, Ai-Jun Sun, Shu-Ning Zhang, Chao-neng Wu, Ming-Qiang Fu, Guang Xia, Ke-Qiang Wang, Yun-Zeng Zou, Jun-Bo Ge. (2010) Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: A meta-analysis. Annals of Medicine 42:4, 305-315
CrossRef288
Alin Stirban. (2010) Die Bedeutung von AGEs und ROS bei Atherosklerose. Herz 35:3, 170-180
CrossRef289
Antonio Ceriello. (2010) Hyperglycaemia and the vessel wall: the pathophysiological aspects on the atherosclerotic burden in patients with diabetes. European Journal of Cardiovascular Prevention & Rehabilitation 17, S15-S19
CrossRef290
Jie You, Wei Peng, Xu Lin, Qing-Ling Huang, Jian-Yin Lin. (2010) PLC/CAMK IV–NF-κB involved in the receptor for advanced glycation end products mediated signaling pathway in human endothelial cells. Molecular and Cellular Endocrinology 320:1-2, 111-117
CrossRef291
P-E Kofoed, J Thomsen, J Ammentorp. (2010) An unplanned delay between control visits influences the metabolic status in children with diabetes: an observational study. Acta Paediatrica 99:5, 774-777
CrossRef292
Irene M. Van Der Meer, Piero Ruggenenti, Giuseppe Remuzzi. (2010) THE DIABETIC CKD PATIENT-A MAJOR CARDIOVASCULAR CHALLENGE. Journal of Renal Care 36, 34-46
CrossRef293
Jessica Beckwith, John A. Nyman, Brian Flanagan, Rudolf Schrover, Henk-Jan Schuurman. (2010) A health-economic analysis of porcine islet xenotransplantation. Xenotransplantation 17:3, 233-242
CrossRef294
A. I. Adler, S. Erqou, T. A. S. Lima, A. H. N. Robinson. (2010) Association between glycated haemoglobin and the risk of lower extremity amputation in patients with diabetes mellitus—review and meta-analysis. Diabetologia 53:5, 840-849
CrossRef295
A. R. Chacra, M. Kipnes, L. L. Ilag, S. Sarwat, J. Giaconia, J. Chan. (2010) Comparison of insulin lispro protamine suspension and insulin detemir in basal-bolus therapy in patients with Type 1 diabetes. Diabetic Medicine 27:5, 563-569
CrossRef296
Satish Garg, Francisco Javier Ampudia-Blasco, Martin Pfohl. (2010) Rapid-Acting Insulin Analogues in Basal-Bolus Regimens in Type 1 Diabetes Mellitus. Endocrine Practice 16:3, 486-505
CrossRef297
Renu A. Kowluru, Qing Zhong, Mamta Kanwar. (2010) Metabolic memory and diabetic retinopathy: Role of inflammatory mediators in retinal pericytes. Experimental Eye Research 90:5, 617-623
CrossRef298
Ángeles Alonso-García, Francisco J. García-Soidán, Arturo Lisbona-Gil. (2010) Tratamiento hipoglucemiante en pacientes con diabetes mellitus tipo 2 con insuficiencia cardiaca estable o cardiopatía isquémica sin insuficiencia cardiaca. Medicina Clínica 134:13, 596-599
CrossRef299
Sabin Shurraw, Sumit R. Majumdar, Ravi Thadhani, Natasha Wiebe, Marcello Tonelli. (2010) Glycemic Control and the Risk of Death in 1,484 Patients Receiving Maintenance Hemodialysis. American Journal of Kidney Diseases 55:5, 875-884
CrossRef300
Cristina Bianchi, Giuseppe Penno, Roberto Miccoli, Stefano Prato. (2010) Blood Glucose Control and Coronary Heart Disease. Herz 35:3, 148-159
CrossRef301
T. J. Quinn, J. Dawson, M. R. Walters. (2010) Sugar and Stroke: Cerebrovascular Disease and Blood Glucose Control. Cardiovascular Therapeuticsno-no
CrossRef302
F. H. El-Khatib, S. J. Russell, D. M. Nathan, R. G. Sutherlin, E. R. Damiano. (2010) A Bihormonal Closed-Loop Artificial Pancreas for Type 1 Diabetes. Science Translational Medicine 2:27, 27ra27-27ra27
CrossRef303
Richard M. Bergenstal, Clifford J. Bailey, David M. Kendall. (2010) Type 2 Diabetes: Assessing the Relative Risks and Benefits of Glucose-lowering Medications. The American Journal of Medicine 123:4, 374.e9-374.e18
CrossRef304
Mark R Rigby. (2010) The role of the physician–scientist in bridging basic and clinical research in type 1 diabetes. Current Opinion in Endocrinology, Diabetes and Obesity 17:2, 131-142
CrossRef305
Oliver Schnell, Eberhard Standl. (2010) Diabetes and cardiovascular disease. Clinical Research in Cardiology Supplements 5:S1, 27-34
CrossRef306
György Jermendy, Tibor Hidvégi, Győző Vándorfi, Gábor Winkler. (2010) A 2-es típusú diabetes és előállapotainak szűrése – módszertani megfontolások, hazai lehetőségek. Orvosi Hetilap 151:17, 683-690
CrossRef307
M. E. Larkin, J.-Y. Backlund, P. Cleary, M. Bayless, B. Schaefer, J. Canady, D. M. Nathan, . (2010) Disparity in management of diabetes and coronary heart disease risk factors by sex in DCCT/EDIC. Diabetic Medicine 27:4, 451-458
CrossRef308
Juan J. Chillarón, Juana A. Flores-Le-Roux, Alberto Goday, David Benaiges, María J. Carrera, Jaume Puig, Juan F. Cano-Pérez, Juan Pedro-Botet. (2010) Síndrome metabólico y diabetes mellitus tipo 1: prevalencia y factores relacionados. Revista Española de Cardiología 63:4, 423-429
CrossRef309
Sujoy Ghosh, Andrew Collier, Mario Hair, Iqbal Malik, Tarik Elhadd. (2010) Metabolic syndrome in type 1 diabetes. International Journal of Diabetes Mellitus 2:1, 38-42
CrossRef310
Joshua M. Stolker, Dazhong Sun, Darcy G. Conaway, Philip G. Jones, Frederick A. Masoudi, Pamela N. Peterson, Harlan M. Krumholz, Mikhail Kosiborod, John A. Spertus. (2010) Importance of Measuring Glycosylated Hemoglobin in Patients With Myocardial Infarction and Known Diabetes Mellitus. The American Journal of Cardiology 105:8, 1090-1094
CrossRef311
Dae-Hyun Ko, Soo Lim, Sang Hoon Song, Sung Hee Choi, Young Joo Park, Kyoung Un Park, Hak Chul Jang, Junghan Song. (2010) Performance Evaluation of the GlucoDr Plus Glucometer. Diabetes Technology & Therapeutics 12:4, 307-312
CrossRef312
H. Ito, Y. Takeuchi, H. Ishida, S. Antoku, M. Abe, M. Mifune, M. Togane. (2010) High frequencies of diabetic micro- and macroangiopathies in patients with type 2 diabetes mellitus with decreased estimated glomerular filtration rate and normoalbuminuria. Nephrology Dialysis Transplantation 25:4, 1161-1167
CrossRef313
Matteo Anselmino, Klas Malmberg, Linda Mellbin, Lars Rydén. (2010) Overview of the importance of glycaemic control for cardiovascular events in the in-and out-patient setting. Reviews in Endocrine and Metabolic Disorders 11:1, 87-94
CrossRef314
Csaba P. Kovesdy, Jong C. Park, Kamyar Kalantar-Zadeh. (2010) Glycemic Control and Burnt-Out Diabetes in ESRD. Seminars in Dialysis 23:2, 148-156
CrossRef315
Erin Cobry, Kim McFann, Laurel Messer, Victoria Gage, Brandon VanderWel, Lauren Horton, H. Peter Chase. (2010) Timing of Meal Insulin Boluses to Achieve Optimal Postprandial Glycemic Control in Patients with Type 1 Diabetes. Diabetes Technology & Therapeutics 12:3, 173-177
CrossRef316
Jean Halford, Claudia Harris. (2010) Determining Clinical and Psychological Benefits and Barriers with Continuous Glucose Monitoring Therapy. Diabetes Technology & Therapeutics 12:3, 201-205
CrossRef317
, H. Sone, S. Tanaka, S. Iimuro, S. Tanaka, K. Oida, Y. Yamasaki, S. Oikawa, S. Ishibashi, S. Katayama, H. Yamashita, H. Ito, Y. Yoshimura, Y. Ohashi, Y. Akanuma, N. Yamada. (2010) Long-term lifestyle intervention lowers the incidence of stroke in Japanese patients with type 2 diabetes: a nationwide multicentre randomised controlled trial (the Japan Diabetes Complications Study). Diabetologia 53:3, 419-428
CrossRef318
Thomas D Aicher, Steven A Boyd, Maralee McVean, Anthony Celeste. (2010) Novel therapeutics and targets for the treatment of diabetes. Expert Review of Clinical Pharmacology 3:2, 209-229
CrossRef319
Diana Hortensia Barbonta, Christopher William Loughlan, JE Claire Dickerson, Diana Hortensia Barbonta. 2010. Pramlintide for diabetes mellitus. .
CrossRef320
I.S. Zagon, Joseph W. Sassani, Melissa A. Carroll, Patricia J. McLaughlin. (2010) Topical application of naltrexone facilitates reepithelialization of the cornea in diabetic rabbits. Brain Research Bulletin 81:2-3, 248-255
CrossRef321
J. Smith-Palmer, B. H. Curtis, K. S. Boye, G. Goodall, S. R. Pillemer. (2010) Anti-CD3 monoclonal antibody treatment in newly diagnosed Type 1 diabetes patients: a hypothetical modelling analysis. Diabetic Medicine 27:2, 189-196
CrossRef322
Lewis H Kuller. (2010) Cardiovascular disease is preventable among women. Expert Review of Cardiovascular Therapy 8:2, 175-187
CrossRef323
S. Garg, I. B. Hirsch. (2010) Self-monitoring of blood glucose. International Journal of Clinical Practice 64, 1-10
CrossRef324
Stuart W. Zarich. (2010) Does Choice of Antidiabetes Therapy Influence Macrovascular Outcomes?. Current Diabetes Reports 10:1, 24-31
CrossRef325
Sayaka Kubo, Hirotaka Watada, Ryuzo Kawamori. (2010) Combination therapy of miglitol and insulin in type 1 diabetes mellitus patients. Journal of Diabetes Investigation 1:1-2, 60-65
CrossRef326
Lee Park, Deborah Wexler. (2010) Update in diabetes and cardiovascular disease: synthesizing the evidence from recent trials of glycemic control to prevent cardiovascular disease. Current Opinion in Lipidology 21:1, 8-14
CrossRef327
Trevor J. Orchard, Tina Costacou. (2010) When Are Type 1 Diabetic Patients at Risk for Cardiovascular Disease?. Current Diabetes Reports 10:1, 48-54
CrossRef328
Hubert Kolb, Kerstin Kempf, Stephan Martin, Michael Stumvoll, Rüdiger Landgraf. (2010) On what evidence-base do we recommend self-monitoring of blood glucose?. Diabetes Research and Clinical Practice 87:2, 150-156
CrossRef329
J. E. Gerich. (2010) Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabetic Medicine 27:2, 136-142
CrossRef330
Craig J Currie, John R Peters, Aodán Tynan, Marc Evans, Robert J Heine, Oswaldo L Bracco, Tony Zagar, Chris D Poole. (2010) Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. The Lancet 375:9713, 481-489
CrossRef331
Giovanna Castoldi, Cira R. T. Di Gioia, Camila Bombardi, Carla Perego, Lucia Perego, Massimiliano Mancini, Martina Leopizzi, Barbara Corradi, Stefano Perlini, Gianpaolo Zerbini, Andrea Stella. (2010) Prevention of myocardial fibrosis by N -acetyl-seryl-aspartyl-lysyl-proline in diabetic rats. Clinical Science 118:3, 211-220
CrossRef332
Jaime S. Rosa, Masato Mitsuhashi, Stacy R. Oliver, Mieko Ogura, Rebecca L. Flores, Andria M. Pontello, Pietro R. Galassetti. (2010) Ex vivo TCR-induced leukocyte gene expression of inflammatory mediators is increased in type 1 diabetic patients but not in overweight children. Diabetes/Metabolism Research and Reviews 26:1, 33-39
CrossRef333
Chee-Tin Christine Lee, Emma L. Gayton, Joline W.J. Beulens, Declan W. Flanagan, Amanda I. Adler. (2010) Micronutrients and Diabetic Retinopathy. Ophthalmology 117:1, 71-78
CrossRef334
Chul Sik Kim, So Young Park, Sung Hoon Yu, Jun Goo Kang, Ohk Hyun Ryu, Seong Jin Lee, Eun Gyung Hong, Hyeon Kyu Kim, Doo-Man Kim, Jae Myung Yoo, Sung Hee Ihm, Moon Gi Choi, Hyung Joon Yoo. (2010) Is A1C Variability an Independent Predictor for the Progression of Atherosclerosis in Type 2 Diabetic Patients?. Korean Diabetes Journal 34:3, 174
CrossRef335
Hsin K. Goh, Michael Chia, Yau W. Ooi, Daniel E. K. Chew. (2010) Silent Myocardial Infarction and Hypoglycaemia. The Endocrinologist 20:1, 2-6
CrossRef336
B. Gallwitz, H.-U. Häring. (2010) Future perspectives for insulinotropic agents in the treatment of type 2 diabetesâDPP-4 inhibitors and sulphonylureas. Diabetes, Obesity and Metabolism 12:1, 1-11
CrossRef337
(2010) Añadir insulina de acción lenta. Dr. J.A. Martin Oterino. Revista Clínica Española 210:1, 26-27
CrossRef338
A. M. Jacobson, A. D. Paterson, C. M. Ryan, P. A. Cleary, B. H. Waberski, K. Weinger, G. Musen, W. Dahms, M. Bayless, N. Silvers, J. Harth, A. P. Boright, . (2010) The associations of apolipoprotein E and angiotensin-converting enzyme polymorphisms and cognitive function in Type 1 diabetes based on an 18-year follow-up of the DCCT cohort. Diabetic Medicine 27:1, 15-22
CrossRef339
RayzelM Shulman, ClodaghS O'Gorman, MarkR Palmert. (2010) The Impact of Telemedicine Interventions Involving Routine Transmission of Blood Glucose Data with Clinician Feedback on Metabolic Control in Youth with Type 1 Diabetes: A Systematic Review and Meta-Analysis. International Journal of Pediatric Endocrinology 2010:1, 536957
CrossRef340
Masayoshi Takeuchi, Jun-ichi Takino, Sho-ichi Yamagishi. (2010) Involvement of TAGE-RAGE System in the Pathogenesis of Diabetic Retinopathy. Journal of Ophthalmology 2010, 1-12
CrossRef341
Guntram Schernthaner. (2010) Diabetes and Cardiovascular Disease: Is intensive glucose control beneficial or deadly? Lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive, and NICE-SUGAR. Wiener Medizinische Wochenschrift 160:1-2, 8-19
CrossRef342
Kenro Nishida, Seiya Shimoda, Kenshi Ichinose. (2010) Glucose control in critically ill patients and clinical application of bedside-type artificial endocrine pancreas. Nihon Shuchu Chiryo Igakukai zasshi 17:4, 464-467
CrossRef343
Brian B. Graham, Angela Keniston, Ognjen Gajic, Cesar A. Trillo Alvarez, Sofia Medvedev, Ivor S. Douglas. (2010) Diabetes mellitus does not adversely affect outcomes from a critical illness*. Critical Care Medicine 38:1, 16-24
CrossRef344
Yan SHEN, Misato FUKUSHIMA, Yoshimasa ITO, Etsuko MURAKI, Takashi HOSONO, Taiichiro SEKI, Toyohiko ARIGA. (2010) Verification of the Antidiabetic Effects of Cinnamon (Cinnamomum zeylanicum) Using Insulin-Uncontrolled Type 1 Diabetic Rats and Cultured Adipocytes. Bioscience, Biotechnology, and Biochemistry 74:12, 2418-2425
CrossRef345
Rayzel M. Shulman, Clodagh S. O'Gorman, Mark R. Palmert. (2010) The Impact of Telemedicine Interventions Involving Routine Transmission of Blood Glucose Data with Clinician Feedback on Metabolic Control in Youth with Type 1 Diabetes: A Systematic Review and Meta-Analysis. International Journal of Pediatric Endocrinology 2010, 1-9
CrossRef346
Zachary Bloomgarden. (2009) Recent cardiovascular trials: What are the drivers of benefit and adverse effect?. Journal of Diabetes 1:4, 227-229
CrossRef347
Ivan Tkáč. (2009) Effect of intensive glycemic control on cardiovascular outcomes and all-cause mortality in type 2 diabetes: Overview and metaanalysis of five trials. Diabetes Research and Clinical Practice 86, S57-S62
CrossRef348
Sho-ichi Yamagishi. (2009) Advanced Glycation End Products and ReceptorâOxidative Stress System in Diabetic Vascular Complications. Therapeutic Apheresis and Dialysis 13:6, 534-539
CrossRef349
Alan Cole, David M. Nathan, Elizabeth Savaria-Porter, Paul Copeland, Alexander Turchin, Melanie Brunt, Randall Zusman, Jo-Ann Barrett, Deborah Wexler, Emily Case, Graham T. McMahon, Elizabeth Mort. (2009) An Algorithm for the Care of Type 2 Diabetes. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 8:4, 156-165
CrossRef350
K. McGeechan, G. Liew, P. Macaskill, L. Irwig, R. Klein, B. E. K. Klein, J. J. Wang, P. Mitchell, J. R. Vingerling, P. T. V. M. de Jong, J. C. M. Witteman, M. M. B. Breteler, J. Shaw, P. Zimmet, T. Y. Wong. (2009) Prediction of Incident Stroke Events Based on Retinal Vessel Caliber: A Systematic Review and Individual-Participant Meta-Analysis. American Journal of Epidemiology 170:11, 1323-1332
CrossRef351
E. P. O’Sullivan, A. Bhargava, M. O’Callaghan, U. Buckley, T. Faoite, K. Moynihan, H. Thabit, C. H. Walsh, S. Sreenan. (2009) Awareness of diabetes complications in an Irish population. Irish Journal of Medical Science 178:4, 401-406
CrossRef352
Alfonso Perez, Zhen Zhao, Randal Jacks, Robert Spanheimer. (2009) Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM. Current Medical Research and Opinion 25:12, 2915-2923
CrossRef353
Riccardo Candido, Stella Bernardi, Terri J Allen. (2009) Linking diabetes and atherosclerosis. Expert Review of Endocrinology & Metabolism 4:6, 603-624
CrossRef354
E. Mannucci, M. Monami, C. Lamanna, F. Gori, N. Marchionni. (2009) Prevention of cardiovascular disease through glycemic control in type 2 diabetes: A meta-analysis of randomized clinical trials. Nutrition, Metabolism and Cardiovascular Diseases 19:9, 604-612
CrossRef355
A. J. Garber. (2009) Restaging insulin therapy for patients with type 2 diabetes. Diabetes, Obesity and Metabolism 11, 1-5
CrossRef356
(2009) Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. American Journal of Transplantation 9, S1-S155
CrossRef357
Geneviève Langlois, Julie Dusseault, Stéphanie Bilodeau, Susan K. Tam, Dalla Magassouba, Jean-Pierre Hallé. (2009) Direct effect of alginate purification on the survival of islets immobilized in alginate-based microcapsules. Acta Biomaterialia 5:9, 3433-3440
CrossRef358
Simone Domenico Aspriello, Antonio Zizzi, Guendalina Lucarini, Corrado Rubini, Emanuela Faloia, Marco Boscaro, Giacomo Tirabassi, Matteo Piemontese. (2009) Vascular Endothelial Growth Factor and Microvessel Density in Periodontitis Patients With and Without Diabetes. Journal of Periodontology 80:11, 1783-1789
CrossRef359
Bianca Hemmingsen, Søren S Lund, Christian Gluud, Allan Vaag, Thomas Almdal, Jørn Wetterslev, Bianca Hemmingsen. 2009. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. .
CrossRef360
Miranda W. Langendam, Lotty Hooft, Hans De Vries, Iris M Wentholt, Aart H Mudde, Anna L Burt, Rob JPM Scholten, Miranda W. Langendam. 2009. Continuous glucose monitoring systems for type 1 diabetes mellitus. .
CrossRef361
Subramanyam N. Murthy, Sergiy Sukhanov, Jennifer McGee, Joel A. Greco, Surabhi Chandra, Patrice Delafontaine, Philip J. Kadowitz, Dennis B. McNamara, Vivian A. Fonseca. (2009) Insulin glargine reduces carotid intimal hyperplasia after balloon catheter injury in Zucker fatty rats possibly by reduction in oxidative stress. Molecular and Cellular Biochemistry 330:1-2, 1-8
CrossRef362
S. S. Lund, L. Tarnow, A. S. Astrup, P. Hovind, P. K. Jacobsen, A. C. Alibegovic, I. Parving, L. Pietraszek, M. Frandsen, P. Rossing, H.-H. Parving, A. A. Vaag. (2009) Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes. Diabetes, Obesity and Metabolism 11:10, 966-977
CrossRef363
S. Akalin, K. Berntorp, A. Ceriello, A. K. Das, E. S. Kilpatrick, T. Koblik, C. S. Munichoodappa, C. Y. Pan, W. Rosenthall, M. Shestakova, B. Wolnik, V. Woo, W. Y. Yang, M. T. Yilmaz, . (2009) Intensive glucose therapy and clinical implications of recent data: a consensus statement from the Global Task Force on Glycaemic Control. International Journal of Clinical Practice 63:10, 1421-1425
CrossRef364
Eric S. Kilpatrick, Alan S. Rigby, Stephen L. Atkin. (2009) The Diabetes Control and Complications Trial: the gift that keeps giving. Nature Reviews Endocrinology 5:10, 537-545
CrossRef365
Dan Gao, Clifford J. Bailey, Helen R. Griffiths. (2009) Metabolic memory effect of the saturated fatty acid, palmitate, in monocytes. Biochemical and Biophysical Research Communications 388:2, 278-282
CrossRef366
M. Rebecca Fokkema, Andries J. Bakker, Fokje de Boer, Jeltsje Kooistra, Sifra de Vries, Albert Wolthuis. (2009) HbA1c measurements from dried blood spots: validation and patient satisfaction. Clinical Chemistry and Laboratory Medicine 47:10, 1259-1264
CrossRef367
A. Liebl. (2009) Insulin intensification â the rationale and the target. International Journal of Clinical Practice 63, 1-5
CrossRef368
D. C. W. Lau. (2009) Dietary cholesterol and other nutritional considerations in people with diabetes. International Journal of Clinical Practice 63, 15-21
CrossRef369
David C. W. Lau. (2009) Le cholestérol alimentaire et autres considérations nutritionnelles chez les personnes atteintes de diabète. International Journal of Clinical Practice 63, 44-51
CrossRef370
Mark S. Kipnes, Hal Joseph, Harry Morris, Jason Manko, Douglas E. Bell. (2009) Clinical Performance of the TRUE2go Blood Glucose System—A Novel Integrated System for Meter and Strips. Diabetes Technology & Therapeutics 11:10, 649-655
CrossRef371
S. Jabbour. (2009) Type 2 diabetes and HbA1c goal: time for individualised therapy. International Journal of Clinical Practice 63:10, 1408-1409
CrossRef372
Christian Weber, Oliver Schnell. (2009) The Assessment of Glycemic Variability and Its Impact on Diabetes-Related Complications: An Overview. Diabetes Technology & Therapeutics 11:10, 623-633
CrossRef373
G. A. Thomson, R. Craig. (2009) Where now for insulin glargine - a time for pragmatic medicine?. International Journal of Clinical Practice 63:10, 1413-1415
CrossRef374
Tamara Isakova, Orlando M Gutiérrez, Myles Wolf. (2009) A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease. Kidney International 76:7, 705-716
CrossRef375
Stuart W. Zarich. (2009) Antidiabetic agents and cardiovascular risk in type 2 diabetes. Nature Reviews Endocrinology 5:9, 500-506
CrossRef376
Xin-Yuan Gao, Hong-Yu Kuang, Wei Zou, Xiao-Min Liu, Hong-Bin Lin, Yi Yang. (2009) The timing of re-institution of good blood glucose control affects apoptosis and expression of Bax and Bcl-2 in the retina of diabetic rats. Molecular Biology Reports 36:7, 1977-1982
CrossRef377
Satish K. Garg, William C. Kelly. (2009) Insulin Delivery via Lungs—Is It Still Possible?. Diabetes Technology & Therapeutics 11:s2, S-1-S-3
CrossRef378
Sunder Mudaliar. (2009) Serum glucose control in diabetic patients with cardiovascular disease: Should we be less aggressive?. Current Atherosclerosis Reports 11:5, 384-390
CrossRef379
Iben Brock Jacobsen, Jan Erik Henriksen, Henning Beck-Nielsen. (2009) The Effect of Metformin in Overweight Patients with Type 1 Diabetes and Poor Metabolic Control. Basic & Clinical Pharmacology & Toxicology 105:3, 145-149
CrossRef380
G. Charpentier, S. Halimi, . (2009) Earlier triple therapy with pioglitazone in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 11:9, 844-854
CrossRef381
Marian Rewers, Catherine Pihoker, Kim Donaghue, Ragnar Hanas, Peter Swift, Georgeanna J Klingensmith. (2009) Assessment and monitoring of glycemic control in children and adolescents with diabetes. Pediatric Diabetes 10, 71-81
CrossRef382
Kim C. Donaghue, Francesco Chiarelli, Daniela Trotta, Jeremy Allgrove, Knut Dahl-Jorgensen. (2009) Microvascular and macrovascular complications associated with diabetes in children and adolescents. Pediatric Diabetes 10, 195-203
CrossRef383
Catherine A. Sheffield, Michael P. Kane, Gary Bakst, Robert S. Busch, Jill M. Abelseth, Robert A. Hamilton. (2009) Accuracy and Precision of Four Value-Added Blood Glucose Meters: the Abbott Optium, the DDI Prodigy, the HDI True Track, and the HypoGuard Assure Pro. Diabetes Technology & Therapeutics 11:9, 587-592
CrossRef384
Veer Chahwala, Rohit Arora. (2009) Cardiovascular Manifestations of Insulin Resistance. American Journal of Therapeutics 16:5, e14-e28
CrossRef385
Sergio F. Rueda, Cristian Fernández, Joana Nicolau, María J. Ricart, Enric Esmatjes. (2009) Prevalence of cardiovascular risk factors in patients with type 1 diabetes in end-stage renal disease: changes in the trend from 1999 to 2006. Journal of Diabetes and its Complications 23:5, 317-322
CrossRef386
Rita F. Redberg, Emelia J. Benjamin, Vera Bittner, Lynne T. Braun, David C. Goff, Stephen Havas, Darwin R. Labarthe, Marian C. Limacher, Donald M. Lloyd-Jones, Samia Mora, Thomas A. Pearson, Martha J. Radford, Gerald W. Smetana, John A. Spertus, Erica W. Swegler. (2009) ACCF/AHA 2009 Performance Measures for Primary Prevention of Cardiovascular Disease in Adults. Journal of the American College of Cardiology 54:14, 1364-1405
CrossRef387
Melvin Samsom, Adil Bharucha, John E. Gerich, Kathrin Herrmann, Jörg Limmer, Rainer Linke, David Maggs, Jörg Schirra, Adrian Vella, Hans-Jürgen Wörle, Burkhard Göke. (2009) Diabetes mellitus and gastric emptying: questions and issues in clinical practice. Diabetes/Metabolism Research and Reviews 25:6, 502-514
CrossRef388
Helen C. Cooper, Robert Geyer. (2009) What can complexity do for diabetes management? Linking theory to practice. Journal of Evaluation in Clinical Practice 15:4, 761-765
CrossRef389
Jing Ma, Christopher K. Rayner, Karen L. Jones, Michael Horowitz. (2009) Insulin secretion in healthy subjects and patients with Type 2 diabetes – role of the gastrointestinal tract. Best Practice & Research Clinical Endocrinology & Metabolism 23:4, 413-424
CrossRef390
Adel B. Mazanderani, Stephanie J. Wise, Hugh D. Tildesley. (2009) Apolipoprotein B levels in adults with type 1 diabetes not receiving lipid-lowering therapy. Clinical Biochemistry 42:12, 1218-1221
CrossRef391
Michael J. Haller, Janet H. Silverstein. (2009) In Pursuit Of Lower A1c. The Journal of Pediatrics 155:2, 161-162
CrossRef392
Brian Hyett, Fernando J. Martinez, Brian M. Gill, Shilpa Mehra, Anthony Lembo, Ciaran P. Kelly, Daniel A. Leffler. (2009) Delayed Radionucleotide Gastric Emptying Studies Predict Morbidity in Diabetics With Symptoms of Gastroparesis. Gastroenterology 137:2, 445-452
CrossRef393
Nancy A. Thornberry, Baptist Gallwitz. (2009) Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Practice & Research Clinical Endocrinology & Metabolism 23:4, 479-486
CrossRef394
Viviane El-Helou, Cindy Proulx, Pauline Béguin, John Assimakopoulos, Hugues Gosselin, Robert Clement, Louis Villeneuve, Julie-Émilie Huot-Marchand, Denis DeBlois, Claude Lajoie, Angelino Calderone. (2009) The cardiac neural stem cell phenotype is compromised in streptozotocin-induced diabetic cardiomyopathy. Journal of Cellular Physiology 220:2, 440-449
CrossRef395
Mark E Cooper. (2009) Metabolic memory: implications for diabetic vascular complications. Pediatric Diabetes 10:5, 343-346
CrossRef396
Alex J. Graveling, Brian M. Frier. (2009) Hypoglycaemia: An overview. Primary Care Diabetes 3:3, 131-139
CrossRef397
Andrew W. Norris, Joseph I. Wolfsdorf. 2009. Diabetes Mellitus. , 458-504.
CrossRef398
Sabreena Basu, Guillermo E Umpierrez. (2009) Does normalization of blood glucose reduce the rate of cardiovascular events?. Therapy 6:4, 459-461
CrossRef399
Louis Monnier, Claude Colette, David R. Owens. (2009) Integrating glycaemic variability in the glycaemic disorders of type 2 diabetes: a move towards a unified glucose tetrad concept. Diabetes/Metabolism Research and Reviews 25:5, 393-402
CrossRef400
Jacob Ilany. (2009) Providing cardiovascular benefits with safe diabetes therapy. Therapy 6:4, 455-457
CrossRef401
Apostolos I. Hatzitolios, Triandafillos P. Didangelos, Anestis T. Zantidis, Konstantinos Tziomalos, George A. Giannakoulas, Dimitrios T. Karamitsos. (2009) Diabetes mellitus and cerebrovascular disease: which are the actual data?. Journal of Diabetes and its Complications 23:4, 283-296
CrossRef402
Marilia Brito Gomes, Roberta Arnold Cobas, Edson Nunes, Hugo Caire Castro-Faria-Neto, Maria Fátima Bevilacqua da Matta, Ricardo Neves, Eduardo Tibiriçá. (2009) Plasma PAF-acetylhydrolase activity, inflammatory markers and susceptibility of LDL to in vitro oxidation in patients with type 1 diabetes mellitus. Diabetes Research and Clinical Practice 85:1, 61-68
CrossRef403
Meaghan St Charles, Peter Lynch, Claudia Graham, Michael E. Minshall. (2009) A Cost-Effectiveness Analysis of Continuous Subcutaneous Insulin Injection versus Multiple Daily Injections in Type 1 Diabetes Patients: A Third-Party US Payer Perspective. Value in Health 12:5, 674-686
CrossRef404
S. Prato. (2009) Megatrials in type 2 diabetes. From excitement to frustration?. Diabetologia 52:7, 1219-1226
CrossRef405
David M. Kendall, Robert M. Cuddihy, Richard M. Bergenstal. (2009) Clinical Application of Incretin-Based Therapy: Therapeutic Potential, Patient Selection and Clinical Use. European Journal of Internal Medicine 20, S329-S339
CrossRef406
Michael A. Zimmerman, Sonia C. Flores. (2009) Autoimmune-Mediated Oxidative Stress and Endothelial Dysfunction: Implications of Accelerated Vascular Injury in Type I Diabetes. Journal of Surgical Research 155:1, 173-178
CrossRef407
A. CERIELLO, K. ESPOSITO, M. IHNAT, J. ZHANG, D. GIUGLIANO. (2009) Simultaneous control of hyperglycemia and oxidative stress normalizes enhanced thrombin generation in type 1 diabetes. Journal of Thrombosis and Haemostasis 7:7, 1228-1230
CrossRef408
Larry A. Weinrauch, Eldrin F. Lewis. (2009) Aiming for the Best Control of Glycemia in Patients With Heart Failure and Type 2 Diabetes. Journal of the American College of Cardiology 54:5, 429-431
CrossRef409
Satish K. Garg. (2009) The Future of Continuous Glucose Monitoring. Diabetes Technology & Therapeutics 11:s1, S-1-S-3
CrossRef410
R. Paul Wadwa, Rosanna Fiallo-Scharer, Brandon VanderWel, Laurel H. Messer, Erin Cobry, H. Peter Chase. (2009) Continuous Glucose Monitoring in Youth with Type 1 Diabetes. Diabetes Technology & Therapeutics 11:s1, S-83-S-91
CrossRef411
Eberhard Standl, Martin Müller, Oliver Schnell. (2009) The impact of glucose-lowering therapy on cardiovascular outcomes. Best Practice & Research Clinical Endocrinology & Metabolism 23:3, 401-411
CrossRef412
A. C. Dale, K. Midthjell, T. I. Nilsen, R. Wiseth, L. J. Vatten. (2009) Glycaemic control in newly diagnosed diabetes patients and mortality from ischaemic heart disease: 20-year follow-up of the HUNT Study in Norway. European Heart Journal 30:11, 1372-1377
CrossRef413
Ole-Petter R. Hamnvik, Graham T. McMahon. (2009) Glycemic Targets for Patients with Type 2 Diabetes Mellitus. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 76:3, 227-233
CrossRef414
Jarinyaporn Naowaboot, Patchareewan Pannangpetch, Veerapol Kukongviriyapan, Bunkerd Kongyingyoes, Upa kukongviriyapan. (2009) Antihyperglycemic, Antioxidant and Antiglycation Activities of Mulberry Leaf Extract in Streptozotocin-Induced Chronic Diabetic Rats. Plant Foods for Human Nutrition 64:2, 116-121
CrossRef415
T. Siegmund. (2009) Aktuelle Aspekte der Insulinpumpentherapie bei Erwachsenen. Der Diabetologe 5:4, 265-274
CrossRef416
A. Giaccari, G. Sorice, G. Muscogiuri. (2009) Glucose toxicity: The leading actor in the pathogenesis and clinical history of type 2 diabetes – mechanisms and potentials for treatment. Nutrition, Metabolism and Cardiovascular Diseases 19:5, 365-377
CrossRef417
Oluf PEDERSEN. (2009) Intensified multifactorial treatment of patients with Type 2 diabetes: What can be achieved and does it pay off?. Journal of Diabetes 1:2, 83-89
CrossRef418
M. Bartnik, F. Cosentino. (2009) Dysglycaemia, cardiovascular outcome and treatment. Is the jury still out?. European Heart Journal 30:11, 1301-1304
CrossRef419
K. K. Danielson, M. E. Elliott, T. LeCaire, N. Binkley, M. Palta. (2009) Poor glycemic control is associated with low BMD detected in premenopausal women with type 1 diabetes. Osteoporosis International 20:6, 923-933
CrossRef420
Suma Dronovalli, Basil O. Burney, George L. Bakris. (2009) Glycemic control and cardiovascular disease in chronic kidney disease. Current Diabetes Reports 9:3, 243-248
CrossRef421
Laurissa Kashmer, William Clarke, Matthew Gurka, Swati Elchuri, Maren Nyer, Linda Gonder-Frederick. (2009) Predictors of Parental Interest in Continuous Glucose Monitoring for Children with Type 1 Diabetes. Diabetes Technology & Therapeutics 11:6, 373-378
CrossRef422
Anthony L. McCall, Daniel J. Cox, Robert Brodows, John Crean, Don Johns, Boris Kovatchev. (2009) Reduced Daily Risk of Glycemic Variability: Comparison of Exenatide with Insulin Glargine. Diabetes Technology & Therapeutics 11:6, 339-344
CrossRef423
Fadi G. Hage, Rajesh Venkataraman, Gilbert J. Zoghbi, Gilbert J. Perry, Angelo M. DeMattos, Ami E. Iskandrian. (2009) The Scope of Coronary Heart Disease in Patients With Chronic Kidney Disease. Journal of the American College of Cardiology 53:23, 2129-2140
CrossRef424
Theodore Mazzone. (2009) Hyperglycaemia and coronary heart disease: the meta picture. The Lancet 373:9677, 1737-1738
CrossRef425
Cyrus DeSouza, Vivian Fonseca. (2009) Therapeutic targets to reduce cardiovascular disease in type 2 diabetes. Nature Reviews Drug Discovery 8:5, 361-367
CrossRef426
Andrew S. Weiss, Gerard Smits, Alexander C. Wiseman. (2009) Simultaneous Pancreas-Kidney Versus Deceased Donor Kidney Transplant: Can a Fair Comparison be Made?. Transplantation 87:9, 1402-1410
CrossRef427
I.M. Jazet, A.E. Meinders. (2009) Glucoregulation in type 2 diabetes: The lower the better? Glycosylated HbA1c of 6.5% seems to be the limit. European Journal of Internal Medicine 20:3, 232-235
CrossRef428
Nigel A. Calcutt, Mark E. Cooper, Tim S. Kern, Ann Marie Schmidt. (2009) Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nature Reviews Drug Discovery 8:5, 417-430
CrossRef429
Paul Zimmet. (2009) Preventing diabetic complications: A primary care perspective. Diabetes Research and Clinical Practice 84:2, 107-116
CrossRef430
Norman R.C. Campbell, Lawrence A. Leiter, Pierre Larochelle, Sheldon Tobe, Arun Chockalingam, Richard Ward, Dorothy Morris, Ross Tsuyuki. (2009) Hypertension in diabetes: A call to action. Canadian Journal of Cardiology 25:5, 299-302
CrossRef431
Ramiro A Sanchez, Miryam Ayala, Hugo Baglivo, Carlos Velazquez, Guillermo Burlando, Oswaldo Kohlmann, Jorge Jimenez, Patricio López Jaramillo, Ayrton Brandao, Gloria Valdes, Luis Alcocer, Mario Bendersky, Agustín José Ramirez, Alberto Zanchetti. (2009) Latin American guidelines on hypertension*. Journal of Hypertension 27:5, 905-922
CrossRef432
Kornél Simon. (2009) Civilizációs stressz, cardiovascularis kockázat, evidence based medicine, guideline-ok. Orvosi Hetilap 150:19, 895-902
CrossRef433
Jacob Dreiher, Gary Ginsberg, Gad Rabinowitz, Anat Raskin-Segal, Ron Weitzman, Avi Porath. (2009) Estimation of mortality savings due to a national program for diabetes care. European Journal of Internal Medicine 20:3, 307-312
CrossRef434
T. Lohmann, M. Möhlig, A. Pfeiffer. (2009) ACCORD, ADVANCE und VADT – Paradigmenwechsel in der Diabetologie?. Clinical Research in Cardiology Supplements 4:S2, 196-199
CrossRef435
E. Jaeckel, F. Lehner. (2009) Pankreas- und Inseltransplantation. Der Internist 50:5, 536-549
CrossRef436
Christian Weber, Serge Kocher, Kurt Neeser, Shashank R. Joshi. (2009) Prevention of diabetic ketoacidosis and self-monitoring of ketone bodies: an overview. Current Medical Research and Opinion 25:5, 1197-1207
CrossRef437
Marga Giménez, Rosa Gilabert, Ignacio Conget. (2009) Aterosclerosis preclínica en un grupo de pacientes jóvenes con diabetes de tipo 1 de un área mediterránea. Medicina Clínica 132:19, 740-742
CrossRef438
Daniel A. Finan, Cesar C. Palerm, Francis J. Doyle, Dale E. Seborg, Howard Zisser, Wendy C. Bevier, Lois Jovanovič. (2009) Effect of input excitation on the quality of empirical dynamic models for type 1 diabetes. AIChE Journal 55:5, 1135-1146
CrossRef439
Sandra L. Tunis, Michael E. Minshall, Christopher Conner, John I. McCormick, Jovana Kapor, Jean-François Yale, Danielle Groleau. (2009) Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis*. Current Medical Research and Opinion 25:5, 1273-1284
CrossRef440
Jaime S Rosa, Pietro R Galassetti. (2009) Altered molecular adaptation to exercise in children with type 1 diabetes: beyond hypoglycemia. Pediatric Diabetes 10:3, 213-226
CrossRef441
Zeina M Nabhan, Nerissa C Kreher, Dennis M Greene, Erica A Eugster, William Kronenberger, Linda A DiMeglio. (2009) A randomized prospective study of insulin pump vs. insulin injection therapy in very young children with type 1 diabetes: 12-month glycemic, BMI, and neurocognitive outcomes. Pediatric Diabetes 10:3, 202-208
CrossRef442
Babak Razani, Clay F Semenkovich. (2009) Getting away from glucose: stop sugarcoating diabetes. Nature Medicine 15:4, 372-373
CrossRef443
J. N. Basile. (2009) Antihypertensive therapy, new-onset diabetes, and cardiovascular disease. International Journal of Clinical Practice 63:4, 656-666
CrossRef444
Joseph I Wolfsdorf. (2009) How effective is continuous glucose monitoring in intensively treated type 1 diabetes mellitus?. Nature Clinical Practice Endocrinology & Metabolism 5:3, 134-135
CrossRef445
O. Heikkilä, N. Lundbom, M. Timonen, P.-H. Groop, S. Heikkinen, S. Mäkimattila. (2009) Hyperglycaemia is associated with changes in the regional concentrations of glucose and myo-inositol within the brain. Diabetologia 52:3, 534-540
CrossRef446
Cristiane B. Leitão, Pablo Cure, Shari Messinger, Antonello Pileggi, Oliver Lenz, Tatiana Froud, Raquel N. Faradji, Gennaro Selvaggi, Warren Kupin, Camillo Ricordi, Rodolfo Alejandro. (2009) Stable Renal Function After Islet Transplantation: Importance of Patient Selection and Aggressive Clinical Management. Transplantation 87:5, 681-688
CrossRef447
Georgia Soldatos, Mark E Cooper. (2009) Does intensive glycemic control for type 2 diabetes mellitus have long-term benefits for cardiovascular disease risk?. Nature Clinical Practice Endocrinology & Metabolism 5:3, 138-139
CrossRef448
Emily Jane GALLAGHER, Derek LE ROITH, Zachary BLOOMGARDEN. (2009) Review of hemoglobin A1c in the management of diabetes. Journal of Diabetes 1:1, 9-17
CrossRef449
Mona Boaz, Katerina Hellman, Julio Wainstein. (2009) An Automated Telemedicine System Improves Patient-Reported Well-Being. Diabetes Technology & Therapeutics 11:3, 181-186
CrossRef450
M. Yenigun, M. Honka. (2009) Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: results from a subgroup of the PREDICTIVE™ study. International Journal of Clinical Practice 63:3, 425-432
CrossRef451
Patricia Burdick, Sonia Cooper, Brian Horner, Erin Cobry, Kim McFann, H Peter Chase. (2009) Use of a subcutaneous injection port to improve glycemic control in children with type 1 diabetes. Pediatric Diabetes 10:2, 116-119
CrossRef452
Meaghan E.St. Charles, Hamid Sadri, Michael E. Minshall, Sandra L. Tunis. (2009) Health economic comparison between continuous subcutaneous insulin infusion and multiple daily injections of insulin for the treatment of adult type 1 diabetes in Canada. Clinical Therapeutics 31:3, 657-667
CrossRef453
Gabriela Orasanu, Jorge Plutzky. (2009) The Pathologic Continuum of Diabetic Vascular Disease. Journal of the American College of Cardiology 53:5, S35-S42
CrossRef454
Gerald H Tomkin. (2009) The effect of antidiabetic drugs on genes regulating lipid metabolism. Current Opinion in Lipidology 20:1, 10-16
CrossRef455
Alan Chait. (2009) Preventing cardiovascular disease in type 2 diabetes: Where do things stand with glycemic control? Part one. Current Diabetes Reports 9:1, 7-8
CrossRef456
Jayanta T. Mukherjee, Richard W. Nesto. (2009) The “legacy effect” associated with intensive glucose control in patients with type 2 diabetes. Current Diabetes Reports 9:1, 63-64
CrossRef457
Alena Nareika, Kamala P. Sundararaj, Yeong-Bin Im, Bryan A. Game, Maria F. Lopes-Virella, Yan Huang. (2009) High glucose and interferon gamma synergistically stimulate MMP-1 expression in U937 macrophages by increasing transcription factor STAT1 activity. Atherosclerosis 202:2, 363-371
CrossRef458
Michelle M. Averill, Karin E. Bornfeldt. (2009) Lipids versus glucose in inflammation and the pathogenesis of macrovascular disease in diabetes. Current Diabetes Reports 9:1, 18-25
CrossRef459
Alice Y. Y. Cheng, Lawrence A. Leiter. (2009) Diabetes and cardiovascular disease: The role of glycemic control. Current Diabetes Reports 9:1, 65-72
CrossRef460
Stuart W. Zarich. (2009) Potential of glucose-lowering drugs to reduce cardiovascular events. Current Diabetes Reports 9:1, 87-94
CrossRef461
Alan Chait. (2009) Preventing cardiovascular disease in type 2 diabetes: Where do things stand with glycemic control? Part two. Current Diabetes Reports 9:1, 9-10
CrossRef462
Ryuzo Kawamori, Toshiro Fujita, Hiroaki Matsuoka, Satoshi Umemura, Yasushi Saito. (2009) Relation between cardiovascular complications and blood pressure/blood glucose control in diabetic patients with hypertension receiving long-term candesartan cilexetil therapy: Challenge-DM study. Diabetes Research and Clinical Practice 83:2, 241-248
CrossRef463
Paresh Dandona, Ajay Chaudhuri, Husam Ghanim, Priya Mohanty. (2009) Insulin as an Anti-Inflammatory and Antiatherogenic Modulator. Journal of the American College of Cardiology 53:5, S14-S20
CrossRef464
Duckworth, William, Abraira, Carlos, Moritz, Thomas, Reda, Domenic, Emanuele, Nicholas, Reaven, Peter D., Zieve, Franklin J., Marks, Jennifer, Davis, Stephen N., Hayward, Rodney, Warren, Stuart R., Goldman, Steven, McCarren, Madeline, Vitek, Mary EllenHenderson, William G., Huang, Grant D., . (2009) Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. New England Journal of Medicine 360:2, 129-139
Full Text465
Hae Ri Lee, Jae Myung Yu, Moon-Gi Choi, Hyung Joon Yoo, Eun-Gyoung Hong. (2009) Risk Factors for Early Development of Macrovascular Complications in Korean Type 2 Diabetes. Korean Diabetes Journal 33:2, 134
CrossRef466
Philip R. Liebson. (2009) Diabetes Control and Cardiovascular Risk, Part II: Intensive Glucose Control - UKPDS Follow-Up. Preventive Cardiology 12:1, 51-58
CrossRef467
Katherine R. Tuttle. (2009) More Is Not Always Better: Intensive Glycemic Control in Type 2 Diabetes. American Journal of Kidney Diseases 53:1, 12-15
CrossRef468
Jay S. Skyler, Richard Bergenstal, Robert O. Bonow, John Buse, Prakash Deedwania, Edwin A.M. Gale, Barbara V. Howard, M. Sue Kirkman, Mikhail Kosiborod, Peter Reaven, Robert S. Sherwin. (2009) Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials. Journal of the American College of Cardiology 53:3, 298-304
CrossRef469
D. M. Nathan, J. B. Buse, M. B. Davidson, E. Ferrannini, R. R. Holman, R. Sherwin, B. Zinman. (2009) Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Diabetologia 52:1, 17-30
CrossRef470
John M Galla, Stephen J Nicholls. (2009) Pharmacologic therapy for coronary atherosclerosis in patients with Type 2 diabetes mellitus. Expert Review of Cardiovascular Therapy 7:1, 85-93
CrossRef471
Laura A. Maile, Lee B. Allen, Umadevi Veluvolu, Byron E. Capps, Walker H. Busby, Michael Rowland, David R. Clemmons. (2009) Identification of Compounds That Inhibit IGF-I Signaling in Hyperglycemia. Experimental Diabetes Research 2009, 1-10
CrossRef472
Michael E Cobble. (2009) Initiating and Intensifying Insulin Therapy for Type 2 Diabetes: Why, When, and How. American Journal of Therapeutics 16:1, 56-64
CrossRef473
William C. Hsu. (2009) Consequences of Delaying Progression to Optimal Therapy in Patients with Type 2 Diabetes Not Achieving Glycemic Goals. Southern Medical Journal 102:1, 67-76
CrossRef474
Richard Bergenstal, Andrew Lewin, Timothy Bailey, Denise Chang, Titus Gylvin, Victor Roberts. (2009) Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. Current Medical Research and Opinion 25:1, 65-75
CrossRef475
Rhonda K. Trousdale, Sharone' Jacobs, David A. Simhaee, June K. Wu, Joyce W. Lustbader. (2009) Wound Closure and Metabolic Parameter Variability in a db/db Mouse Model for Diabetic Ulcers. Journal of Surgical Research 151:1, 100-107
CrossRef476
Inge Tarnow, Alan D. Michelson, Marc R. Barnard, Andrew L. Frelinger, Bent Aasted, Berit R. Jensen, Hans-Henrik Parving, Peter Rossing, Lise Tarnow. (2009) Nephropathy in Type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity. Platelets 20:7, 513-519
CrossRef477
James B. Meigs, Frederick A. Masoudi. (2009) Cardiovascular disease is prevented over the long term by better blood glucose control. Current Cardiovascular Risk Reports 3:1, 33-34
CrossRef478
D.G. Federman, M. Shelling, S. Prodanovich, C.G. Gunderson, R.S. Kirsner. (2009) Psoriasis: an opportunity to identify cardiovascular risk. British Journal of Dermatology 160:1, 1-7
CrossRef479
P. Raskin, G. Matfin, S. L. Schwartz, L. Chaykin, P.-L. Chu, R. Braceras, A. Wynne. (2009) Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts). Diabetes, Obesity and Metabolism 11:1, 27-32
CrossRef480
A. M. Sheehy, D. B. Coursin, R. A. Gabbay. (2009) Back to Wilson and Jungner: 10 Good Reasons to Screen for Type 2 Diabetes Mellitus. Mayo Clinic Proceedings 84:1, 38-42
CrossRef481
Lisa R. Tannock, Victoria L King. (2008) Proteoglycan mediated lipoprotein retention: A mechanism of diabetic atherosclerosis. Reviews in Endocrine and Metabolic Disorders 9:4, 289-300
CrossRef482
Etie S. Moghissi, FACE. (2008) Insulin strategies for managing inpatient and outpatient hyperglycemia and diabetes. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 75:6, 558-566
CrossRef483
Vasilios G Athyros, Konstantinos Tziomalos, Asterios Karagiannis, Dimitri P Mikhailidis. (2008) Preventing macrovascular complications of diabetes: where do we stand with glycemic control?. Expert Opinion on Investigational Drugs 17:12, 1777-1779
CrossRef484
Elizabeth A. Spencer, Kirstin L. Pirie, Richard J. Stevens, Valerie Beral, Anna Brown, Bette Liu, Jane Green, Gillian K. Reeves, . (2008) Diabetes and modifiable risk factors for cardiovascular disease: the prospective Million Women Study. European Journal of Epidemiology 23:12, 793-799
CrossRef485
Scott Nelson. (2008) The role of insulin analogs in type 2 diabetes in the rural community. Current Medical Research and Opinion 24:11, 3129-3140
CrossRef486
M Fisher. (2008) Straight to you: retinopathy results of the DIRECT studies. Practical Diabetes International 25:9, 348-349
CrossRef487
R. Rubinstein, A. M. Genaro, A. Motta, G. Cremaschi, M. R. Wald. (2008) Impaired immune responses in streptozotocin-induced type I diabetes in mice. Involvement of high glucose. Clinical & Experimental Immunology 154:2, 235-246
CrossRef488
Chalmers, John, Cooper, Mark E., . (2008) UKPDS and the Legacy Effect. New England Journal of Medicine 359:15, 1618-1620
Full Text489
The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. (2008) Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes. New England Journal of Medicine 359:14, 1464-1476
Full Text490
Sharon D. Jackson. (2008) The ACCORD study: Are any of the results truly in?. Current Diabetes Reports 8:5, 391-392
CrossRef491
Benjamin A. Steinberg, Deepak L. Bhatt, Shamir Mehta, Philip A. Poole-Wilson, Philip O'Hagan, Gilles Montalescot, Christie M. Ballantyne, Christopher P. Cannon. (2008) Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease. American Heart Journal 156:4, 719-727
CrossRef492
Robert M. Califf, Mitradev Boolell, Steven M. Haffner, M. Angelyn Bethel, John McMurray, Anil Duggal, Rury R. Holman. (2008) Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: Rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. American Heart Journal 156:4, 623-632
CrossRef493
M.Á. Gómez Marcos, L. García Ortiz. (2008) Manejo general y extrahospitalario del paciente con diabetes. Valoración de la sintomatología. Procesos intercurrentes. Medicine - Programa de Formación Médica Continuada Acreditado 10:17, 1138-1148
CrossRef494
Satish K. Garg, Tevin R. Bookout, Kim K. McFann, William C. Kelly, Christie Beatson, Samuel L. Ellis, Raymond S. Gutin, Peter A. Gottlieb. (2008) Improved Glycemic Control in Intensively Treated Adult Subjects with Type 1 Diabetes Using Insulin Guidance Software. Diabetes Technology & Therapeutics 10:5, 369-375
CrossRef495
W. Pommer. (2008) Prevalence of nephropathy in the German diabetes population--Is early referral to nephrological care a realistic demand today?. NDT Plus 1:Supplement 4, iv2-iv5
CrossRef496
Csaba P. Kovesdy, Kumar Sharma, Kamyar Kalantar-Zadeh. (2008) Glycemic Control in Diabetic CKD Patients: Where Do We Stand?. American Journal of Kidney Diseases 52:4, 766-777
CrossRef497
M. Tiburcy, W.-H. Zimmermann. (2008) Therapie des Diabetes mellitus Typ 2 und kardiovaskuläre Komplikationen. Der Kardiologe 2:5, 417-429
CrossRef498
Yamile Roselló Azcanio, Alfredo Vázquez Vigoa, José Emilio Fernández-Britto Rodríguez, Jorge Bacallao Gallestey, Nelson Roselló Silva, Nélida María Cruz Álvarez. (2008) Disglucemia de ayuno asociada o no a la tolerancia alterada a la glucosa como marcador de riesgo en la aterosclerosis carotídea subclínica. Clínica e Investigación en Arteriosclerosis 20:5, 177-182
CrossRef499
Juan José Chillarón, Juan Francisco Cano, Juan Pedro-Botet. (2008) Diabetes mellitus tipo 1 y riesgo cardiovascular. Clínica e Investigación en Arteriosclerosis 20:5, 210-217
CrossRef500
D.R. Owens, G.B. Bolli. (2008) Beyond the Era of NPH Insulin—Long-Acting Insulin Analogs: Chemistry, Comparative Pharmacology, and Clinical Application. Diabetes Technology & Therapeutics 10:5, 333-349
CrossRef501
A. El-Osta, D. Brasacchio, D. Yao, A. Pocai, P. L. Jones, R. G. Roeder, M. E. Cooper, M. Brownlee. (2008) Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. Journal of Experimental Medicine 205:10, 2409-2417
CrossRef502
John S Yudkin. (2008) Hyperglycaemia as a cardiovascular risk factor in diabetes. The Lancet 372:9643, 1036-1037
CrossRef503
S. Artola Menéndez. (2008) Tratamiento de la hiperglucemia: ¿hasta dónde los objetivos de control?. Revista Clínica Española 208, 19-25
CrossRef504
T. T. L. Pang, P. Narendran. (2008) Addressing insulin resistance in Type 1 diabetes. Diabetic Medicine 25:9, 1015-1024
CrossRef505
M Wallymahmed. (2008) The management of type 1 diabetes: more than just glycaemic control?. Practical Diabetes International 25:7, 285-289
CrossRef506
E. S. Kilpatrick, A. K. Das, C. Ørskov, K. Berntorp. (2008) Good glycaemic control: an international perspective on bridging the gap between theory and practice in type 2 diabetes. Current Medical Research and Opinion 24:9, 2651-2661
CrossRef507
Rekha Mankad, Patricia JM Best. (2008) Cardiovascular disease in older women: a challenge in diagnosis and treatment. Women's Health 4:5, 449-464
CrossRef508
T. M. S. Wolever, C. Mehling, J.-L. Chiasson, R. G. Josse, L. A. Leiter, P. Maheux, R. Rabasa-Lhoret, N. W. Rodger, E. A. Ryan. (2008) Low glycaemic index diet and disposition index in type 2 diabetes (the Canadian trial of Carbohydrates in Diabetes): a randomised controlled trial. Diabetologia 51:9, 1607-1615
CrossRef509
Andrew Zinn, Sabrina Felson, Edward Fisher, Arthur Schwartzbard. (2008) Reassessing the Cardiovascular Risks and Benefits of Thiazolidinediones. Clinical Cardiology 31:9, 397-403
CrossRef510
Jean-Pierre Després, Benoit J. Arsenault, Mélanie Côté, Amélie Cartier, Isabelle Lemieux. (2008) Abdominal obesity: The cholesterol of the 21st century?. Canadian Journal of Cardiology 24, 7D-12D
CrossRef511
Carolyn Quan, Nicholas J. Talley, Michael P. Jones, Stuart Howell, Michael Horowitz. (2008) Gastrointestinal symptoms and glycemic control in diabetes mellitus: a longitudinal population study. European Journal of Gastroenterology & Hepatology 20:9, 888-897
CrossRef512
George Rammos, Vasileios Peppes, Nicolaos Zakopoulos. (2008) Transient Insulin Resistance in Normal Subjects: Acute Hyperglycemia Inhibits Endothelial-Dependent Vasodilatation in Normal Subjects. Metabolic Syndrome and Related Disorders 6:3, 159-170
CrossRef513
Bernard Zinman. (2008) Does an intensive multifactorial intervention reduce mortality in type 2 diabetes mellitus?. Nature Clinical Practice Endocrinology & Metabolism 4:8, 434-435
CrossRef514
Deborah A Butler, Jessica B Zuehlke, Alison Tovar, Lisa K Volkening, Barbara J Anderson, Lori MB Laffel. (2008) The impact of modifiable family factors on glycemic control among youth with type 1 diabetes. Pediatric Diabetes 9:4pt2, 373-381
CrossRef515
S. Genuth. (2008) The UKPDS and its global impact. Diabetic Medicine 25, 57-62
CrossRef516
Khalida Ismail, Barbara Mühlhans. (2008) Die Effektivität psychologischer Behandlungsansätze zur Verbesserung der Stoffwechselkontrolle bei Patienten mit Diabetes mellitus. Psychosomatik und Konsiliarpsychiatrie 2:3, 131-137
CrossRef517
Norbert Hermanns, Bernhard Kulzer, Thomas Haak. (2008) Dosing Accuracy with a Novel Pen Device (SoloSTAR ® ) as Performed by Patients with Diabetes in a Clinical Setting. Diabetes Technology & Therapeutics 10:4, 322-327
CrossRef518
Irl B. Hirsch, Dana Armstrong, Richard M. Bergenstal, Bruce Buckingham, Belinda P. Childs, William L. Clarke, Anne Peters, Howard Wolpert. (2008) Clinical Application of Emerging Sensor Technologies in Diabetes Management: Consensus Guidelines for Continuous Glucose Monitoring (CGM). Diabetes Technology & Therapeutics 10:4, 232-246
CrossRef519
L. Meneghini. (2008) Demonstrating strategies for initiation of insulin therapy: matching the right insulin to the right patient. International Journal of Clinical Practice 62:8, 1255-1264
CrossRef520
Stephen Brunton. (2008) Initiating Insulin Therapy in Type 2 Diabetes: Benefits of Insulin Analogs and Insulin Pens. Diabetes Technology & Therapeutics 10:4, 247-256
CrossRef521
Toshinari Asakura, Hiroaki Seino, Klaus H. Jensen. (2008) Patient Acceptance and Issues of Education of Two Durable Insulin Pen Devices. Diabetes Technology & Therapeutics 10:4, 299-304
CrossRef522
S.-i. Yamagishi. (2008) Possible involvement of advanced glycation end products in carry-over benefits of atorvastatin in ASCOT-BPLA. European Heart Journal 29:15, 1922-1922
CrossRef523
Robert M Cohen, Eric P Smith. (2008) Frequency of HbA1c discordance in estimating blood glucose control. Current Opinion in Clinical Nutrition and Metabolic Care 11:4, 512-517
CrossRef524
Nicole M. Engel-Nitz, Sherry Martin, Peter Sun, Don Buesching, Vivian Fonseca. (2008) Cardiovascular events and insulin therapy: A retrospective cohort analysis. Diabetes Research and Clinical Practice 81:1, 97-104
CrossRef525
Angela T. Dearinger, John F. Wilson, Charles H. Griffith, F. Douglas Scutchfield. (2008) The Effect of Physician Continuity on Diabetic Outcomes in a Resident Continuity Clinic. Journal of General Internal Medicine 23:7, 937-941
CrossRef526
Z. T. Bloomgarden, S. E. Inzucchi, E. Karnieli, D. Roith. (2008) The proposed terminology ‘A1c-derived average glucose’ is inherently imprecise and should not be adopted. Diabetologia 51:7, 1111-1114
CrossRef527
Sho-ichi Yamagishi, Kazuo Nakamura, Takanori Matsui, Seiji Ueda, Kei Fukami, Seiya Okuda. (2008) Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Expert Opinion on Investigational Drugs 17:7, 983-996
CrossRef528
M Florentin, EN Liberopoulos, DP Mikhailidis, Elisaf MS. (2008) Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy 9:10, 1705-1720
CrossRef529
Rohana J. Wright, Brian M. Frier. (2008) Vascular disease and diabetes: is hypoglycaemia an aggravating factor?. Diabetes/Metabolism Research and Reviews 24:5, 353-363
CrossRef530
P. M. Spooner. (2008) Sudden cardiac death: influence of diabetes. Diabetes, Obesity and Metabolism 10:7, 523-532
CrossRef531
Me Wallymahmed, C Morgan, Gv Gill, V Osman-hicks, P Chamberlain, IA Macfarlane. (2008) Changes in cardiovascular risk factors in a type 1 diabetes population: a 3.5-year study. Practical Diabetes International 25:6, 223-227
CrossRef532
Luigi F Meneghini. (2008) Insulin detemir: a long-acting insulin analog for the treatment of Type 1 and 2 diabetes. Therapy 5:4, 513-529
CrossRef533
Jill P Crandall, William C Knowler, Steven E Kahn, David Marrero, Jose C Florez, George A Bray, Steven M Haffner, Mary Hoskin, David M Nathan. (2008) The prevention of type 2 diabetes. Nature Clinical Practice Endocrinology & Metabolism 4:7, 382-393
CrossRef534
L. M. Villeneuve, M. A. Reddy, L. L. Lanting, M. Wang, L. Meng, R. Natarajan. (2008) Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes. Proceedings of the National Academy of Sciences 105:26, 9047-9052
CrossRef535
John M. Lachin. (2008) Sample size evaluation for a multiply matched case–control study using the score test from a conditional logistic (discrete Cox PH) regression model. Statistics in Medicine 27:14, 2509-2523
CrossRef536
Dluhy, Robert G., McMahon, Graham T., . (2008) Intensive Glycemic Control in the ACCORD and ADVANCE Trials. New England Journal of Medicine 358:24, 2630-2633
Full Text537
Roger S. Mazze, Ellie Strock, David Wesley, Sarah Borgman, Blaine Morgan, Richard Bergenstal, Robert Cuddihy. (2008) Characterizing Glucose Exposure for Individuals with Normal Glucose Tolerance Using Continuous Glucose Monitoring and Ambulatory Glucose Profile Analysis. Diabetes Technology & Therapeutics 10:3, 149-159
CrossRef538
Paresh Dandona, Ajay Chaudhuri, Husam Ghanim, Priya Mohanty. (2008) Use of Insulin to Improve Glycemic Control in Diabetes Mellitus. Cardiovascular Drugs and Therapy 22:3, 241-251
CrossRef539
Satish K. Garg. (2008) Glucose Monitoring: An Important Tool for Improving Glucose Control and Reducing Hypoglycemia. Diabetes Technology & Therapeutics 10:s1, S-1-S-4
CrossRef540
Shoba L. Subramanian, Irl B. Hirsch. (2008) The Utility and Recent Advances in Self-Monitoring of Blood Glucose in Type 1 Diabetes. Diabetes Technology & Therapeutics 10:s1, S-43-S-50
CrossRef541
Eric A Huang, Stephen E Gitelman. (2008) The effect of oral alpha-lipoic acid on oxidative stress in adolescents with type 1 diabetes mellitus. Pediatric Diabetes 9:3pt2, 69-73
CrossRef542
P. Narendran. (2008) Glycaemic control in Type 2 diabetesnot for sidelining. Diabetic Medicine 25:6, 639-642
CrossRef543
Roger Mazze. (2008) The Future of Self-Monitored Blood Glucose: Mean Blood Glucose Versus Glycosylated Hemoglobin. Diabetes Technology & Therapeutics 10:s1, S-93-S-101
CrossRef544
Oliver Schnell, Michael Hummel, Christian Weber. (2008) Economic and Clinical Aspects of Diabetes Regarding Self-Monitoring of Blood Glucose. Diabetes Technology & Therapeutics 10:s1, S-72-S-81
CrossRef545
E. Nobécourt, J. Zeng, M. J. Davies, B. E. Brown, S. Yadav, P. J. Barter, K.-A. Rye. (2008) Effects of cross-link breakers, glycation inhibitors and insulin sensitisers on HDL function and the non-enzymatic glycation of apolipoprotein A-I. Diabetologia 51:6, 1008-1017
CrossRef546
O. Vaccaro, M. Boemi, F. Cavalot, P. De Feo, R. Miccoli, L. Patti, A.A. Rivellese, M. Trovati, D. Ardigò, I. Zavaroni. (2008) The clinical reality of guidelines for primary prevention of cardiovascular disease in type 2 diabetes in Italy. Atherosclerosis 198:2, 396-402
CrossRef547
(2008) Multifactorial Intervention and Mortality in Type 2 Diabetes. New England Journal of Medicine 358:21, 2292-2293
Full Text548
Paresh Dandona, Ajay Chaudhuri, Husam Ghanim, Priya Mohanty. (2008) Potential use of insulin as an anti-inflammatory drug. Drug Development Research 69:3, 101-110
CrossRef549
Antonio Ceriello, Stephen Colagiuri, John Gerich, Jaakko Tuomilehto. (2008) Guideline for management of postmeal glucose. Nutrition, Metabolism and Cardiovascular Diseases 18:4, S17-S33
CrossRef550
Jean-Claude Desmangles. (2008) Treatment of type 1 diabetes in children and adolescents. Drug Development Research 69:3, 158-164
CrossRef551
Anders H. Boss, Wen Yu, Karen Ellerman. (2008) Prandial insulin: is inhaled enough?. Drug Development Research 69:3, 138-142
CrossRef552
Ravi Retnakaran, Bernard Zinman. (2008) Type 1 diabetes, hyperglycaemia, and the heart. The Lancet 371:9626, 1790-1799
CrossRef553
Louise S. Conwell, Elena Pope, Ana M. Artiles, Arun Mohanta, Alan Daneman, Denis Daneman. (2008) Dermatological Complications of Continuous Subcutaneous Insulin Infusion in Children and Adolescents. The Journal of Pediatrics 152:5, 622-628
CrossRef554
P. C. Bartley, M. Bogoev, J. Larsen, A. Philotheou. (2008) Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal–bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabetic Medicine 25:4, 442-449
CrossRef555
Allison B Goldfine. (2008) The rough road for rosiglitazone. Current Opinion in Endocrinology, Diabetes and Obesity 15:2, 113-117
CrossRef556
Linda E. Thomas, Michael P. Kane, Gary Bakst, Robert S. Busch, Robert A. Hamilton, Jill M. Abelseth. (2008) A Glucose Meter Accuracy and Precision Comparison: The FreeStyle Flash Versus the Accu-Chek Advantage, Accu-Chek Compact Plus, Ascensia Contour, and the BD Logic. Diabetes Technology & Therapeutics 10:2, 102-110
CrossRef557
Steven Leichter. (2008) Is the use of insulin analogues cost-effective?. Advances in Therapy 25:4, 285-299
CrossRef558
Juan José Chillarón, Albert Goday, Juan Pedro-Botet. (2008) Síndrome metabólico, diabetes mellitus tipo 1 y resistencia a la insulina. Medicina Clínica 130:12, 466-471
CrossRef559
Deborah P Wubben, Eva M Vivian. (2008) Effects of Pharmacist Outpatient Interventions on Adults with Diabetes Mellitus: A Systematic Review. Pharmacotherapy 28:4, 421-436
CrossRef560
H. D. Margeirsdottir, J. R. Larsen, C. Brunborg, N. C. Øverby, K. Dahl-Jørgensen, . (2008) High prevalence of cardiovascular risk factors in children and adolescents with type 1 diabetes: a population-based study. Diabetologia 51:4, 554-561
CrossRef561
Erin Cobry, H. Peter Chase, Patricia Burdick, Kim McFann, Hannah Yetzer, Laura Scrimgeour. (2008) Use of CoZmonitor ® in youth with type 1 diabetes. Pediatric Diabetes 9:2, 148-151
CrossRef562
Christopher J. Lockhart, Paul K. Hamilton, Katherine A. McVeigh, Gary E. McVeigh. (2008) A cardiologist view of vascular disease in diabetes. Diabetes, Obesity and Metabolism 10:4, 279-292
CrossRef563
Thomas W. Donner, Kristin M. Flammer. (2008) Diabetes Management in the Hospital. Medical Clinics of North America 92:2, 407-425
CrossRef564
Chin-Wei Huang, Jing-Jane Tsai, Horng-Yih Ou, Shin-Tair Wang, Juei-Tang Cheng, Sheng-Nan Wu, Chao-Ching Huang. (2008) Diabetic hyperglycemia is associated with the severity of epileptic seizures in adults. Epilepsy Research 79:1, 71-77
CrossRef565
Jeffrey P. Levine. (2008) Type 2 Diabetes Among Women: Clinical Considerations for Pharmacological Management to Achieve Glycemic Control and Reduce Cardiovascular Risk. Journal of Women's Health 17:2, 249-260
CrossRef566
Sho-ichi Yamagishi, Kazuo Nakamura, Takanori Matsui, So Ueda, Yoshihiro Noda, Tsutomu Imaizumi. (2008) Inhibitors of Advanced Glycation End Products (AGEs): Potential Utility for the Treatment of Cardiovascular Disease. Cardiovascular Drug Reviews 26:1, 50-58
CrossRef567
M Skamagas, TL Breen, D LeRoith. (2008) Update on diabetes mellitus: prevention, treatment, and association with oral diseases. Oral Diseases 14:2, 105-114
CrossRef568
Suphachai Chirakup, Nathorn Chaiyakunapruk, Usa Chaikledkeaw, Petcharat Pongcharoensuk, Boonsong Ongphiphadhanakul, Stephane Roze, William J. Valentine, Andrew J. Palmer. (2008) Cost-Effectiveness Analysis of Thiazolidinediones in Uncontrolled Type 2 Diabetic Patients Receiving Sulfonylureas and Metformin in Thailand. Value in Health 11, S43-S51
CrossRef569
Ning Cheung, Tien Y. Wong. (2008) Diabetic retinopathy and systemic vascular complications. Progress in Retinal and Eye Research 27:2, 161-176
CrossRef570
Dawn Kernaghan, Tom Farrell, Peter Hammond, Philip Owen. (2008) Fetal growth in women managed with insulin pump therapy compared to conventional insulin. European Journal of Obstetrics & Gynecology and Reproductive Biology 137:1, 47-49
CrossRef571
D. C. Duke, G. R. Geffken, A. B. Lewin, L. B. Williams, E. A. Storch, J. H. Silverstein. (2008) Glycemic Control in Youth with Type 1 Diabetes: Family Predictors and Mediators. Journal of Pediatric Psychology 33:7, 719-727
CrossRef572
F. Johansson, F. Kramer, S. Barnhart, J. E. Kanter, T. Vaisar, R. D. Merrill, L. Geng, K. Oka, L. Chan, A. Chait, J. W. Heinecke, K. E. Bornfeldt. (2008) Type 1 diabetes promotes disruption of advanced atherosclerotic lesions in LDL receptor-deficient mice. Proceedings of the National Academy of Sciences 105:6, 2082-2087
CrossRef573
Gæde, Peter, Lund-Andersen, Henrik, Parving, Hans-Henrik, Pedersen, Oluf, . (2008) Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes. New England Journal of Medicine 358:6, 580-591
Full Text574
Michael J Haller, Desmond A Schatz. (2008) Cytokines and type 1 diabetes complications: casual or causal association?. Pediatric Diabetes 9:1, 1-2
CrossRef575
John A. Farmer. (2008) Diabetic dyslipidemia and atherosclerosis: Evidence from clinical trials. Current Diabetes Reports 8:1, 71-77
CrossRef576
Mark A Malesker. (2008) Optimizing Antidiabetic Treatment Options for Patients with Type 2 Diabetes Mellitus and Cardiovascular Comorbidities. Pharmacotherapy 28:2, 193-206
CrossRef577
Christine K Choy, Jo E Rodgers, Jean M Nappi, Stuart T Haines. (2008) Type 2 Diabetes Mellitus and Heart Failure. Pharmacotherapy 28:2, 170-192
CrossRef578
Bastiaan E de Galan. (2008) Can inhaled insulin be used for the treatment of diabetes mellitus?. Expert Review of Pharmacoeconomics & Outcomes Research 8:1, 33-42
CrossRef579
Helen D. Berlie, William H. Herman, Morton B. Brown, Adnan Hammad, Linda A. Jaber. (2008) Quality of diabetes care in Arab Americans. Diabetes Research and Clinical Practice 79:2, 249-255
CrossRef580
Jaime S Rosa, Rebecca L Flores, Stacy R Oliver, Andria M Pontello, Frank P Zaldivar, Pietro R Galassetti. (2008) Sustained IL-1α, IL-4, and IL-6 elevations following correction of hyperglycemia in children with type 1 diabetes mellitus. Pediatric Diabetes 9:1, 9-16
CrossRef581
J. Sáez de la Fuente, V. Granja Berna, J.M. Ferrari Piquero, M.Á. Valero Zanuy, A. Herreros de Tejada López-Coterilla. (2008) Tipos de insulinoterapia. Revista Clínica Española 208:2, 76-86
CrossRef582
Gabriel Gregoratos, Gordon Leung. 2008. Diabetes Mellitus and Cardiovascular Disease in the Elderly. , 179-214.
CrossRef583
Matthew Coghlan, Brendan Leighton. (2008) Glucokinase activators in diabetes management. Expert Opinion on Investigational Drugs 17:2, 145-167
CrossRef584
E. S. Kilpatrick, A. S. Rigby, S. L. Atkin. (2008) Mean blood glucose compared with HbA1c in the prediction of cardiovascular disease in patients with type 1 diabetes. Diabetologia 51:2, 365-371
CrossRef585
S. Hadjadj, P.-J. Saulnier, F. Torremocha, L. Labbé, R. Maréchaud. (2008) To what extent should we lower HbA1c in diabetic subjects?. Diabetes & Metabolism 34, 37-40
CrossRef586
Anne Dornhorst, Hans-Joachim Lüddeke, Marek Honka, Ralf W. Ackermann, Markus Meriläinen, Baptist Gallwitz, Seamus Sreenan. (2008) Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study. Current Medical Research and Opinion 24:2, 369-376
CrossRef587
Tammy R. Kopelman, Patrick J. OʼNeill, Shalini R. Kanneganti, Karole M. Davis, David A. Drachman. (2008) The Relationship of Plasma Glucose and Glycosylated Hemoglobin A1C Levels Among Nondiabetic Trauma Patients. The Journal of Trauma: Injury, Infection, and Critical Care 64:1, 30-34
CrossRef588
Amanda Adler. (2008) Glycemic control to prevent cardiovascular disease in type 2 diabetes. Current Cardiovascular Risk Reports 2:1, 66-71
CrossRef589
Prakash Deedwania, Sundararajan Srikanth. (2008) Diabetes and vascular disease. Expert Review of Cardiovascular Therapy 6:1, 127-138
CrossRef590
Woo Je Lee, Kyung Soo Ko, Byoung Doo Rhee. (2008) Intensive Glucose Control and Cardiovascular Outcomes: Focused on Recent Clinical Trials. Journal of Korean Endocrine Society 23:5, 289
CrossRef591
Tetsuya Tabeya, Hirofumi Ohnishi, Shigeyuki Saitoh, Hiroshi Akasaka, Kaneto Mitsumata, Mizue Chiba, Makoto Furugen, Mitsuru Mori, Kazuaki Shimamoto. (2008) Relationship of metabolic syndrome and insulin resistance with microalbuminuria in senior citizens of rural communities in Japan -The Tanno and Sobetsu Study-. Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics 45:3, 302-307
CrossRef592
Yunsheng Ma, Barbara C. Olendzki, Philip A. Merriam, David E. Chiriboga, Annie L. Culver, Wenjun Li, James R. Hébert, Ira S. Ockene, Jennifer A. Griffith, Sherry L. Pagoto. (2008) A randomized clinical trial comparing low–glycemic index versus ADA dietary education among individuals with type 2 diabetes. Nutrition 24:1, 45-56
CrossRef593
Alan J Garber, Morali D Sharma. (2008) Update: vildagliptin for the treatment of Type 2 diabetes. Expert Opinion on Investigational Drugs 17:1, 105-113
CrossRef594
Karen Furie, Silvio E. Inzucchi. (2008) Diabetes mellitus, insulin resistance, hyperglycemia, and stroke. Current Neurology and Neuroscience Reports 8:1, 12-19
CrossRef595
The ORIGIN Trial Investigators. (2008) Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). American Heart Journal 155:1, 26.e1-26.e13
CrossRef596
Bertram L. Kasiske, Ajay K. Israni. 2008. Cardiovascular Complications after Renal Transplantation. , 469-491.
CrossRef597
Tae Sun Park, Hong-Sun Baek, Ji-Hyun Park. (2008) General Principles for Diabetes Mellitus Management. Journal of the Korean Medical Association 51:9, 806
CrossRef598
Katrin E Schimke, Timothy ME Davis. (2008) Inhaled human insulin (Exubera ® ): its pharmacologic profile, efficacy and safety in the treatment of adults with diabetes mellitus. Expert Review of Clinical Pharmacology 1:1, 13-25
CrossRef599
Dimitri P Mikhailidis, Martin Press. (2007) The importance of treating multiple cardiometabolic risk factors in patients with Type 2 diabetes. Expert Opinion on Pharmacotherapy 8:17, 3009-3020
CrossRef600
Jeff Unger. (2007) Management of Diabetes in Pregnancy, Childhood, and Adolescence. Primary Care: Clinics in Office Practice 34:4, 809-843
CrossRef601
M. Giménez, I. Conget, M. Jansà, M. Vidal, G. Chiganer, I. Levy. (2007) Efficacy of continuous subcutaneous insulin infusion in Type 1 diabetes: a 2-year perspective using the established criteria for funding from a National Health Service. Diabetic Medicine 24:12, 1419-1423
CrossRef602
James T. Lane, Agnes Ferguson, Joyce Hall, Maxine McElligott, Marilyn Miller, Pascale H. Lane, Elizabeth Pfeffer. (2007) Glycemic control over 3 years in a young adult clinic for patients with type 1 diabetes. Diabetes Research and Clinical Practice 78:3, 385-391
CrossRef603
Vijay Srinivasan. (2007) Strict control of blood glucose concentrations in critically ill children utilizing adequately explicit methodologies to improve outcomes. Pediatric Health 1:2, 241-258
CrossRef604
Timothy M.E. Davis, David G. Bruce, Wendy A. Davis. (2007) Prevalence and prognostic implications of the metabolic syndrome in community-based patients with type 1 diabetes: The Fremantle Diabetes Study. Diabetes Research and Clinical Practice 78:3, 412-417
CrossRef605
M. S. Roy, B. Peng, A. Roy. (2007) Risk factors for coronary disease and stroke in previously hospitalized African-Americans with Type 1 diabetes: a 6-year follow-up. Diabetic Medicine 24:12, 1361-1368
CrossRef606
Jeff Unger. (2007) Diagnosis and Management of Type 2 Diabetes and Prediabetes. Primary Care: Clinics in Office Practice 34:4, 731-759
CrossRef607
S. Del Prato, E. Horton, R. Nesto, . (2007) We have the evidence, we need to act to improve diabetes care. International Journal of Clinical Practice 61, 9-15
CrossRef608
S. Del Prato. (2007) A call to action - the UN Resolution on diabetes. International Journal of Clinical Practice 61, 1-4
CrossRef609
Elbert S. Huang, Qi Zhang, Sydney E. S. Brown, Melinda L. Drum, David O. Meltzer, Marshall H. Chin. (2007) The Cost-Effectiveness of Improving Diabetes Care in U.S. Federally Qualified Community Health Centers. Health Services Research 42:6p1, 2174-2193
CrossRef610
Marian Rewers, Catherine Pihoker, Kim Donaghue, Ragnar Hanas, Peter Swift, Georgeanna J Klingensmith. (2007) Assessment and monitoring of glycemic control in children and adolescents with diabetes. Pediatric Diabetes 8:6, 408-418
CrossRef611
Toby C Trujillo, Paul P Dobesh. (2007) Traditional Management of Chronic Stable Angina. Pharmacotherapy 27:12, 1677-1692
CrossRef612
Ateeq Syed, Sania Hussain, Peter Nightingale, Parijat De, Mary H. Charlton, Kalyan Gangopadhyay, Anthony H. Barnett, Parth Narendran. (2007) Cardiovascular risk factors and their management in 1282 adult people with type 1 diabetes. Current Medical Research and Opinion 23:12, 2921-2927
CrossRef613
I. M. E. Wentholt, W. Kulik, R. P. J. Michels, J. B. L Hoekstra, J. H. DeVries. (2007) Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes. Diabetologia 51:1, 183-190
CrossRef614
Paul Kuo, Christopher K. Rayner, Michael Horowitz. (2007) Gastric Emptying, Diabetes, and Aging. Clinics in Geriatric Medicine 23:4, 785-808
CrossRef615
Alan C. Moses. (2007) Commentary: Will It Take Harry Potter to Solve Diabetes? Divining the Future of Diabetes Care. Journal of Periodontology 78:11, 2077-2080
CrossRef616
Noah D. Lubowsky, Richard Siegel, Anastassios G. Pittas. (2007) Management of Glycemia in Patients With Diabetes Mellitus and CKD. American Journal of Kidney Diseases 50:5, 865-879
CrossRef617
T Danne, D Becker. (2007) Paediatric diabetes: achieving practical, effective insulin therapy in type 1 and type 2 diabetes. Acta Paediatrica 96:11, 1560-1570
CrossRef618
Sherita H. Golden, Elizabeth Selvin, Kayla E. Cunningham. (2007) Glycaemic status and cardiovascular disease in type 2 diabetes mellitus: re-visiting glycated haemoglobin targets for cardiovascular disease prevention. Diabetes, Obesity and Metabolism 9:6, 792-798
CrossRef619
Ariane Godbout, Jean-Louis Chiasson. (2007) Who should benefit from the use of alpha-glucosidase inhibitors?. Current Diabetes Reports 7:5, 333-339
CrossRef620
Deborah J Wexler. (2007) Inpatient diabetes management in general medical and surgical settings: evidence and update. Expert Review of Pharmacoeconomics & Outcomes Research 7:5, 491-502
CrossRef621
C. T. Prince, D. J. Becker, T. Costacou, R. G. Miller, T. J. Orchard. (2007) Changes in glycaemic control and risk of coronary artery disease in type 1 diabetes mellitus: findings from the Pittsburgh Epidemiology of Diabetes Complications Study (EDC). Diabetologia 50:11, 2280-2288
CrossRef622
Andrea K Steck, Georgeanna J Klingensmith, Rosanna Fiallo-Scharer. (2007) Recent advances in insulin treatment of children. Pediatric Diabetes 8:s6, 49-56
CrossRef623
Hjalmar R Hansen, Jef L Wolfs, Lois Bruggemann, Dirkje W Sommeijer, Eduard Bevers, Arnaud D Hauer, Johan Kuiper, C Arnold Spek, Henri MH Spronk, Pieter H Reitsma, Hugo ten Cate. (2007) Hyperglycemia accelerates arterial thrombus formation and attenuates the antithrombotic response to endotoxin in mice. Blood Coagulation & Fibrinolysis 18:7, 627-636
CrossRef624
M. J. Alberts, B. Ovbiagele. (2007) Current strategies for ischemic stroke prevention: role of multimodal combination therapies. Journal of Neurology 254:10, 1414-1426
CrossRef625
N. C. Øverby, H. D. Margeirsdottir, C. Brunborg, L. F. Andersen, K. Dahl-Jørgensen. (2007) The influence of dietary intake and meal pattern on blood glucose control in children and adolescents using intensive insulin treatment. Diabetologia 50:10, 2044-2051
CrossRef626
Jens Sandahl Christiansen. (2007) Insulin aspart: rapid control for postmeal glucose excursions. Expert Review of Endocrinology & Metabolism 2:5, 587-597
CrossRef627
Victor M Montori, Gunjan Y Gandhi, Gordon H Guyatt. (2007) Patient-important outcomes in diabetes—time for consensus. The Lancet 370:9593, 1104-1106
CrossRef628
Klaus-Dieter Kohnert, Petra Augstein, Peter Heinke, Eckhard Zander, Karolina Peterson, Ernst-Joachim Freyse, Eckhard Salzsieder. (2007) Chronic hyperglycemia but not glucose variability determines HbA1c levels in well-controlled patients with type 2 diabetes. Diabetes Research and Clinical Practice 77:3, 420-426
CrossRef629
Harald Sourij, Thomas C Wascher. (2007) Pioglitazone in the management of Type 2 diabetes and beyond. Therapy 4:5, 517-533
CrossRef630
R. W. Bilous. (2007) Rosiglitazone and myocardial infarction: cause for concern or misleading meta-analysis?. Diabetic Medicine 24:9, 931-933
CrossRef631
W. Pommer. (2007) Nephropathie bei Diabetespatienten. Der Nephrologe 2:5, 313-318
CrossRef632
Negar Sadrzadeh, Michael J. Glembourtt, Cynthia L. Stevenson. (2007) Peptide drug delivery strategies for the treatment of diabetes. Journal of Pharmaceutical Sciences 96:8, 1925-1954
CrossRef633
Michael J Haller, Jennifer Stein, Jon Shuster, Douglas Theriaque, Janet Silverstein, Desmond A Schatz, Michael G Earing, Amir Lerman, Farid H Mahmud. (2007) Peripheral artery tonometry demonstrates altered endothelial function in children with type 1 diabetes. Pediatric Diabetes 8:4, 193-198
CrossRef634
M. Koga, S. Morita, H. Saito, M. Mukai, S. Kasayama. (2007) Association of erythrocyte indices with glycated haemoglobin in pre-menopausal women. Diabetic Medicine 24:8, 843-847
CrossRef635
Ian Goodall, Peter G. Colman, Hans G. Schneider, Mark McLean, George Barker. (2007) Desirable performance standards for HbA 1c analysis – precision, accuracy and standardisation Consensus statement of the Australasian Association of Clinical Biochemists (AACB), the Australian Diabetes Society (ADS), the Royal College of Pathologists of Australasia (RCPA), Endocrine Society of Australia (ESA), and the Australian Diabetes Educators Association (ADEA). Clinical Chemistry and Laboratory Medicine 45:8, 1083-1097
CrossRef636
U. Smith. (2007) Introduction: Symposium on diabetes, inflammation and cardiovascular disease. Journal of Internal Medicine 262:2, 142-144
CrossRef637
David L. Russell-Jones. (2007) Insulin Detemir and Basal Insulin Therapy. Endocrinology & Metabolism Clinics of North America 36, 7-13
CrossRef638
Anne Daly. (2007) Use of Insulin and Weight Gain: Optimizing Diabetes Nutrition Therapy. Journal of the American Dietetic Association 107:8, 1386-1393
CrossRef639
Peter Kurtzhals. (2007) Pharmacology of Insulin Detemir. Endocrinology & Metabolism Clinics of North America 36, 14-20
CrossRef640
Frank Doyle, Lois Jovanovič, Dale Seborg. (2007) I. Glucose control strategies for treating type 1 diabetes mellitus. Journal of Process Control 17:7, 572-576
CrossRef641
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Rosenberg, Eric S., Cort, Alice M., Ebeling, Sally H.Peters, Christine C., Greer, David M., Cagliero, Enrico, Krakauer, Eric L., Gonzalez, R. Gilberto, Hedley-Whyte, E. Tessa, . (2007) Case 21-2007. New England Journal of Medicine 357:2, 164-173
Full Text642
A. Hoang, A. J. Murphy, M. T. Coughlan, M. C. Thomas, J. M. Forbes, R. O’Brien, M. E. Cooper, J. P. F. Chin-Dusting, D. Sviridov. (2007) Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties. Diabetologia 50:8, 1770-1779
CrossRef643
Mark R. Nicolls, Kathryn Haskins, Sonia C. Flores. (2007) Oxidant Stress, Immune Dysregulation, and Vascular Function in Type I Diabetes. Antioxidants & Redox Signaling 9:7, 879-889
CrossRef644
J. Seissler. (2007) Normnahe Blutzuckereinstellung beim Typ-2-Diabetes. Der Internist 48:7, 676-685
CrossRef645
Subramaniam Pennathur, Jay W. Heinecke. (2007) Mechanisms for Oxidative Stress in Diabetic Cardiovascular Disease. Antioxidants & Redox Signaling 9:7, 955-969
CrossRef646
Psaty, Bruce M., Furberg, Curt D., . (2007) Rosiglitazone and Cardiovascular Risk. New England Journal of Medicine 356:24, 2522-2524
Full Text647
Ann Albright. (2007) The Public Health Approach to Diabetes. AJN, American Journal of Nursing 107:Supplement, 39-42
CrossRef648
M. A. Ihnat, J. E. Thorpe, A. Ceriello. (2007) Hypothesis: the ?metabolic memory?, the new challenge of diabetes. Diabetic Medicine 24:6, 582-586
CrossRef649
Michel Marre. (2007) Reducing cardiovascular risk in diabetes. Journal of Hypertension 25:Suppl 1, S19-S22
CrossRef650
J. A. McKnight. (2007) Assessing vascular risk in people with Type 1 diabetes: implications for the effectiveness of statin therapy. Diabetic Medicine 24:6, 575-578
CrossRef651
Farid M Nakhoul, Rachel Miller-Lotan, Huda Awaad, Rabea Asleh, Andrew P Levy. (2007) Hypothesis—haptoglobin genotype and diabetic nephropathy. Nature Clinical Practice Nephrology 3:6, 339-344
CrossRef652
N. D. Cohen, J. E. Shaw. (2007) Diabetes: advances in treatment. Internal Medicine Journal 37:6, 383-388
CrossRef653
Kim C Donaghue, Francesco Chiarelli, Daniela Trotta, Jeremy Allgrove, Knut Dahl-Jorgensen. (2007) Microvascular and macrovascular complications. Pediatric Diabetes 8:3, 163-170
CrossRef654
Timothy S. Bailey, Howard C. Zisser, Satish K. Garg. (2007) Reduction in Hemoglobin A1c with Real-Time Continuous Glucose Monitoring: Results from a 12-Week Observational Study. Diabetes Technology & Therapeutics 9:3, 203-210
CrossRef655
Lori M.B. Laffel, William C. Hsu, Janet B. McGill, Luigi Meneghini, Lisa K. Volkening. (2007) Continued Use of an Integrated Meter with Electronic Logbook Maintains Improvements in Glycemic Control Beyond a Randomized, Controlled Trial. Diabetes Technology & Therapeutics 9:3, 254-264
CrossRef656
M. Nieuwdorp, F. Holleman, E. Groot, H. Vink, J. Gort, A. Kontush, M. J. Chapman, B. A. Hutten, C. B. Brouwer, J. B. L. Hoekstra, J. J. P. Kastelein, E. S. G. Stroes. (2007) Perturbation of hyaluronan metabolism predisposes patients with type 1 diabetes mellitus to atherosclerosis. Diabetologia 50:6, 1288-1293
CrossRef657
The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. (2007) Long-Term Effect of Diabetes and Its Treatment on Cognitive Function. New England Journal of Medicine 356:18, 1842-1852
Full Text658
Russell D. White. (2007) The treat-to-target A1C approach to control type 2 diabetes and prevent complications. Advances in Therapy 24:3, 545-559
CrossRef659
W T Cefalu, S Waldman, S Ryder. (2007) Pharmacotherapy for the Treatment of Patients with Type 2 Diabetes Mellitus: Rationale and Specific Agents. Clinical Pharmacology & Therapeutics 81:5, 636-649
CrossRef660
(2007) Guías de práctica clínica sobre diabetes, prediabetes y enfermedades cardiovasculares: versión resumida. Revista Española de Cardiología 60:5, 525.e1-525.e64
CrossRef661
G. Dahlquist, B. Källén, . (2007) School performance in children with type 1 diabetes—a population-based register study. Diabetologia 50:5, 957-964
CrossRef662
C. M. Bennett, M. Guo, S. C. Dharmage. (2007) HbA 1c as a screening tool for detection of Type 2 diabetes: a systematic review. Diabetic Medicine 24:4, 333-343
CrossRef663
Allison B Goldfine. (2007) Changing horizons: approaches to diabetes care, current and future. Current Opinion in Endocrinology, Diabetes and Obesity 14:2, 95-97
CrossRef664
John A. Farmer. (2007) Diabetic dyslipidemia and atherosclerosis: Evidence from clinical trials. Current Atherosclerosis Reports 9:2, 162-168
CrossRef665
Thomas E. Burroughs, Jason Swindle, Steven Takemoto, Krista L. Lentine, Gerardo Machnicki, William D. Irish, Daniel C. Brennan, Mark A. Schnitzler. (2007) Diabetic Complications Associated With New-Onset Diabetes Mellitus in Renal Transplant Recipients. Transplantation 83:8, 1027-1034
CrossRef666
T. Staeva-Vieira, M. Peakman, M. Von Herrath. (2007) Translational Mini-Review Series on Type 1 Diabetes: Immune-based therapeutic approaches for type 1 diabetes. Clinical & Experimental Immunology 148:1, 17-31
CrossRef667
Ravichandran Ramasamy, Shi Fang Yan, Ann Marie Schmidt. (2007) The RAGE connection to diabetes and atherosclerosis: an intertwined web of advanced glycation and inflammation. Future Lipidology 2:2, 239-250
CrossRef668
Andrew J. Palmer, William J. Valentine, Joshua A. Ray, Volker Foos, Francesco Lurati, Inger Smith, Morten Lammert, Stéphane Roze. (2007) An economic assessment of analogue basal–bolus insulin versus human basal–bolus insulin in subjects with type 1 diabetes in the UK. Current Medical Research and Opinion 23:4, 895-901
CrossRef669
Cüneyt Köksoy, Erpulat Oziş, Atıl Çakmak, Uğur Yazgan, Aylin Okcu-Heper, Aslıhan Köksoy, Ediz Demirpençe, U. Deniz Dinçer. (2007) Simvastatin pretreatment reduces the severity of limb ischemia in an experimental diabetes model. Journal of Vascular Surgery 45:3, 590-596
CrossRef670
Xilin Yang, Alice P. S. Kong, Wing Yee So, Ronald C. W. Ma, Chung Shun Ho, Christopher W. K. Lam, Chun Chung Chow, Clive S. Cockram, Peter C. Y. Tong, Juliana C. N. Chan. (2007) Effects of chronic hyperglycaemia on incident stroke in Hong Kong Chinese patients with type 2 diabetes. Diabetes/Metabolism Research and Reviews 23:3, 220-226
CrossRef671
K Livingstone, M Fisher. (2007) Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC). Practical Diabetes International 24:2, 102-106
CrossRef672
A. Blinc, P. Poredoš. (2007) Pharmacological prevention of atherothrombotic events in patients with peripheral arterial disease. European Journal of Clinical Investigation 37:3, 157-164
CrossRef673
Kathleen M. McCauley. (2007) Modifying Women’s Risk for Cardiovascular Disease. Journal of Obstetric, Gynecologic, & Neonatal Nursing 36:2, 116-124
CrossRef674
Emile R Mohler. (2007) Therapy Insight: peripheral arterial disease and diabetes—from pathogenesis to treatment guidelines. Nature Clinical Practice Cardiovascular Medicine 4:3, 151-162
CrossRef675
Amal Yazigi, Fabrizio Andreelli. (2007) Insuline et prise de poids. Cahiers de Nutrition et de Diététique 42:1, 31-35
CrossRef676
Patrick J. Boyle, John Zrebiec. (2007) Physiological and Behavioral Aspects of Glycemic Control and Hypoglycemia in Diabetes. Southern Medical Journal 100:2, 175-182
CrossRef677
Ram Weiss, Yevgeny Yegorchikov, Alexander Shusterman, Itamar Raz. (2007) Noninvasive Continuous Glucose Monitoring Using Photoacoustic Technology—Results from the First 62 Subjects. Diabetes Technology & Therapeutics 9:1, 68-74
CrossRef678
Colin Berry, Jean-Claude Tardif, Martial G. Bourassa. (2007) Coronary Heart Disease in Patients With Diabetes. Journal of the American College of Cardiology 49:6, 631-642
CrossRef679
D. B. Dunger, C. P. Schwarze, J. D. Cooper, B. Widmer, H. A. W. Neil, J. Shield, J. A. Edge, T. W. Jones, D. Daneman, R. N. Dalton. (2007) Can we identify adolescents at high risk for nephropathy before the development of microalbuminuria?. Diabetic Medicine 24:2, 131-136
CrossRef680
(2007) References. American Journal of Kidney Diseases 49:2, S160-S179
CrossRef681
Gabriel I. Uwaifo, Robert E. Ratner. (2007) Differential Effects of Oral Hypoglycemic Agents on Glucose Control and Cardiovascular Risk. The American Journal of Cardiology 99:4, 51-67
CrossRef682
Frederick A. Masoudi, Silvio E. Inzucchi. (2007) Diabetes Mellitus and Heart Failure: Epidemiology, Mechanisms, and Pharmacotherapy. The American Journal of Cardiology 99:4, 113-132
CrossRef683
Luigi Meneghini. (2007) Why and How to Use Insulin Therapy Earlier in the Management of Type 2 Diabetes. Southern Medical Journal 100:2, 164-174
CrossRef684
Sanne Swinnen, Frits Holleman, Joost Hoekstra, Hans De Vries, Sanne Swinnen. 2007. Long-acting insulin analogue versus another long-acting insulin analogue for type 2 diabetes mellitus. .
CrossRef685
R. Paul Wadwa. (2007) Cardiovascular disease risk in youth with diabetes mellitus. Reviews in Endocrine and Metabolic Disorders 7:3, 197-204
CrossRef686
Marlien Pieters, Danie G. van Zyl, Paul Rheeder, Johann C. Jerling, Du Toit Loots, Francois H. van der Westhuizen, Louise T. Gottsche, John W. Weisel. (2007) Glycation of fibrinogen in uncontrolled diabetic patients and the effects of glycaemic control on fibrinogen glycation. Thrombosis Research 120:3, 439-446
CrossRef687
Marie-Claude Brindisi, Jina Hahn, Jean-Louis Chiasson, Rémi Rabasa-Lhoret. (2007) Under-utilization of capillary glucose monitoring by type 2 diabetic patients. Diabetes Research and Clinical Practice 75:1, 123-125
CrossRef688
Tomonari Okada, Toshiyuki Nakao, Hiroshi Matsumoto, Tamami Shino, Yume Nagaoka, Ryo Tomaru, Toshikazu Wada. (2007) Association between Markers of Glycemic Control, Cardiovascular Complications and Survival in Type 2 Diabetic Patients with End-Stage Renal Disease. Internal Medicine 46:12, 807-814
CrossRef689
Masafumi MATSUDA. (2007) Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 38:4, 179-182
CrossRef690
Nathan D Wong. (2007) Metabolic Syndrome. American Journal of Cardiovascular Drugs 7:4, 259-272
CrossRef691
Ritsuko Yamamoto-Honda, Yoshihiko Takahashi, Yoko Yoshida, Yoko Hara, Atsuo Kawai, Hiroji Kitazato, Takahisa Tanaka, Hiroshi Kajio, Masatoshi Kikuchi, Yasuo Akanuma, Mitsuhiko Noda. (2007) Use of Insulin Glargine in Japanese Patients with Type 1 Diabetes. Internal Medicine 46:13, 937-943
CrossRef692
Franklin J. Zieve, Marcia F. Kalin, Sherwyn L. Schwartz, Michael R. Jones, William L. Bailey. (2007) Results of the glucose-lowering effect of WelChol study (GLOWS): A randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clinical Therapeutics 29:1, 74-83
CrossRef693
Antonella Maffei, Paul E Harris. (2007) Targeting vesicular monoamine transporter Type 2 for noninvasive PET-based β-cell mass measurements. Expert Review of Endocrinology & Metabolism 2:1, 35-46
CrossRef694
G.L. Moneta. (2007) Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes. Yearbook of Vascular Surgery 2007, 96-98
CrossRef695
Steven V Edelman, Brock E Schroeder, Juan P Frias. (2007) Pramlintide acetate in the treatment of Type 2 and Type 1 diabetes mellitus. Expert Review of Endocrinology & Metabolism 2:1, 9-18
CrossRef696
L. Kennedy, J.L. Leahy. (2007) Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes. Yearbook of Medicine 2007, 533-539
CrossRef697
SH Song, CA Hardisty. (2007) Cardiovascular risk profile of early and later onset type 2 diabetes. Practical Diabetes International 24:1, 20-24
CrossRef698
Rucha Jani, Curtis Triplitt, Charles Reasner, Ralph A DeFronzo. (2007) First approved inhaled insulin therapy for diabetes mellitus. Expert Opinion on Drug Delivery 4:1, 63-76
CrossRef699
C. Stettler, A. Bearth, S. Allemann, M. Zwahlen, L. Zanchin, M. Deplazes, E. R. Christ, A. Teuscher, P. Diem. (2006) QTc interval and resting heart rate as long-term predictors of mortality in type 1 and type 2 diabetes mellitus: a 23-year follow-up. Diabetologia 50:1, 186-194
CrossRef700
Bernard Zinman. (2006) Type 2 Diabetes Mellitus: Magnitude of the Problem and Failure to Achieve Glycemic Control. Endocrinology & Metabolism Clinics of North America 35, 3-5
CrossRef701
Luigi Meneghini, Irl B. Hirsch. (2006) Pharmacotherapies for Diabetes Management: An Update for the Practicing Clinician. Seminars in Thoracic and Cardiovascular Surgery 18:4, 379-389
CrossRef702
Gregory E. Peterson. (2006) Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir. Current Medical Research and Opinion 22:12, 2613-2619
CrossRef703
John E. Gerich. (2006) Glycemic Control in the Metabolic Syndrome and Implications in Preventing Cardiovascular Disease. Metabolic Syndrome and Related Disorders 4:4, 315-327
CrossRef704
Jonathan R Jaffe, Soma S Nag, Pamela B Landsman, Charles M Alexander. (2006) Reassessment of cardiovascular risk in diabetes. Current Opinion in Lipidology 17:6, 644-652
CrossRef705
Kay-Tee Khaw, Nicholas Wareham. (2006) Glycated hemoglobin as a marker of cardiovascular risk. Current Opinion in Lipidology 17:6, 637-643
CrossRef706
S. V. EDELMAN, T. DARSOW, J. P. FRIAS. (2006) Pramlintide in the treatment of diabetes. International Journal of Clinical Practice 60:12, 1647-1653
CrossRef707
Jill Hamilton, Torild Skrivarhaug. (2006) Science and Art: in harmony. Pediatric Diabetes 7:6, 336-340
CrossRef708
S. Martin. (2006) Risikomanagement bei Typ-2-Diabetes durch Blutzuckerselbstkontrolle. Der Diabetologe 2:6, 493-501
CrossRef709
E. Renard, G. Costalat, H. Chevassus, J. Bringer. (2006) Artificial β-cell: clinical experience toward an implantable closed-loop insulin delivery system. Diabetes & Metabolism 32:5, 497-502
CrossRef710
Andrew P. Levy. (2006) Application of pharmacogenomics in the prevention of diabetic cardiovascular disease: Mechanistic basis and clinical evidence for utilization of the haptoglobin genotype in determining benefit from antioxidant therapy. Pharmacology & Therapeutics 112:2, 501-512
CrossRef711
Yunsheng Ma, Barbara C. Olendzki, Andrea R. Hafner, David E. Chiriboga, Annie L. Culver, Victoria A. Andersen, Philip A. Merriam, Sherry L. Pagoto. (2006) Low-carbohydrate and high-fat intake among adult patients with poorly controlled type 2 diabetes mellitus. Nutrition 22:11-12, 1129-1136
CrossRef712
A. GIRACH, D. MANNER, M. PORTA. (2006) Diabetic microvascular complications: can patients at risk be identified? A review. International Journal of Clinical Practice 60:11, 1471-1483
CrossRef713
Lawrence Blonde, Judith Dempster, Joanne M. Gallivan, Elizabeth Warren-Boulton. (2006) Reducing cardiovascular disease risk in patients with diabetes: A message from the National Diabetes Education Program. Journal of the American Academy of Nurse Practitioners 18:11, 524-533
CrossRef714
U. SMITH, M. LAAKSO, B. ELIASSON, C. WESSLAU, J. BORÉN, O. WIKLUND, S. ATTVALL. (2006) Pathogenesis and treatment of diabetic vascular disease ? illustrated by two cases. Journal of Internal Medicine 260:5, 409-420
CrossRef715
Chantal Mathieu. (2006) Inhaled human insulin ((insulin human [rDNA origin]) Inhalation Powder) in diabetes mellitus. Expert Opinion on Drug Metabolism & Toxicology 2:5, 779-791
CrossRef716
Y Vainilovich, L Danilova, Z Zabarovskaya. (2006) Improving the diabetes care in Belarus. Practical Diabetes International 23:8, 370-373
CrossRef717
Ian S. Zagon, Matthew S. Klocek, Joseph W. Sassani, David T. Mauger, Patricia J. McLaughlin. (2006) Corneal Safety of Topically Applied Naltrexone. Journal of Ocular Pharmacology and Therapeutics 22:5, 377-387
CrossRef718
Steven J. Atlas. (2006) Point of View. Spine 31:22, 2600-2601
CrossRef719
B Feldt-Rasmussen. (2006) Is there a need to optimize glycemic control in hemodialyzed diabetic patients?. Kidney International 70:8, 1392-1394
CrossRef720
W. A. Scherbaum. (2006) Kardiovaskuläre Prävention durch intensivierte Insulintherapie. Der Internist 47:9, 960-962
CrossRef721
Matthias Turina, Mirjam Christ-Crain, Hiram C. Polk. (2006) Diabetes and hyperglycemia: Strict glycemic control. Critical Care Medicine 34:Suppl, S291-S300
CrossRef722
D. Raccah. (2006) Importance of blood glucose management in the multifactorial approach of absolute cardiovascular risk in type 2 diabetes: the lessons from the Steno 2 Study. Diabetes & Metabolism 32, 2S48-2S51
CrossRef723
S. Claiborne Johnston, Mai N. Nguyen-Huynh, Miriam E. Schwarz, Kate Fuller, Christina E. Williams, S. Andrew Josephson, Graeme J. Hankey, Robert G. Hart, Steven R. Levine, Jose Biller, Robert D. Brown, Ralph L. Sacco, L. Jaap Kappelle, Peter J. Koudstaal, Julien Bogousslavsky, Louis R. Caplan, Jan van Gijn, Ale Algra, Peter M. Rothwell, Harold P. Adams, Gregory W. Albers. (2006) National Stroke Association guidelines for the management of transient ischemic attacks. Annals of Neurology 60:3, 301-313
CrossRef724
W. Pommer. (2006) Epidemiologische Daten zur Nephropathie bei Diabetespatienten. Der Diabetologe 2:5, 394-399
CrossRef725
C Sachon, S Jacqueminet, A Hartemann-Heurtier, A Grimaldi. (2006) Should diabetic patients be asked to test their blood glucose 90 to 120 minutes after the beginning of their meals?. Diabetes & Metabolism 32:4, 377-381
CrossRef726
Tamara Darsow, David Kendall, David Maggs. (2006) Is the metabolic syndrome a real clinical entity and should it receive drug treatment?. Current Diabetes Reports 6:5, 357-364
CrossRef727
Christian A. Schneider. (2006) Improving macrovascular outcomes in type 2 diabetes: outcome studies in cardiovascular risk and metabolic control. Current Medical Research and Opinion 22:s2, S15-S26
CrossRef728
D. M. Nathan, J. B. Buse, M. B. Davidson, R. J. Heine, R. R. Holman, R. Sherwin, B. Zinman. (2006) Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetologia 49:8, 1711-1721
CrossRef729
John Pullman, Tamara Darsow, Juan P Frias. (2006) Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes. Vascular Health and Risk Management 2:3, 203-212
CrossRef730
Matthew I. Kim. (2006) An Integrated Graphic Scheme for the Display of Insulin Prescription and Blood Glucose Information. Diabetes Technology & Therapeutics 8:4, 505-512
CrossRef731
Kevan C Herold. (2006) Lessons from New York City—how diabetes might be affecting overall rates of coronary heart disease. Nature Clinical Practice Endocrinology & Metabolism 2:8, 434-435
CrossRef732
A. Kretowski, J. E. Hokanson, K. McFann, G. L. Kinney, J. K. Snell-Bergeon, D. M. Maahs, R. P. Wadwa, R. H. Eckel, L. G. Ogden, S. K. Garg, J. Li, S. Cheng, H. A. Erlich, M. Rewers. (2006) The apolipoprotein A-IV Gln360His polymorphism predicts progression of coronary artery calcification in patients with type 1 diabetes. Diabetologia 49:8, 1946-1954
CrossRef733
B. J. GOLDSTEIN. (2006) Closing the gap between clinical research and clinical practice: can outcome studies with thiazolidinediones improve our understanding of type 2 diabetes?. International Journal of Clinical Practice 60:7, 873-883
CrossRef734
Elaine Urbina. (2006) Noninvasive Assessment of Target Organ Injury in Children With the Metabolic Syndrome. Journal of the CardioMetabolic Syndrome 1:4, 277-281
CrossRef735
Carmelo J. Panetta, Charles A. Herzog, Timothy D. Henry. (2006) Acute coronary syndromes in patients with renal disease: What are the issues?. Current Cardiology Reports 8:4, 296-300
CrossRef736
Mori J Krantz. (2006) Implications of Thiazolidinedione Use and Cardiovascular Risk: Is It All About the Sugar?. Pharmacotherapy 26:7, 1049-1050
CrossRef737
D PACKARD, J MILTON, L SHULER, R SHORT, K TUTTLE. (2006) Implications of Chronic Kidney Disease for Dietary Treatment in Cardiovascular Disease. Journal of Renal Nutrition 16:3, 259-268
CrossRef738
Harold Brem, Peter Sheehan, Harvey J. Rosenberg, Jillian S. Schneider, Andrew J. M. Boulton. (2006) Evidence-Based Protocol for Diabetic Foot Ulcers. Plastic and Reconstructive Surgery 117:SUPPLEMENT, 193S-209S
CrossRef739
R. Taylor. (2006) Digami too?. Diabetologia 49:6, 1134-1137
CrossRef740
m. horowitz, k. l. jones, c. k. rayner, n. w. read. (2006) 'Gastric' hypoglycaemia - an important concept in diabetes management. Neurogastroenterology and Motility 18:6, 405-407
CrossRef741
Mary Ann Banerji, Robyn B. Stewart. (2006) A public health approach to the diabetes epidemic: New York city’s diabetes registry. Current Diabetes Reports 6:3, 169-171
CrossRef742
José F. Cara, Rochelle L. Chaiken. (2006) Type 2 diabetes and the metabolic syndrome in children and adolescents. Current Diabetes Reports 6:3, 241-250
CrossRef743
Michael Roden. (2006) Diabetes mellitus. Wiener klinische Wochenschrift Education 1:1, 19-30
CrossRef744
(2006) Intensive Diabetes Treatment and Cardiovascular Disease. New England Journal of Medicine 354:16, 1751-1752
Full Text745
Scott M. Grundy. (2006) Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nature Reviews Drug Discovery 5:4, 295-309
CrossRef746
Allison B Goldfine. (2006) Diabetes and cardiovascular disease: does sugar matter?. Current Opinion in Endocrinology & Diabetes 13:2, 99-102
CrossRef747
Steinbrook, Robert, . (2006) Facing the Diabetes Epidemic — Mandatory Reporting of Glycosylated Hemoglobin Values in New York City. New England Journal of Medicine 354:6, 545-548
Full Text748
Smadar Eventov-Friedman, Dalit Tchorsh, Helena Katchman, Elias Shezen, Anna Aronovich, Gil Hecht, Benjamin Dekel, Gideon Rechavi, Bruce R. Blazar, Ilan Feine, Orna Tal, Enrique Freud, Yair Reisner. (2006) Embryonic Pig Pancreatic Tissue Transplantation for the Treatment of Diabetes. PLoS Medicine 3:7, e215
CrossRef749
Cefalu, William T., . (2005) Glycemic Control and Cardiovascular Disease — Should We Reassess Clinical Goals?. New England Journal of Medicine 353:25, 2707-2709
Full Text
- Letters
